Neuroactive steroids, compositions and uses thereof

JP7579639B2Active Publication Date: 2024-11-08SAGE THERAPEUTICS INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2020008895
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2013-03-13
Filing Date
2020-01-23
Publication Date
2024-11-08
Estimated Expiration
2034-03-13

AI Technical Summary

Benefits of technology

【0041】 他の目的および利点は、次の詳細な説明、実施例および請求項を考慮に入れることによ って、当業者には明らかになるだろう。 特定の実施形態では、例えば以下が提供される: (項目1) 患者、例えば、本明細書中に記載される障害を有する患者を評価するかまたは処置する方法であって、該方法は、 a)必要に応じて患者サンプルを取得する工程; b)対照基準と比較したときの24(S)-ヒドロキシコレステロールのレベルの変化について、該サンプルの評価を取得する工程および/または該サンプルを評価する工程 を含む、方法。 (項目2) 有効量の、24(S)-ヒドロキシコレステロールまたは構造的に関係するステロールもしくはステロイド、オキシステロール、NMDARのアゴニストまたはNMDARの正のアロステリックモジュレーター(PAM)あるいは式(I)の化合物などの本明細書中に記載される化合物を(例えば、前記サンプルの前記評価に応答性の)前記患者に投与する工程をさらに含む、項目1に記載の方法。 (項目3) 有効量の、NMDARのアンタゴニストまたはNMDARの負のアロステリックモジュレーター(NAM)を(例えば、前記サンプルの前記評価に応答性の)前記患者に投与する工程をさらに含む、項目1に記載の方法。 (項目4) 有効量の、24(s)-ヒドロキシコレステロールの内在活性または内在量を高める(例えば、増加させる)化合物(例えば、24(s)-ヒドロキシコレステロールを代謝する酵素を阻害する化合物(例えば、24-ヒドロキシコレステロール7アルファ-ヒドロキシラーゼ(CYP39)を阻害する化合物))を(例えば、前記サンプルの前記評価に応答性の)前記患者に投与する工程をさらに含む、項目1に記載の方法。 (項目5) 有効量の、24(s)-ヒドロキシコレステロールの内在活性または内在量を減少させる化合物(例えば、24(s)-ヒドロキシコレステロールを生成する酵素を活性化する化合物(例えば、コレステロール24(S)-ヒドロキシラーゼ(CYP46)を活性化する化合物))を(例えば、前記サンプルの前記評価に応答性の)前記患者に投与する工程をさらに含む、項目1に記載の方法。 (項目6) 前記方法が、前記患者を処置する工程をさらに含み、該患者は、記憶障害について処置されるか、または学習を改善するために処置される、項目1に記載の方法。 (項目7) 前記方法が、前記患者を薬物の過量服用について処置する工程をさらに含む、項目1に記載の方法。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579639000001
    Figure 0007579639000001
  • Figure 0007579639000002
    Figure 0007579639000002
  • Figure 0007579639000003
    Figure 0007579639000003
Patent Text Reader

Abstract

To provide neuroactive steroids, compositions, and uses thereof.SOLUTION: Provided are methods of evaluating or treating a patient, e.g., a patient having a disorder described herein, comprising: a) optionally, acquiring a patient sample; and b) acquiring an evaluation of the sample and / or evaluating the sample for an alteration in the level of 24(S)-hydroxycholesterol compared with a reference standard.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application is a continuation of U.S. Provisional Patent Application No. 61 / 780,671, filed March 13, 2013. This application claims priority under 35 U.S.C. §119(e) to the present application. It is incorporated by reference in the specification. [Background technology]

[0002] 2. Background of the Invention Brain excitability is defined as the level of alertness of an animal on a continuum ranging from coma to convulsions, and can vary In general, neurotransmitters are substances that transmit information across the neuronal membrane. At rest, the neuronal membrane has a potential of approximately -70 mV. The inside of the cell is negative relative to the outside of the cell. ) is a membrane-permeable membrane that balances ions (K+, Na+, Cl-, organic anions) across the neuronal membrane. Neurotransmitters are stored in presynaptic vesicles and are the result of neuronal action potentials. As a result, they are released into the synaptic cleft, where they release excitatory chemicals such as acetylcholine. The transmitter causes depolarization of the membrane (a change in potential from -70 mV to -50 mV). The action of is to stimulate the synapse by acetylcholine to increase the membrane permeability of Na+ ions. The decrease in membrane potential generates postsynaptic action potentials. This increases the probability that neurons will respond to stimulation, which increases neuronal excitability.

[0003] NMDA receptors are highly expressed in the CNS and are involved in excitatory synaptic transmission. Activation of these receptors contributes to synaptic plasticity in some situations and to synaptic plasticity in others. These receptors mediate the expression of the neurotransmitter glutamate. and ligand-gated, which allows Ca2+ to pass after glycine binding. ) ion channels that are essential for excitatory neurotransmission and normal CNS function. NM DA receptors are heteromers containing NR1, NR2 and / or NR3 subunits. It is a complex that has different recognition sites for exogenous and endogenous ligands. The recognition sites are for glycine and glutamate agonists and modulators. Positive modulators have potential clinical uses as nootropics and as Clinical application in the treatment of psychiatric disorders in which glutamatergic transmission is reduced or defective These may be useful as therapeutic agents of potential use (see, for example, Horak et al., J. of See Neuroscience, 2004, 24(46), 10318-10325 In contrast, negative modulators may be used to block pathological increases in glutamatergic transmission. Therapies having potential clinical use in the treatment of certain psychiatric disorders (e.g., treatment-resistant depression). It may be useful as a therapeutic agent.

[0004] Neuroactive steroids such as pregnenolone sulfate (PS) have been shown to have a number of neuroprotective effects on several types of Transmitter receptors (e.g., GABAA receptors, glycine receptors, AMPA receptors) Direct modulatory effects on NMDA receptors (neuronal receptors, kainate receptors, and NMDA receptors) NMDA receptors are positively regulated by PS; However, the degree of regulation varies considerably, depending, for example, on the subunit composition of the receptor. do. In addition to PS, several other 3β-hydroxysteroids activate NMDA receptors. It has been shown to enhance the er.1994,271,677-682;Madau et al., Program No.61 3.2 / B87.2009 Neuroscience Meeting Planne r.Chicago,IL:Society for Neuroscience,20 09; Connick et al., Program No. 613.1 / B86.2009 Ne uroscience Meeting Planner.Chicago,IL:So society for Neuroscience, 2009; Paul et al., J. Neurology, 2009 (see osci.2013,33,17290-17300). [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Horak et al., J. of Neuroscience, 2004, 24(46), 10318-10325 [Non-Patent Document 2] Paul et al., J. Pharm. and Exp. Ther. 1994, 271, 677-682 [Non-Patent Document 3] Madau et al., Program No.613.2 / B87.2009 Neuroscience Meeting Planner.Chicago,IL:Society for Neuroscience,2009 [Non-Patent Document 4] Connick et al., Program No. 613.1 / B86.2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009 [Non-Patent Document 5] Paul et al., J.Neurosci.2013,33,17290-17300 Summary of the Invention [Means for solving the problem]

[0006] Summary of the Invention Evaluating or treating patients, e.g., patients with a disorder described herein Methods are inter alia described herein, which include: a) optionally administering to a patient sample b) obtaining a concentration of 24(S)-hydroxycholesterol relative to a control. Obtaining an evaluation of the sample for changes in the level and / or evaluating the sample. In certain embodiments, the method includes administering an effective amount of 24(S)-his hydroxycholesterol or structurally related sterols or steroids, Sterols, NMDAR agonists or positive allosteric modulators of NMDAR Positive allosteric modulator (PAM) or a compound described herein, such as a compound of formula (I), to the patient. In certain embodiments, the method includes administering an effective amount of an antagonist of NMDAR to a subject. Negative allosteric modulators of serotonin receptors or NMDARs The present invention relates to a compound of formula (I), such as a compound of formula (I) or a compound of formula (I), In some embodiments, the method further comprises administering to the patient a compound described herein. The method includes increasing the endogenous activity or amount of 24(s)-hydroxycholesterol. Compounds that promote (e.g., increase) 24(s)-hydroxycholesterol Compounds that inhibit the enzymes that metabolize it, such as 24-hydroxycholesterol 7 alpha- The method further comprises administering to the subject a compound that inhibits CYP39 (CYP39 hydroxylase). In some embodiments, the method comprises administering to the patient a 24(s)-hydroxycholesterol Compounds that decrease the endogenous activity or amount of Compounds that activate the enzyme that produces cholesterol, such as cholesterol 24(S)-hydrogenase The method further comprises administering to the patient a compound that activates CYP46.

[0007] In certain embodiments, 24(S)-hydroxycholesterol, structurally related The sterols or steroids or oxysterols that are involved are naturally occurring compounds ( For example, compounds naturally occurring in the brain of a subject, such as naturally occurring sterols or In some embodiments, the method comprises the step of: In some embodiments, the method includes administering cholesterol to the subject. The method includes administering to the subject a compound described herein, such as a compound of formula (I). In certain embodiments, the method includes administering an effective amount of an NMDAR antagonist. or NMDAR negative allosteric modulators (NAMs) or The method includes administering to the patient a compound described herein, such as a compound of formula (I). In an embodiment, the method comprises determining the endogenous activity or activity of 24(s)-hydroxycholesterol. Compounds that increase (e.g., increase) endogenous levels (e.g., 24(s)-hydroxycholesterol) Compounds that inhibit enzymes that metabolize terols, such as 24-hydroxycholesterol 7 administering to the subject a compound that inhibits alpha-hydroxylase (CYP39). In some embodiments, the method comprises administering 24(s)-hydroxycholesterol to a subject. Compounds that decrease the endogenous activity or amount of cholesterol (e.g., 24(s)-hydroxycholesterol) Compounds that activate enzymes that produce sterols, such as cholesterol 24(S)-hybrid The method further comprises administering to the patient a compound that activates hydroxylase (CYP46). .

[0008] In some embodiments, 24(S)-hydroxycholesterol is used as a control. The control is compared to a baseline previously obtained from the patient. In an embodiment, the control is an external control not related to the patient sample (e.g., a universal (either from clinical criteria or treatment and / or diagnostic guidelines). In some embodiments, the level of 24(S)-hydroxycholesterol is increased relative to the reference. When the patient is experiencing a decrease in 24(S)-hydroxycholesterol or structurally related sterols or steroids, oxysterols, NMDAR agonists or NMDAR positive allosteric modulators (PAMs), 24 ( Increase (e.g., increase) the endogenous activity or amount of s-hydroxycholesterol ) compounds (e.g., compounds that inhibit the enzyme that metabolizes 24(s)-hydroxycholesterol) Compounds such as 24-hydroxycholesterol 7 alpha-hydroxylase (CYP 39) or a compound described herein, such as a compound of formula (I) In certain embodiments, the subject is a suitable candidate for treatment with the agent. When 24(S)-hydroxycholesterol levels are elevated compared to control levels The method further comprises administering to the patient an NMDAR antagonist, an NMDAR negative allosteric inhibitor, Endogenous activity of neurotransmitter agonist (NAM) or 24(s)-hydroxycholesterol Or compounds that decrease the endogenous amount (e.g., 24(s)-hydroxycholesterol) Compounds that activate the enzyme that produces it, such as cholesterol 24(S)-hydroxylase These results suggest that these patients are good candidates for treatment with CYP46-activating compounds. In certain embodiments, the method includes administering an effective amount of 24(S)-hydroxycholine to a subject. esterol or structurally related sterols or steroids, oxysterols , NMDAR agonists or NMDAR positive allosteric modulators (PA M), increasing the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g. , increasing) compounds (e.g., enzymes that metabolize 24(s)-hydroxycholesterol) Compounds that inhibit 24-hydroxycholesterol, e.g., 7alpha-hydroxylase Compounds that inhibit CYP39 (CYP39 inhibitors) or compounds of formula (I) described herein In certain embodiments, the method further comprises administering to a patient the compound described above. The method includes the step of isolating 24(S)-hydroxycholesterol or a structurally related sterol. These include steroids, oxysterols, NMDAR agonists, or NMDAR positive antagonists. Perosteric Modulator (PAM), 24(s)-Hydroxycholesterol Compounds that enhance (e.g., increase) activity or endogenous amount (e.g., 24(s)-hydro Compounds that inhibit the enzyme that metabolizes 24-hydroxycholesterol, e.g. Compounds that inhibit tertol 7-alpha-hydroxylase (CYP39) or the formula ( and further comprising the step of refraining from treating the patient with a compound described herein, such as a compound of formula I). In certain embodiments, the method includes administering an effective amount of an antagonist of NMDAR to a subject. or NMDAR negative allosteric modulators (NAMs), 24(s)- Compounds that decrease the endogenous activity or amount of hydroxycholesterol (e.g., 24 Compounds that activate the enzyme that produces (s)-hydroxycholesterol, e.g., cholesterol Compounds that activate tertol 24(S)-hydroxylase (CYP46) or The method further comprises administering to the patient a compound described herein, such as a compound of formula I).

[0009] In some embodiments, the level of 24(S)-hydroxycholesterol is When the IL-16 level is elevated compared to the control baseline or decreased compared to the control baseline, the patient is (s) Mutations in biosynthetic enzymes involved in the synthesis or metabolism of hydroxycholesterol The polymorphism is further evaluated. Cholesterol levels are elevated compared to a control or compared to a control When decreased, patients have problems with the synthesis or metabolism of 24(s) hydroxycholesterol. It is determined that the biosynthetic enzyme involved in the oxidative stress response is a mutation or polymorphism.

[0010] In certain embodiments, the level of 24(S)-hydroxycholesterol is 24(S)-hydroxycholesterol or its fragments or derivatives in a subject In certain embodiments, the level of 24(S)- Hydroxycholesterol levels can be measured using chromatographic (e.g., HPLC) methods, It may be measured by optical (eg, MS) or nuclear magnetic resonance (NMR) methods.

[0011] In certain embodiments, the patient sample is a bodily fluid sample, e.g., a blood sample. In certain embodiments, the patient sample is a biopsy, e.g., a brain biopsy. In certain embodiments, the patient sample is a therapeutic sample, an isolated specimen, or a surgical specimen. In certain embodiments, the first treatment is obtained prior to evaluation of the patient, and / or 24(S)-hydroxycholesterol or structurally related sterols steroids, oxysterols, NMDAR agonists or NMDAR Positive allosteric modulator (PAM), 24(s)-hydroxycholesterol Compounds that enhance (e.g., increase) the endogenous activity or amount of 24(s) Compounds that inhibit the enzyme that metabolizes 24-hydroxycholesterol, e.g. Compounds that inhibit cholesterol 7-alpha-hydroxylase (CYP39) or prior to administration of a compound described herein, such as a compound of formula (I). In certain embodiments, the patient sample contains 24(S)-hydroxycholesterol or The steroids and oxysterols are structurally related, and the NMDAR Gonists or NMDAR positive allosteric modulators (PAMs), 24(s) -Enhancing (e.g., increasing) the endogenous activity or amount of hydroxycholesterol Compounds (e.g., compounds that inhibit the enzyme that metabolizes 24(s)-hydroxycholesterol) , e.g., 24-hydroxycholesterol 7 alpha-hydroxylase (CYP39 ) or a compound described herein, such as a compound of formula (I) In certain embodiments, the first treatment is administered after administration of a treatment other than administration of Prior to evaluation of the patient and / or administration of an NMDAR antagonist or NMDAR negative Allosteric Modulator (NAM) of 24(s)-Hydroxycholesterol Compounds that decrease the endogenous activity or amount (e.g., 24(s)-hydroxycholesterol) Compounds that activate the enzyme that produces cholesterol, such as cholesterol 24(S)-hydrogenase Compounds that activate xylase (CYP46) or compounds of formula (I) In certain embodiments, the patient sample is administered prior to administration of the compound described in The drugs act as NMDAR antagonists or negative allosteric modulators of NMDAR. Reduces the endogenous activity or amount of 24(s)-hydroxycholesterol Compounds that reduce cholesterol levels (e.g., compounds that activate the enzyme that produces 24(s)-hydroxycholesterol) Compounds that inhibit cholesterol 24(S)-hydroxylase (CYP46), for example or a compound described herein, such as a compound of formula (I) It is obtained after administration of treatment other than the drug.

[0012] In one embodiment, a plurality of 24(S)-hydroxycholesterol-interacting polypeptides are provided. Kits or articles of manufacture comprising the agents are also described herein. In some embodiments, the agent is NMDAR or NMDA. In some embodiments, the agent is / includes a label, such as a radioactive label or a fluorescent label. In an embodiment, the agent interacts with 24(S)-hydroxycholesterol. It is a probe that

[0013] In certain embodiments, 24(S)-hydroxycholesterol is administered to a patient sample. from blood, plasma, serum, cerebrospinal fluid, circulating and interstitial fluid levels or surgical specimens Obtained.

[0014] In certain embodiments, the level of 24(S)-hydroxycholesterol is In certain embodiments, the value is measured based on a control, e.g., a patient's The level of 24(S)-hydroxycholesterol in the sample is compared.

[0015] In one embodiment, 24(S)-hydroxycholesterol and 24 ( Methods for assaying levels of S)-hydroxycholesterol are also described herein; wherein the method comprises assaying the level of 24(S)-hydroxycholesterol. Includes the process.

[0016] In certain embodiments, 24(S)-hydroxycholesterol is administered to a patient sample. from blood, plasma, serum, cerebrospinal fluid, circulating and interstitial fluid levels or surgical specimens Obtained.

[0017] In certain embodiments, the level of 24(S)-hydroxycholesterol is In certain embodiments, the value is measured based on a control, e.g., a patient's The level of 24(S)-hydroxycholesterol in the sample is compared.

[0018] In one embodiment, 24(S)-hydroxycholesterol and 24(S)-hyd An agent capable of interacting with oxycholesterol (e.g., a probe, NMDA or N Also described herein are reaction mixtures that include MDAR.

[0019] In one embodiment, a method of making a reaction mixture is also described herein, the method comprising: , 24(S)-hydroxycholesterol was compared with 24(S)-hydroxycholesterol. mixing with an agent capable of interacting with the probe (e.g., a probe, NMDA or NMDAR); Includes.

[0020] The novel compounds described herein are potential NMDA receptor modulators ( For example, positive allosteric modulators (i.e., PAMs) or negative allosteric modulators Neuroprotective Agents (i.e., NAMs) and 24(S)-Hydroxycholesterol It increases or decreases the endogenous activity of the steroids, resulting in a wide range of CNS-related symptoms (psychiatric Schizophrenia, depression, bipolar disorder (e.g., I and / or II), schizoaffective disorder, mood swings personality disorder, psychosis, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), Autism spectrum disorder (ASD), dysthymia (mild depression), social anxiety disorder, obsessive-compulsive disorder (OCD) ), pain (e.g., painful syndromes or disorders), sleep disorders, memory disorders (e.g., memory function dementia, Alzheimer's disease, seizure disorders (e.g., epilepsy), traumatic brain injury, stroke , addictive disorders (e.g., addiction to opiates, cocaine and / or alcohol) , autism, Huntington's disease, insomnia, Parkinson's disease, withdrawal syndrome or tinnitus, These compounds are useful for the prevention and / or treatment of diseases such as, but not limited to, The compounds have been shown to have improved in vivo efficacy, pharmacokinetic (PK) properties, and oral bioavailability. The drug product is required to meet the following criteria: In some embodiments, the compounds described herein are In some embodiments, the methods described herein can be used to improve the performance of the The compounds are intended to be used in the treatment of overdoses, e.g., drug overdoses (e.g., ketamine or PCP overdoses). It can be used to treat

[0021] The methods described herein, e.g., methods of evaluation and treatment, are Exemplary compounds described herein include N MDAR agonists or NMDAR positive allosteric modulators (PAMs) In some embodiments, the compounds described herein include The compounds described herein are negative allosteric modulators (NAMs) of AR. The compounds include naturally occurring and non-naturally occurring steroids and sterols, e.g., Also contains 24(S)-hydroxycholesterol In some embodiments, the compound is an oxysterol. In an embodiment, the compound is a cyclic amine having a C-17β moiety, as shown in the compound of formula (I). It has an alkyl side chain and a steroid skeleton. It is a 3-β hydroxyl steroid with optional substitutions at various positions. In an embodiment, the method comprises determining the endogenous activity or activity of 24(s)-hydroxycholesterol. Compounds that increase (e.g., increase) endogenous levels (e.g., 24(s)-hydroxycholesterol) Compounds that inhibit enzymes that metabolize terols, such as 24-hydroxycholesterol 7 Compounds that inhibit alpha-hydroxylase (CYP39) or 24(s)-hydroxylase Compounds that decrease the endogenous activity or amount of oxycholesterol (e.g., 24(s Compounds that activate the enzyme that produces hydroxycholesterol, e.g., cholesterol It is used in combination with a compound that activates 24(S)-hydroxylase (CYP46). can be.

[0022] In some embodiments, the methods described herein, e.g., The compounds used in the methods of evaluation or treatment described herein are compounds according to formula (I): [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer thereof. isomers, isotopic variants, or N-oxides, or combinations thereof; During the ceremony: Z is a group of formula (i), (ii), (iii), (iv) or (v): [ka] L 1 , L 2 , L 3 , X 1 , X 2 , Y, R Z4 , R Z5 , R Z6 , n, R 1 , R 2 , R 3a , R 3b , R4a , R 4b , R 6a , R 6b , R 7a , R 7b , R 11a , R 11b , R 14 , R 17 , R 19 , R 20 , R 23a , R 23b and R 24 is defined herein and the group -XR at the C3 position is as shown. 3b is either alpha or beta.

[0023] For example, in certain embodiments, the compound of formula (I) is a compound of formula (Iw): [ka] or a pharma- ceutically acceptable salt thereof; During the ceremony: Z is a group of formula (i), (ii), (iii), (iv) or (v): [ka] L 1 and L 2 is a bond, substituted or unsubstituted C 1 -C 6 Alkylene, substituted or unsubstituted C 2 -C 6 Alkenylene, substituted or unsubstituted C 2 -C 6 Alkynylene, substituted or unsubstituted Terror C 1 -C 6 Alkylene, substituted or unsubstituted hetero C 2 -C 6 Alkenylene and Substituted or unsubstituted hetero C 2 -C 6alkynylene; L 3 is a substituted or unsubstituted C 1 -C 6 Alkylene, substituted or unsubstituted C 2 -C 6 Al Kenylene, substituted or unsubstituted C 2 -C 6 Alkynylene, substituted or unsubstituted hetero C 1 -C 6 Alkylene, substituted or unsubstituted hetero C 2 -C 6 Alkenylene or substituted or is unsubstituted heterocyclic C 2 -C 6 alkynylene; X 1 and X 2 each instance of is independently -O-, -S-, or -NH-; R 1 is hydrogen or substituted or unsubstituted alkyl; R 3b is hydrogen; R 3a is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; R 2 , R 11a and R 11b Each instance of is independently hydrogen or -OR B1 And this So, R B1 is hydrogen or substituted or unsubstituted alkyl, or R 11a oh YobiR 11b taken together form an oxo (=O) group; R 6a and R 6b Each of is independently hydrogen, halo, or substituted or unsubstituted alkyl. and [ka] represents a single bond or a double bond, provided that when a double bond is present, R 6a or R 6 b If one of the bonds is absent and a single bond is present, the hydrogen at C5 is or beta position; R 19 and R 20 Each instance of is independently hydrogen or -CH 3 and; R 23a and R 23b Each instance of is independently hydrogen, halogen, or substituted or unsubstituted. is a substituted alkyl group or R 23a and R 23b are connected together to form a replacement or non-replacement substitution C 3 -C 6 Forming a cycloalkyl; R 24 is hydrogen or substituted or unsubstituted alkyl; Y is -O-, -S- or -NR Z5 - and; R Z4 are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted Heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, - OR Z5 , -SR Z5 or -N(R Z5 ) 2 and; R Z5 Each instance of is independently hydrogen or substituted or unsubstituted alkyl; R Z6 Each instance of is independently hydrogen or substituted or unsubstituted alkyl or There are two R Z6 The group is connected, C 3-6 Forming a carbocyclic ring; The subscript n is either 0 or 1; However, the following compounds are specifically excluded: [ka] In some embodiments, the compound used in the methods described herein is , [ka] It is.

[0024] In certain embodiments, Z is a group of the formula: [ka]

[0025] In certain embodiments, L 3 is a radical of the formula: [ka] where p is 1, 2 or 3; R Z7 and R Z8 Each instance of is independently hydrogen, Halo, substituted or unsubstituted C 1-6 Alkyl or -OR Z5 It is.

[0026] In certain embodiments, L 3 is a radical of the formula: [ka] wherein w is 0 or 1 and p is 1, 2 or 3, or w is 1 and p is 0, 1, 2 or 3; RZ7 and R Z8 Each example is In the above, hydrogen, halo, substituted or unsubstituted C 1-6 Alkyl or -OR Z5 It is.

[0027] In certain embodiments, L 3 is a radical of the formula: [ka]

[0028] In certain embodiments, L 3 is a radical of the formula: [ka]

[0029] In certain embodiments, L 3 is a radical of the formula: [ka]

[0030] In certain embodiments, Z is of the formula [ka] It is.

[0031] In certain embodiments, the group [ka] is the formula: [ka] [ka]

[0032] In certain embodiments, Z is of the formula [ka] It is.

[0033] In certain embodiments, Y is -O-, and L 3 is an alkylene group or a heterocyclic group. It is an alkylene group.

[0034] In certain embodiments, the group [ka] is the formula: [ka]

[0035] In certain embodiments, Z is of the formula [ka] It is.

[0036] In certain embodiments, Y is -O-, and L 3 is an alkylene or hetero It is alkylene.

[0037] In certain embodiments, the group [ka] is the formula: [ka]

[0038] In certain embodiments, the group -X 1 R 3b is in the beta position, and R 3a Is, Al In certain embodiments, -X 1 R 3b is -OH. In certain embodiments, R 3a is hydrogen. In certain embodiments, R 3a is substituted or unsubstituted alkyl. In certain embodiments, R 6b Ha, Hello In certain embodiments, R 2 Water Plain or -OR B1 In certain embodiments, R 11b is hydrogen or -O R B1 and R 11a is hydrogen. In certain embodiments, R 11a and R 11b taken together form an oxo group. In certain embodiments, [ka] represents a single bond, and the hydrogen at C5 is in the alpha position. Leave, [ka] represents a double bond. In certain embodiments, R 19 -CH 3 It is.

[0039] In another embodiment, a pharmaceutical composition comprising a compound of the present invention and a pharma- ceutical acceptable carrier is provided. Compositions are provided. In certain embodiments, the compounds of the invention are provided in an effective amount. In certain embodiments, the compounds of the invention are provided in a therapeutically effective amount. In certain embodiments, the compounds of the invention are provided in a prophylactically effective amount.

[0040] In certain embodiments, the compounds of the present invention inhibit the negative allosteric activity of the NMDA receptor. It is provided as a neuromodulator (NAM), and is therefore useful for treating schizophrenia, depression, and bipolar disorder. Harm (I and II), schizoaffective disorder, mood disorder, anxiety disorder, personality disorder, psychosis, obsession Sexual disorders, Post-Traumatic Stress Disorder (PTSD), Autism Spectrum Disorder (ASD), Dysthymia (Mild depression, social anxiety disorder, obsessive-compulsive disorder (OCD), all pain syndromes and disorders, sleep disorders memory impairment and dementia (including Alzheimer's disease, epilepsy and any seizure disorder), Traumatic brain injury (TBI), stroke, addictive disorders (opiates and cocaine and alcohol) including rheumatoid arthritis, autism, Huntington's disease, insomnia, Parkinson's disease, withdrawal syndrome or tinnitus are useful for the prevention and / or treatment of a wide range of CNS conditions, including but not limited to For example, in one embodiment, a method of modulating an NMDA receptor is provided, the method comprising: The method includes administering an effective amount of a compound of the present invention to a subject in need thereof. In one embodiment, a method of modulating CNS activity is provided, the method comprising administering an effective amount of a compound of the invention to a subject. In yet another embodiment, the method comprises administering to a subject in need thereof a method for treating brain activation. A method for modulating excitability is provided, the method comprising administering an effective amount of a compound of the present invention to a subject in need thereof. The method includes administering the compound to a subject.

[0041] Other objects and advantages will become apparent from a consideration of the following detailed description, examples and claims. It will be apparent to one skilled in the art. In certain embodiments, for example, the following are provided: (Item 1) A method of evaluating or treating a patient, e.g., a patient having a disorder described herein, the method comprising: a) obtaining a patient sample if necessary; b) obtaining an assessment of and / or evaluating the sample for a change in the level of 24(S)-hydroxycholesterol as compared to a control standard; A method comprising: (Item 2) The method of claim 1, further comprising administering to the patient (e.g., responsive to said evaluating said sample) an effective amount of 24(S)-hydroxycholesterol or a structurally related sterol or steroid, an oxysterol, an agonist of NMDAR or a positive allosteric modulator (PAM) of NMDAR, or a compound described herein, such as a compound of formula (I). (Item 3) The method of claim 1, further comprising administering to the patient (e.g., responsive to said evaluation of said sample) an effective amount of an NMDAR antagonist or an NMDAR negative allosteric modulator (NAM). (Item 4) The method of claim 1, further comprising administering to the patient (e.g., responsive to said evaluating said sample) an effective amount of a compound that enhances (e.g., increases) the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., a compound that inhibits an enzyme that metabolizes 24(s)-hydroxycholesterol (e.g., a compound that inhibits 24-hydroxycholesterol 7 alpha-hydroxylase (CYP39)). (Item 5) The method of claim 1, further comprising administering to the patient (e.g., responsive to said evaluating said sample) an effective amount of a compound that decreases the endogenous activity or amount of 24(s)-hydroxycholesterol (e.g., a compound that activates an enzyme that produces 24(s)-hydroxycholesterol (e.g., a compound that activates cholesterol 24(S)-hydroxylase (CYP46)). (Item 6) 2. The method of claim 1, wherein the method further comprises treating the patient, wherein the patient is treated for memory impairment or is treated to improve learning. (Item 7) 2. The method of claim 1, wherein the method further comprises treating the patient for drug overdose. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0042] definition chemical definition 0 Specific functional groups and chemical terminology definitions are explained in more detail below. Chemical elements are Elementary periodic table, CAS version, Handbook of Chemistry and Physics, 75 th Ed., inside cover, and specific functional groups are generally and as set forth therein. In addition, the General Principles of Organic Chemistry, Specific functional moieties and reactivities are described in detail in Thomas Sorrell, Organic Chemistry,University Science Books,Saus alito,1999;Smith and March,March's Advan ced Organic Chemistry, 5 th Edition, John W iley & Sons, Inc., New York, 2001; Larock, Co. mprehensive Organic Transformations,VCH Publishers, Inc., New York, 1989; and Carruth ers,Some Modern Methods of Organic Synth esis,3 rd Edition,Cambridge University Pr. ess, Cambridge, 1987.

[0043] The compounds described herein may contain one or more asymmetric centers and therefore, Can exist in various isomeric forms, e.g., as enantiomers and / or diastereomers For example, the compounds described herein may exist in the form of individual enantiomers, diastereomers or It may be in the form of a racemic mixture or one or more geometric isomers. It may be in the form of a mixture of stereoisomers, including a stereoisomerically enriched mixture. The isomers were characterized by chiral high pressure liquid chromatography (HPLC) and chiral salt formation and They may be isolated from the mixture by methods known to those of skill in the art, including crystallization; or, preferably, The isomers can be prepared by asymmetric synthesis. See, for example, Jacques et al., Enantiom ers, Racemates and Resolutions(Wiley Inte rscience, New York, 1981);Wilen et al., Tetrahedr on 33:2725(1977);Eliel,Stereochemistry o f Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen,Tables of Resolving Agents and Optical Resolutions p.268(ELEliel,Ed., Univ. of Notre Dame Press, Notre Dame, IN 1 The present invention relates to the individual isomers, substantially free of other isomers, Alternatively, it further includes the compounds described herein as mixtures of various isomers. do.

[0044] When a range of values ​​is recited, it is intended to include each value and subrange within the range. For example, "C 1-6 Alkyl" is C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1 -6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2 -3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 and C 5-6 Alkyl-containing It is intended to include.

[0045] The following terms are intended to have the meanings set forth below and are used in conjunction with the present invention. The present invention is useful for the clear description and understanding of the intended scope of the present invention. The present invention describes the present invention, which may include biological compositions and methods of using such compounds and compositions. For purposes of clarity, the following terms, if present, have the following meanings unless otherwise indicated: As described herein, any of the moieties defined below may be substituted with various substituents. and that each definition may be such within their scope as set forth below. It should also be understood that all such substitute moieties are intended to be included unless otherwise stated. The term "substituted" is to be defined as set forth below. It is understood that the terms "radical" and "radicals" as used herein may be considered interchangeable. It should be further understood that the articles "a" and "an" refer to one or more than one. Many (i.e., at least one) For example, "an analogue" can be used in a Log or more than one analogue.

[0046] "Alkyl" means a straight-chain or branched, saturated hydrocarbon group having 1 to 20 carbon atoms. Radical of ("C 1-20 In some embodiments, a refers to an alkyl group. The alkyl group has 1 to 12 carbon atoms ("C 1-12 Some real In embodiments, the alkyl group has 1 to 10 carbon atoms ("C 1-10 Alkyl In some embodiments, the alkyl group has 1 to 9 carbon atoms ("C 1-9 In some embodiments, an alkyl group is a group having 1 to 8 carbon atoms. ("C 1-8 In some embodiments, the alkyl group is 1 to having seven carbon atoms ("C 1-7 In some embodiments, the alkyl The alkyl group has 1 to 6 carbon atoms (also referred to herein as "lower alkyl"). C 1-6 In some embodiments, an alkyl group is a 1 to 5 carbon atom. Has children ("C 1-5 In some embodiments, the alkyl group is 1 having 4 to 5 carbon atoms ("C 1-4 In some embodiments, the alkyl The alkyl group has 1 to 3 carbon atoms ("C 1-3 Some embodiments include In this embodiment, the alkyl group has 1 to 2 carbon atoms ("C 1-2 "Alkyl" In some embodiments, the alkyl group has one carbon atom ("C 1 Alkyl In some embodiments, the alkyl group has 2 to 6 carbon atoms ("C 2 -6 "Alkyl"). C 1-6 Examples of alkyl groups include methyl (C 1 ), ethyl (C 2 ) , n-propyl (C 3 ), isopropyl (C 3 ), n-Butyl (C 4 ), tert-Butyl Lu (C 4 ), sec-Butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ) , 3-pentanyl (C 5 ), Amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2- Butanyl (C 5 ), tertiary amyl (C 5 ) and n-hexyl (C 6 ) can be mentioned. Further examples of alkyl groups include n-heptyl (C 7), n-octyl (C 8 ) are listed. Unless otherwise specified, each instance of an alkyl group is independently optionally substituted. is unsubstituted ("unsubstituted alkyl") or has one or more For example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. ("substituted alkyl"). In certain embodiments, the alkyl group is an unsubstituted C 1 -10 Alkyl (e.g., -CH 3 In certain embodiments, the alkyl group is is a substitution C 1-10 Alkyl. A common abbreviation for alkyl is Me(-CH 3 ), Et(-CH 2 CH 3 ), iPr(-CH(CH 3 ) 2 ), nPr(-CH 2 CH 2 CH 3 ), n-Bu(-CH 2 CH 2 CH 2 CH 3 ) or i-Bu(-CH 2 CH(C H 3 ) 2 ) are mentioned.

[0047] As used herein, "alkylene," "alkenylene," and "alkynylene" are The terms "alkyl", "alkenyl" and "alkynyl" refer to divalent radicals of alkyl, alkenyl and alkynyl groups, respectively. The range or number of carbons refers to certain "alkylene," "alkenylene," and "aryl." When provided for a "alkynylene" group, the range or number refers to the number of carbon atoms in a linear divalent carbon chain. It is understood that the terms "alkylene", "alkenylene" and "alkylene" refer to the range or number of carbon atoms in the alkylene group. " and "alkynylene" groups refer to one or more alkyl groups as described herein. It may be substituted or unsubstituted.

[0048] "Alkylene" means an alkyl group from which two hydrogens have been removed to provide a divalent radical. The term "alkylene group" refers to a substituted or unsubstituted alkylene group, which may be substituted or unsubstituted. , methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), propylene (-CH 2 CH 2 CH 2 -), butylene (-CH 2 CH 2 CH 2 CH 2 -), pentylene (-CH 2 CH 2 CH 2 CH 2 CH 2 -), hexylene (-CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 -) Exemplary substituted alkylene groups include, but are not limited to, one or more As an alkylene group substituted with an alkyl (methyl) group or more, substituted methyl groups are N(-CH(CH 3 )-, (-C(CH 3 ) 2 -), substituted ethylene (-CH(CH 3 ) C H 2 -, -CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 -, -CH 2 C(CH 3 ) 2-), substituted propylene (-CH(CH 3 )CH 2 CH 2 -, -CH 2 CH(CH 3 ) C H 2 -, -CH 2 CH 2 CH(CH 3 )-, -C(CH 3 ) 2 CH 2 CH 2 -, -CH 2 C(CH 3 ) 2 CH 2 -, -CH 2 CH 2 C(CH 3 ) 2 -) and others are listed. Not limited to.

[0049] "Alkenyl" means an alkyl group having 2 to 20 carbon atoms and one or more carbon-carbon bilayers. Straight-chain or is a branched-chain hydrocarbon radical ("C 2-20 Some In one embodiment, the alkenyl group has 2 to 10 carbon atoms ("C 2-10 a In some embodiments, the alkenyl group has 2 to 9 carbon atoms. ("C 2-9 In some embodiments, the alkenyl group is selected from the group consisting of 2 to 10 alkyl groups. having 8 carbon atoms ("C 2-8 In some embodiments, alkenyl is The alkenyl group has 2 to 7 carbon atoms ("C 2-7 Some alkenyls. In embodiments, the alkenyl group has 2 to 6 carbon atoms ("C 2-6 Alkenyl In some embodiments, the alkenyl group has 2 to 5 carbon atoms (" C 2-5 In some embodiments, the alkenyl group is an alkyl group having 2 to 4 carbon atoms. Having elementary atoms ("C 2-4 In some embodiments, the alkenyl The group has 2 to 3 carbon atoms ("C 2-3 In some embodiments, In the present invention, the alkenyl group has two carbon atoms ("C 2 alkenyl). Further carbon-carbon double bonds may be internal (e.g., 2-butenyl) or may be present at the end (e.g., 1-butenyl). 2-4 Examples of alkenyl groups are ethoxylated alkenyl groups. Tennille (C 2 ), 1-propenyl (C 3 ), 2-propenyl (C 3 ), 1-butenyl (C 4 ), 2-butenyl (C 4 ), butadienyl (C 4 ) etc. 2-6 Arke Examples of yl groups include the above-mentioned C 2-4 Alkenyl groups, as well as pentenyl (C 5 ),pen Tadienyl (C 5 ), hexenyl (C 6 Further examples of alkenyl include: As for heptenyl (C 7 ), octenyl (C 8 ), octatrienyl (C 8 ) are listed. Unless otherwise specified, each instance of an alkenyl group is independently optionally substituted. substituted, i.e., unsubstituted ("unsubstituted alkenyl") or one or more of More than one substituent, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In certain embodiments, an alkenyl group is unsubstituted ("substituted alkenyl"). exchange C 2-10 In certain embodiments, the alkenyl group is a substituted C 2-10 It is alkenyl.

[0050] "Alkenylene" means an alkynyl group in which two hydrogens have been removed to provide a divalent radical. "N" refers to an aryl group, which may be substituted or unsubstituted. Exemplary unsubstituted divalent Alkenylene groups include ethenylene (-CH=CH-) and propenylene (e.g., -CH=CHCH 2 -, -CH 2 -CH=CH-) Exemplary substituted alkenylene groups include, for example, one or more alkyl(methyl) groups. The alkenylene group substituted with ethylene (-C(CH 3 )=CH-, -CH =C(CH 3 )-), substituted propylene (e.g., -C(CH 3 )=CHCH 2 -, -CH =C(CH 3 )CH 2 -, -CH=CHCH(CH 3 )-, -CH=CHC(CH 3 ) 2 -, -CH(CH 3 )-CH=CH-, -C(CH 3 ) 2 -CH=CH-, -CH 2 -C (CH 3 )=CH-, -CH 2 -CH=C(CH 3 )-) are some examples, but are not limited to these. Not determined.

[0051] "Alkynyl" means an alkyl group having 2 to 20 carbon atoms and one or more carbon-carbon triple bonds. bonds (e.g., 1, 2, 3 or 4 triple bonds) and optionally one or more of them. Straight or branched chains with more than one double bond (e.g., 1, 2, 3 or 4 double bonds) The radical of the hydrocarbon group ("C 2-20 It refers to one or more of the An alkynyl group having more than one triple bond and one or more double bonds is called an "ene In some embodiments, the alkynyl group is an alkynyl group having 2 to 10 alkynyl groups. ("C 2-10 In some embodiments, alkynyl is The quinyl group has 2 to 9 carbon atoms ("C 2-9 Some implementations include In the form, the alkynyl group has 2 to 8 carbon atoms ("C 2-8 Alkynyl" In some embodiments, the alkynyl group has 2 to 7 carbon atoms ("C 2-7 In some embodiments, the alkynyl group is an alkynyl group having 2 to 6 carbon atoms. atoms ("C 2-6 In some embodiments, the alkynyl group has 2 to 5 carbon atoms ("C 2-5 In some embodiments, In the present invention, an alkynyl group has 2 to 4 carbon atoms ("C 2-4 "Alkynyl"). In some embodiments, the alkynyl group has 2 to 3 carbon atoms ("C 2-3 a In some embodiments, the alkynyl group has 2 carbon atoms. ("C 2 alkynyl). One or more carbon-carbon triple bonds are present internally. It can be either equimolar (e.g., 2-butynyl) or terminal (e.g., 1-butynyl). 2-4 Examples of alkynyl groups include ethynyl (C 2 ), 1-propynyl (C 3 ), 2-P Ropinil (C 3 ), 1-butynyl (C 4 ), 2-butynyl (C 4 ) are some of the Not limited to these. 2-6 Examples of alkenyl groups include the above-mentioned C 2-4 Alkynyl group , and pentynyl (C 5 ), Hexynyl (C 6 ) and the like. Examples of such aryl groups include heptynyl (C 7 ), Octynyl (C 8 ) and others. Unless specified, each instance of an alkynyl group is independently optionally substituted, i.e. , unsubstituted ("unsubstituted alkynyl") or with one or more substituents; For example, the group is substituted with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent ("substituted group"). In certain embodiments, the alkynyl group is an unsubstituted C 2-10 a In certain embodiments, the alkynyl group is a substituted C 2-10 Alki It's Nil.

[0052] "Alkynylene" means a straight chain in which two hydrogens have been removed to provide a divalent radical.

[0043] An exemplary divalent alkynyl group is The alkenylene group includes substituted or unsubstituted ethynylene, substituted or unsubstituted propynylene, etc. These include, but are not limited to:

[0053] The term "heteroalkyl" as used herein refers to one or more heterocyclic groups in a parent chain. More than (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, The term "alkyl group" refers to an alkyl group as defined herein that further contains an alkyl group (such as boron, silicon, phosphorus). refers to a heteroatom having one or more heteroatoms spaced apart from adjacent carbon atoms in a parent carbon chain. Interposed between the carbon atoms and / or one or more heteroatoms are carbon In certain embodiments, the bond is inserted between the atom and the parent molecule, i.e., between the attachment points. In this context, a heteroalkyl group is a group having 1 to 10 carbon atoms and 1, 2, 3 or 4 heteroalkyl groups. Saturated groups with 1 atom ("hetero C" 1-10 In some implementations, In the form, the heteroalkyl group is a group having 1 to 9 carbon atoms and 1, 2, 3 or 4 Saturated groups containing heteroatoms ("hetero C 1-9 In some embodiments, In the formula, the heteroalkyl group is a group having 1 to 8 carbon atoms and 1, 2, 3 or 4 heteroalkyl groups. Saturated groups with 1 atom ("hetero C" 1-8 In some embodiments, In this case, the heteroalkyl group is a group having 1 to 7 carbon atoms and 1, 2, 3 or 4 heteroatoms. Saturated groups with heterocyclic groups ("heterocyclic 1-7 In some embodiments, The heteroalkyl group has 1 to 6 carbon atoms and 1, 2 or 3 heteroatoms. Groups ("Hetero C 1-6 In some embodiments, heteroaryl is a heteroaryl group. The alkyl group is a saturated group having 1 to 5 carbon atoms and 1 or 2 heteroatoms ("heteroatoms"). RO C 1-5 In some embodiments, the heteroalkyl group is 1 A saturated group having up to 4 carbon atoms and 1 or 2 heteroatoms ("hetero C 1-4 a In some embodiments, the heteroalkyl group is a 1 to 3 carbon A saturated group having one heteroatom and one heteroatom ("hetero C 1-3 It is "alkyl" In some embodiments, a heteroalkyl group contains 1 to 2 carbon atoms and one heteroalkyl group. Saturated groups with 1 atom ("hetero C" 1-2 In some embodiments, In this regard, a heteroalkyl group is a saturated group having one carbon atom and one heteroatom (" Hetero C 1 In some embodiments, the heteroalkyl group is 2 Saturated groups having up to 6 carbon atoms and 1 or 2 heteroatoms ("hetero C 2-6 a Unless otherwise specified, each instance of a heteroalkyl group is independently a non- Heteroalkyl may be substituted ("unsubstituted heteroalkyl") or may have one or more substituents. In certain embodiments, heteroalkyl is substituted ("substituted heteroalkyl"). The group is an unsubstituted heteroC 1-10 In certain embodiments, heteroaryl is alkyl. The alkyl group is a substituted heteroC 1-10 It is an alkyl.

[0054] The term "heteroalkenyl" as used herein means one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, refers to an alkenyl group as defined herein further containing an atom (silicon, phosphorus), wherein the one or more heteroatoms are adjacent carbon atoms in the parent carbon chain. Interposed between and / or one or more heteroatoms are carbon atoms and In certain embodiments, the carboxyl group is inserted between the parent molecule, i.e., between the attachment points. Heteroalkenyl groups are groups having 2 to 10 carbon atoms, at least one double bond and one, Groups containing 2, 3 or 4 heteroatoms ("hetero C 2-10 alkenyl) In some embodiments, a heteroalkenyl group is a heteroaryl group having 2 to 9 carbon atoms, at least At least one double bond and 1, 2, 3 or 4 heteroatoms ("hetero C" 2 -9 In some embodiments, the heteroalkenyl group is selected from the group consisting of 2 to 8 heteroaryl groups. Contains carbon atoms, at least one double bond and 1, 2, 3 or 4 heteroatoms ("Hetero C 2-8 In some embodiments, the heteroalkenyl group It has 2 to 7 carbon atoms, at least one double bond and 1, 2, 3 or 4 heterocyclic groups. Hetero C 2-7 In some embodiments, the heteroaryl group is Alkenyl groups have 2 to 6 carbon atoms, at least one double bond and 1, 2 or 3 alkyl groups. 3 heteroatoms ("hetero C 2-6 In some embodiments, In the present invention, a heteroalkenyl group has 2 to 5 carbon atoms, at least one double bond and one or two heteroatoms ("hetero C 2-5 alkenyl). In certain embodiments, a heteroalkenyl group has 2 to 4 carbon atoms, at least one double bond, and and 1 or 2 heteroatoms ("hetero C 2-4 alkenyl). In embodiments, a heteroalkenyl group has 2 to 3 carbon atoms, at least one double bond, bond and one heteroatom ("hetero C 2-3 Some alkenyls. In embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and one or two heteroatoms ("hetero C 2-6 alkenyl). Unless specified, each instance of a heteroalkenyl group is independently unsubstituted (see, for example, "unsubstituted heteroalkenyl"). or substituted with one or more substituents ("substituted heptyl"); In certain embodiments, a heteroalkenyl group is an unsubstituted heteroalkenyl. RO C 2-10 In certain embodiments, a heteroalkenyl group is Substituted Hetero C 2-10 It is alkenyl.

[0055] The term "heteroalkynyl" as used herein refers to one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, Refers to an alkynyl group as defined herein further containing an alkynyl atom (silicon, phosphorus), wherein the one or more heteroatoms are adjacent carbon atoms in the parent carbon chain. Interposed between and / or one or more heteroatoms are carbon atoms and In certain embodiments, the carboxyl group is inserted between the parent molecule, i.e., between the attachment points. Heteroalkynyl groups are groups having 2 to 10 carbon atoms, at least one triple bond and one, Groups containing 2, 3 or 4 heteroatoms ("hetero C 2-10 "alkynyl" In some embodiments, the heteroalkynyl group is an aryl group having from 2 to 9 carbon atoms, at least At least one triple bond and 1, 2, 3 or 4 heteroatoms ("hetero C"). 2 -9 In some embodiments, the heteroalkynyl group is an alkynyl group having 2 to 8 Contains carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms ("Hetero C 2-8 In some embodiments, the heteroalkynyl group It has 2 to 7 carbon atoms, at least one triple bond and 1, 2, 3 or 4 heterocyclic groups. Hetero C 2-7 In some embodiments, the heteroaryl group is alkynyl. Alkynyl groups have 2 to 6 carbon atoms, at least one triple bond and 1, 2 or 3 alkyl groups. 3 heteroatoms ("hetero C 2-6 In some embodiments, In the present invention, a heteroalkynyl group has 2 to 5 carbon atoms, at least one triple bond, and or two heteroatoms ("hetero C 2-5 alkynyl). In some embodiments In certain embodiments, a heteroalkynyl group has 2 to 4 carbon atoms, at least one triple bond, and and 1 or 2 heteroatoms ("hetero C 2-4 alkynyl). In embodiments, a heteroalkynyl group contains 2 to 3 carbon atoms, at least one triplet, bond and one heteroatom ("hetero C 2-3 Some In embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and one or two heteroatoms ("hetero C 2-6 "alkynyl"). Unless specified, each instance of a heteroalkynyl group is independently unsubstituted (see, for example, "unsubstituted heteroalkynyl"). or substituted with one or more substituents ("substituted aryl group"). In certain embodiments, a heteroalkynyl group is an unsubstituted heteroalkynyl group. RO C 2-10 In certain embodiments, a heteroalkynyl group is Substituted Hetero C 2-10 It is alkynyl.

[0056] As used herein, "alkylene," "alkenylene," and "alkynylene" "Heteroalkylene", "heteroalkenylene" and "heteroalkynylene" are alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl and The term refers to a divalent radical of a heteroalkynyl or heteroaryl group. "Alkylene", "alkenylene", "alkynylene", "heteroalkylene", "hetero When provided for an "alkenylene" or "heteroalkynylene" group, the range or The numbers are understood to refer to the range or number of carbons in a linear divalent carbon chain. "Alkylene", "alkenylene", "alkynylene", "heteroalkylene", "hetero "Heteroalkenylene" and "heteroalkynylene" groups are defined as any one of the 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 29, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 It may be substituted with one or more substituents or it may be unsubstituted.

[0057] "Aryl" means an aromatic ring system having 6 to 14 ring carbon atoms and 0 aryl groups. Monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic rings containing heteroatoms systems (e.g., with 6, 10, or 14 π electrons shared in a ring arrangement) Radical ("C 6-14In some embodiments, aryl refers to A ring group has six ring carbon atoms ("C 6 aryl"; for example, phenyl). In some embodiments, an aryl group has 10 ring carbon atoms ("C 10 Aryl "; for example, naphthyl, such as 1-naphthyl and 2-naphthyl). In some embodiments, the aryl group has 14 ring carbon atoms ("C 14 aryl"; e.g. "Aryl" means a group containing one or more aryl rings as defined above. Also included are ring systems fused to more than one carbocyclyl or heterocyclyl group, where The radical or point of attachment is on an aryl ring, in which case the number of carbon atoms is The number of carbon atoms in the aryl ring system will be indicated subsequently. Exemplary aryl groups include acetonitrile, ... Anthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzo Zene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, Hexalene, as-indacene, s-indacene, indane, indene, naphthalene, o Cutacene, Octaphene, Octalene, Ovalene, Penta-2,4-diene, Pentacene , pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, prey Obtained from adenine, pyrene, pyranthrene, rubicene, triphenylene and trinaphthalene In particular, aryl groups include, but are not limited to, phenyl, naphthyl ... Unless otherwise specified, aryl, indenyl and tetrahydronaphthyl are included. Each instance of a alkyl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted"). or substituted with one or more substituents ("substituted aryl"); In certain embodiments, the aryl group is an unsubstituted C 6-14 Aryl In certain embodiments, the aryl group is a substituted C 6-14 It is aryl.

[0058] In certain embodiments, halo, C 1 -C 8 Alkyl, C 1 -C 8 Haloalkyl, Cyano, Hydroxy, C 1 -C 8 one of the groups selected from alkoxy and amino or more substituted aryl groups.

[0059] Representative examples of substituted aryl are as follows: [ka] In the formula, R 56 and R 57 may be hydrogen, and one of R 56 and R 57 At least one of 1 -C 8 Alkyl, C 1 -C 8 HelloA alkyl, 4-10 membered heterocyclyl, alkanoyl, C 1 -C 8 Alkoxy, Heteroaryl alkyloxy, alkylamino, arylamino, heteroarylamino, NR 58 COR 59 , N.R. 58 SOR 59 NR 58 SO 2 R 59 , COO alkyl, COO aryl, C ONR 58 R 59 ,CONR 58 OR 59 , N.R. 58 R 59 , S.O. 2 NR 58 R 59 , S -Alkyl, SOalkyl, SO 2 Alkyl, S aryl, SO aryl, SO 2 Ally or R 56 and R 57 is connected to 5 to 8 atoms, N, O or S, It may form a cyclic ring (saturated or unsaturated). 60 and R 61 are independently hydrogen, C 1 -C 8 Alkyl, C 1 -C 4 Haloalkyl, C 3 -C 10 Cycloalkyl, 4 to 10 members Heterocyclyl, C 6 -C 10 Aryl, Substituted C 6 -C 10 Aryl, 5-10 membered hetero It is aryl or a substituted 5-10 membered heteroaryl.

[0060] Other representative aryl groups having a fused heterocyclyl group include the following: [ka] wherein each W is C(R 66 ) 2 , N.R. 66 , O, and S; each Y is carbonyl, NR 66 , O and S; R 66are independently hydrogen, C 1 -C 8 Alkyl, C 3 -C 10 Cycloalkyl, 4-10 membered heterocyclyl, C 6 -C 1 0 aryl and 5-10 membered heteroaryl.

[0061] A "fused aryl" is an aryl group having two of its ring carbons bonded to a second aryl ring or an aryl ring, a carbocyclyl ring, or a heterocyclyl ring; This refers to the

[0062] "Aralkyl" is a subset of alkyl and aryl, as defined herein. and optionally substituted with an optionally substituted aryl group. It refers to an alkyl group.

[0063] "Heteroaryl" means an aromatic ring system having 1 to 4 ring carbon atoms and 1 to 4 ring heteroatoms. 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring systems with heteroatoms (e.g., This refers to a radical with 6 or 10 π electrons shared side-by-side. wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-10 membered In heteroaryl groups containing one or more nitrogen atoms, The attachment point may be a carbon atom or a nitrogen atom, if valence permits. The cyclic ring system may contain one or more heteroatoms in one or both rings. "Heteroaryl" refers to a group containing one or more heteroaryl rings as defined above. and ring systems fused to a carbocyclyl or heterocyclyl group, where the attachment The dots may be present on a heteroaryl ring, in which case the number of ring members is determined by the The number of ring members of the heterocyclic ring system will be noted below. "Heteroaryl" includes any of the groups defined above. Also included are ring systems in which such heteroaryl rings are fused to one or more aryl groups; wherein the point of attachment is on an aryl or heteroaryl ring, In this case, the number of ring members is the number of ring members in a fused (aryl / heteroaryl) ring system. Indicate the number of rings in a bicyclic heteroaryl group (e.g., aryls, The point of attachment is either ring, i.e., heteroyl, quinolinyl, carbazolyl, etc. A ring having a heteroatom (e.g., 2-indolyl) or a ring not containing a heteroatom (e.g., 5-indolyl).

[0064] In some embodiments, the heteroaryl group is a ring carbon provided as an aromatic ring system. A 5-10 membered aromatic ring system having an atom and 1-4 ring heteroatoms, where each heteroatom is The heteroatoms are independently selected from nitrogen, oxygen and sulfur ("5- to 10-membered heteroaryls"). In some embodiments, the heteroaryl group is provided as an aromatic ring system. is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5- to 8-membered heteroatoms"). In some embodiments, the heteroaryl group is provided as an aromatic ring system. A 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5- to 6-membered heteroatoms"). In some embodiments, the 5- to 6-membered heteroaryl is a nitrogen, acid, In some embodiments, the ring heteroatoms are selected from nitrogen and sulfur. In the above, the 5-6 membered heteroaryl is a heteroaryl having 1-2 ring members selected from nitrogen, oxygen and sulfur. In some embodiments, the 5-6 membered heteroaryl has a nitrogen, acid, has one ring heteroatom selected from nitrogen and sulfur. Each instance of an aryl group is independently optionally substituted, i.e., unsubstituted ( "Unsubstituted heteroaryl") or substituted with one or more substituents ( "substituted heteroaryl"). In certain embodiments, a heteroaryl group is unsubstituted In certain embodiments, the heteroaryl group is It is a substituted 5-14 membered heteroaryl.

[0065] Exemplary 5-membered heteroaryl groups containing one heteroatom include pyrrolyl, furanyl, Examples containing two heteroatoms include, but are not limited to, phenyl and thiophenyl. Exemplary 5-membered heteroaryl groups include imidazolyl, pyrazolyl, oxazolyl, isopropyl, ethyl ... Examples include, but are not limited to, xazolyl, thiazolyl and isothiazolyl. Exemplary 5-membered heteroaryl groups containing 5 heteroatoms include triazolyl, oxazolyl, Examples include, but are not limited to, azolyl and thiadiazolyl. 4 heteroatoms Exemplary 5-membered heteroaryl groups include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include pyridinyl. Exemplary 6-membered heteroaryls containing two heteroatoms include, but are not limited to, Examples of alkyl groups include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing 3 or 4 heteroatoms include: These include, but are not limited to, triazinyl and tetraazinyl, respectively. Exemplary 7-membered heteroaryl groups containing heteroatoms include azepinyl, oxepinyl, and Exemplary 5,6-bicyclic heteroaryls include, but are not limited to, thiepinyl and thiepinyl. The aryl group includes indolyl, isoindolyl, indazolyl, benzotriazolyl, Benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzisofuranyl, Benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazol Zolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, indolizine Exemplary 6,6-bicyclic heterocyclic rings include, but are not limited to, phenyl and purinyl. The aryl group includes naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, Examples of such aryl groups include cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. Not limited to.

[0066] Representative examples of heteroaryls include the following: [ka] wherein each Y is carbonyl, N, NR 65 , O and S; R 6 5 are independently hydrogen, C 1 -C 8 Alkyl, C 3 -C 10 Cycloalkyl, 4 to 10 members Heterocyclyl, C 6 -C 10 aryl and 5-10 membered heteroaryl.

[0067] "Heteroaralkyl" refers to an alkyl and heteroaryl group, as defined herein. substituted by an optionally substituted heteroaryl group. It refers to an optionally substituted alkyl group.

[0068] "Carbocyclyl" or "carbocyclic" means a ring system having 3 to 10 ring carbon atoms ( "C 3-10 "Carbocyclyl" and non-aromatic cyclic carbonyls with 0 heteroatoms In some embodiments, the carbocyclyl group is a 3 ~8 ring carbon atoms ("C 3-8 In some embodiments, In this case, the carbocyclyl group has 3 to 6 ring carbon atoms ("C 3-6 Carbocyclyl In some embodiments, the carbocyclyl group has 3 to 6 ring carbon atoms. ("C 3-6 In some embodiments, the carbocyclyl group is , having 5 to 10 ring carbon atoms ("C 5-10 Carbocyclyl). Exemplary C 3- 6 The carbocyclyl group is cyclopropyl (C 3 ), cyclopropenyl (C 3 ), S Chlorobutyl (C 4 ), cyclobutenyl (C 4 ), cyclopentyl (C 5 ), cyclopentene Nil (C 5 ), cyclohexyl (C 6 ), cyclohexenyl (C 6), cyclohexadiene Nil (C 6 ) and the like. Exemplary C 3-8 Carbocycli The above-mentioned C 3-6 Carbocyclyl groups, as well as cycloheptyl (C 7 ), S Chloheptenyl (C 7 ), cycloheptadienyl (C 7 ), cycloheptatrienyl (C 7 ), cyclooctyl (C 8 ), cyclooctenyl (C 8 ), bicyclo[2.2.1]he Butanyl (C 7 ), bicyclo[2.2.2]octanyl (C 8 ) are listed, but this Exemplary C 3-10 The carbocyclyl group is the above-mentioned C 3-8 Cal The bocyclyl group, as well as the cyclononyl (C 9 ), cyclononenyl (C 9 ), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C 9 ), De Cahydronaphthalenyl (C 10 ), spiro[4.5]decanyl (C 10 ) etc. As the above examples illustrate, in certain embodiments, A carbocyclyl group can be monocyclic ("monocyclic carbocyclyl") or fused. Ring systems, bridged ring systems or spiro ring systems (e.g., bicyclic systems) (see "Bicyclic Carbocyclic Systems"). "Carbocyclyl" can be saturated or partially unsaturated. wherein the carbocyclyl ring as defined above is substituted with one or more aryl groups or Also included are ring systems fused to heteroaryl groups, where the point of attachment is on the carbocyclyl ring. In such cases, the number of carbons continues to refer to the number of carbons in the carbocyclic ring system. Unless otherwise specified, each instance of a carbocyclyl group is independently optionally substituted; That is, it may be unsubstituted ("unsubstituted carbocyclyl") or may contain one or more In certain embodiments, the carbocyclyl is substituted with a substituent that can be selected from the group consisting of aryl, ... The rubocyclyl group is an unsubstituted C 3-10 In certain embodiments, The carbocyclyl group is a substituted C 3-10 It is a carbocyclyl.

[0069] In some embodiments, a "carbocyclyl" has from 3 to 10 ring carbon atoms. A monocyclic saturated carbocyclyl group ("C 3-10 Some are cycloalkyl. In embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms ("C 3-8 S In some embodiments, the cycloalkyl group has 3 to 6 ring carbon atoms. Having elementary atoms ("C 3-6 In some embodiments, the cycloalkyl The alkyl group has 5 to 6 ring carbon atoms ("C 5-6 "Cycloalkyl"). In some embodiments, the cycloalkyl group has 5 to 10 ring carbon atoms ("C 5 -10 "Cycloalkyl"). C 5-6 Examples of cycloalkyl groups include cyclopentyl ( C 5 ) and cyclohexyl (C 5 ) are listed. C 3-6 Examples of cycloalkyl groups include For details, see C above.5-6 Cycloalkyl groups, as well as cyclopropyl (C 3 ) and Cyclo Butyl (C 4 ) are listed. C 3-8 Examples of cycloalkyl groups include the above-mentioned C 3-6 Cycloalkyl groups, as well as cycloheptyl (C 7 ) and cyclooctyl (C 8 ) was mentioned Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted. ("unsubstituted cycloalkyl") or substituted with one or more substituents. ("substituted cycloalkyl"). In certain embodiments, the cycloalkyl group is non- substitution C 3-10 In certain embodiments, the cycloalkyl group is is a substitution C 3-10 It is cycloalkyl.

[0070] "Heterocyclyl" or "heterocyclic" means a ring system having ring carbon atoms and 1 to 4 ring heteroatoms. refers to a 3- to 10-membered non-aromatic ring system radical having heteroatoms, where each heteroatom is Independently selected from nitrogen, oxygen, sulfur, boron, phosphorus and silicon ("3 to 10-membered In heterocyclyl groups containing one or more nitrogen atoms The point of attachment may be a carbon atom or a nitrogen atom, when valence permits. The heterocyclic group can be monocyclic ("monocyclic heterocyclyl") or can be a fused ring system, a cyclic heterocyclic group, or a cyclic heterocyclic group. It may be a bridged or spiro ring system, e.g., a bicyclic system (see "bicyclic heterocyclyl"). "), which may be saturated or partially unsaturated. Heterocyclyl bicyclic ring systems include One or both rings may contain one or more heteroatoms. " includes a heterocyclyl ring as defined above, which is substituted with one or more carbocyclyl rings. ring systems fused to a carbocyclyl group (where the point of attachment is on the carbocyclyl ring or on the heterocyclyl ring) ring) or one or more heterocyclyl rings as defined above ring systems fused to an aryl or heteroaryl group, where the point of attachment is the heteroaryl In such cases, the number of ring members is reduced by 1. The number of ring members in the ring system will be noted subsequently. Unless otherwise specified, heterocyclyl Each instance of is independently optionally substituted, i.e., unsubstituted ("unsubstituted heterocyclic group"). or substituted with one or more substituents ("substituted heterocyclyl"); In certain embodiments, the heterocyclyl group is an unsubstituted 3- to 10-membered heterocyclyl. In certain embodiments, the heterocyclyl group is 3 to 10 substituted It is a membered heterocyclyl.

[0071] In some embodiments, a heterocyclyl group has from 1 to 4 ring carbon atoms and A 5-10 membered non-aromatic ring system having heteroatoms, where each heteroatom is independently Nitrogen, oxygen, sulfur, boron, phosphorus and silicon ("5- to 10-membered heterocyclic In some embodiments, a heterocyclyl group has 1 to 4 ring carbon atoms and is a 5-8 membered non-aromatic ring system having ring heteroatoms, where each heteroatom is independently and selected from nitrogen, oxygen and sulfur ("5- to 8-membered heterocyclyl"). In one embodiment, the heterocyclyl group contains ring carbon atoms and 1 to 4 ring heteroatoms. wherein each heteroatom is independently selected from nitrogen, oxygen, and and sulfur ("5- to 6-membered heterocyclyl"). 5-6 membered heterocyclyl is a heterocyclic ring having 1-3 ring heteroatoms selected from nitrogen, oxygen and sulfur. In some embodiments, the 5- to 6-membered heterocyclyl has nitrogen, oxygen, and and sulfur. , 5-6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen and sulfur has.

[0072] Exemplary 3-membered heterocyclyl groups containing one heteroatom include azirdinyl, oxydiphenyl, phenyl ... Examples of heteroatoms include, but are not limited to, silanyl and thiolenyl. Exemplary 4-membered heterocyclyl groups include azetidinyl, oxetanyl and thietanyl. Exemplary 5-membered heterocyclyls containing one heteroatom include, but are not limited to, Examples of the aryl group include tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, Dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2,5-dithiophenyl Exemplary 5-membered heterocyclic rings containing two heteroatoms include, but are not limited to, The acrylic group includes dioxolanyl, oxasulfuranyl, disulfuranyl and oxa. Examples of heteroatoms include, but are not limited to, zolidin-2-one. Representative 5-membered heterocyclyl groups include triazolinyl, oxadiazolinyl and thiadiazole. Exemplary 6-membered alkyl groups containing one heteroatom include, but are not limited to, azolinyl. Heterocyclyl groups include piperidinyl, tetrahydropyranyl, and dihydropyridinyl. Exemplary heteroatoms containing two heteroatoms include, but are not limited to, thianyl and thianyl. Examples of the 6-membered heterocyclyl group include piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclic rings containing two heteroatoms include, but are not limited to, Acryl groups include, but are not limited to, triazinanyl. Exemplary seven-membered heterocyclyl groups containing one heteroatom include azepanyl. , oxepanyl and thiepanyl. Exemplary 8-membered heterocyclyl groups containing aryl groups include azocanyl, oxecanyl, and thiocanyl. Canyl. 6 Exemplary 5-Membered Compounds Fused to Aryl Rings Heterocyclyl groups (also referred to herein as 5,6-bicyclic heterocyclic rings) include i) 5,6-bicyclic heterocyclic rings; Indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, Examples of aryl rings include, but are not limited to, benzoxazolinonyl. Exemplary 6-membered heterocyclyl groups (also referred to herein as 6,6-bicyclic heterocyclic rings) are: ) include tetrahydroquinolinyl, tetrahydroisoquinolinyl, etc. Not limited to these.

[0073] Particular examples of heterocyclyl groups are the following illustrative examples: [ka] where each W is a CR 67 , C(R 67 ) 2 , N.R. 67 , O and S Each Y is NR 67 , O and S; R 67 are independently hydrogen, C 1 -C 8 Alkyl, C 3 -C 10 Cycloalkyl, 4-10 membered heterocyclyl, C 6 -C 10 a These heterocyclyl rings are acyl, acyl, and 5-10 membered heteroaryl. Amino, acyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonyl Amino, amino, substituted amino, aminocarbonyl (carbamoyl or amido), aminocarbonyl carbonylamino, aminosulfonyl, sulfonylamino, aryl, aryloxy, Dido, carboxyl, cyano, cycloalkyl, halogen, hydroxy, keto, nitro, Thiol, -S-alkyl, -S-aryl, -S(O)-alkyl, -S(O)-aryl , -S(O) 2 -Alkyl and -S(O) 2 -aryl It may be optionally substituted with one or more groups. Substituents include, for example, lactam derivatives. Contains carbonyl or thiocarbonyl, providing conductors and urea derivatives.

[0074] "Hetero," when used to describe a compound or a group present on a compound, One or more carbon atoms in the compound or group may be replaced by nitrogen, oxygen or sulfur. Hetero means replaced by 1 to 5 heteroatoms, especially 1 to 5 heteroatoms. Any of the hydrocarbyl groups described above, such as alkyl, having three heteroatoms. (e.g., heteroalkyl, cycloalkyl, e.g., heterocyclyl, Aryl, for example, heteroaryl; cycloalkenyl, for example, cycloheteroalkenyl; (e.g., ru).

[0075] "Acyl" means the radical -C(O)R 20 Here, R 20 is hydrogen, Substituted or unsubstituted aryl as defined herein. alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted Substituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl. "Alkanoyl" refers to R 20 More than hydrogen The other group is the acyl group. Representative acyl groups are formyl (-CHO), acetonitrile (-CHO), Chill (-C(=O)CH 3 ), cyclohexylcarbonyl, cyclohexylmethylcarbonyl nyl, benzoyl (-C(=O)Ph), benzylcarbonyl (-C(=O)CH 2 Ph ), -C(O)-C 1 -C 8 Alkyl, -C(O)-(CH 2 ) t (C 6 -C 10 Ally -C(O)-(CH 2 ) t (5-10 membered heteroaryl), -C(O)-(CH 2 ) t (C 3 -C 10 Cycloalkyl) and -C(O)-(CH 2 ) t (4~10 members and the like. Examples of the aryl group include, but are not limited to, aryloxyalkyl (wherein t is an integer of 0 to 4). In certain embodiments, R 21 is a halo or hydroxy substituted C 1 -C 8 Alkyl; or C 3 -C 10Cycloalkyl, 4-10 membered heterocyclyl, C 6 -C 10 Aryl, arylalkyl, 5-10 membered heteroaryl or heteroaryl each of which is an unsubstituted C 1 -C 4 Alkyl, halo, unsubstituted C 1 -C 4 Alkoxy, unsubstituted C 1 -C 4 Haloalkyl, unsubstituted C 1 -C 4 Hydroxyalkyl or unsubstituted C 1 -C 4 Substituted with haloalkoxy or hydroxy.

[0076] "Acylamino" refers to the radical -NR 22 C(O)R 23 Here, R 22 and each instance of R23 is independently selected from hydrogen, substituted or unsubstituted, as defined herein. or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl , substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or is unsubstituted aryl or substituted or unsubstituted heteroaryl, or R 22 teeth , and amino protecting groups. Exemplary "acylamino" groups include formylamino, acetylamino, and acetylamino. cyclohexylcarbonylamino, cyclohexylmethyl-carbonylamino , benzoylamino and benzylcarbonylamino. Certain exemplary "acylamino" groups are -NR 24 C(O)-C 1 -C 8 Alkyl, -NR 24 C(O)-(CH 2) t (C 6 -C 10 Aryl), -NR 24 C(O)-( CH 2 ) t (5-10 membered heteroaryl), -NR 24 C(O)-(CH 2 ) t (C 3 - C 10 Cycloalkyl) and -NR 24 C(O)-(CH 2 ) t (4-10 membered heterocyclic where t is an integer from 0 to 4, and each R 24 are independently H or is C 1 -C 8 In certain embodiments, R 25 is H, halo or is a hydroxy-substituted C 1 -C 8 Alkyl;C 3 -C 10 Cycloalkyl, 4-10 C 6 -C 10 Aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl, each of which is an unsubstituted C 1 -C 4 Alkyl, Halo, unsubstituted C 1 -C 4 Alkoxy, unsubstituted C 1 -C 4 Haloalkyl, unsubstituted C 1 -C 4 Hydroxyalkyl or unsubstituted C 1 -C 4 Substituted with haloalkoxy or hydroxy R 26 is H, halo or hydroxy substituted C 1 -C 8 Alkyl;C 3-C 10 Cycloalkyl, 4-10 membered heterocyclyl, C 6 -C 10 Aryl, aryl ar alkyl, 5-10 membered heteroaryl or heteroarylalkyl, each of which is , unsubstituted C 1 -C 4 Alkyl, halo, unsubstituted C 1 -C 4 Alkoxy, unsubstituted C 1 -C 4 Ha alkyl, unsubstituted C 1 -C 4 Hydroxyalkyl or unsubstituted C 1 -C 4 Haloarco substituted with oxy or hydroxyl; 25 and R 26 At least one of , other than H.

[0077] "Acyloxy" means the radical -OC(O)R 27 Here, R 27 teeth , hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted as defined herein. substituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, Substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted Representative examples are formyl, acetyl, and cyclohexyl. carbonyl, cyclohexylmethylcarbonyl, benzoyl and benzylcarbonyl In certain embodiments, R 28 Hello, Hydroxy-substituted C 1 -C 8 Alkyl;C 3 -C 10 Cycloalkyl, 4-1 0-membered heterocyclyl, C 6 -C 10 Aryl, arylalkyl, 5-10 membered heteroaryl aryl or heteroarylalkyl, each of which is an unsubstituted C 1 -C 4 Alkyl , halo, unsubstituted C 1 -C 4 Alkoxy, unsubstituted C 1 -C 4 Haloalkyl, unsubstituted C 1 -C 4 Hydroxyalkyl or unsubstituted C 1 -C 4 Substituted with haloalkoxy or hydroxy will be done.

[0078] "Alkoxy" means the group -OR 29 Here, R 29 is a substitution or non- Substituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl. Particular alkoxy groups are meth Oxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy , sec-butoxy, n-pentoxy, n-hexoxy and 1,2-dimethylbutoxy Particular alkoxy groups are lower alkoxy, i.e. having 1 to 6 carbon atoms. Further particular alkoxy groups have 1 to 4 carbon atoms.

[0079] In certain embodiments, R 29 is amino, substituted amino, C 6 -C 10 Aryl , aryloxy, carboxyl, cyano, C 3 -C10 Cycloalkyl, 4 to 10 membered Tetracyclyl, halogen, 5-10 membered heteroaryl, hydroxyl, nitro, thioaryl Koxy, thioaryloxy, thiol, alkyl-S(O)-, aryl-S(O)- , alkyl-S(O) 2 - and aryl-S(O) 2 -One selected from the group consisting of or more substituents, for example 1 to 5 substituents, in particular 1 to 3 substituents, especially Exemplary "substituted alkoxy" groups include -O-(C H 2 ) t (C 6 -C 10 Aryl), -O-(CH 2 ) t (5-10 membered heteroaryl) , -O-(CH 2 ) t (C 3 -C 10 Cycloalkyl) and -O-(CH 2 ) t (4~ 10-membered heterocyclyl) (wherein t is an integer of 0 to 4), without limitation, any aryl, heteroaryl, cycloalkyl or heteroaryl Cyclyl groups are themselves unsubstituted C 1 -C 4 Alkyl, halo, unsubstituted C 1 -C 4 Al Koxy, unsubstituted C 1 -C 4 Haloalkyl, unsubstituted C 1 -C 4 Hydroxyalkyl or unsubstituted C 1 -C 4 Specific exemplary alkoxy groups include alkoxy groups, alkoxy groups, and hydroxy groups. An example of a "substituted alkoxy" group is -OCF 3 , -OCH2 CF 3 , -OCH 2 Ph, -OCH 2 -Cyclopropyl, -OCH 2 CH 2 OH and -OCH 2 CH 2 NMe 2 It is.

[0080] "Amino" means the radical -NH 2 This refers to:

[0081] "Substituted amino" refers to a group of the formula -N(R 38 ) 2 where R 38 teeth , hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted Substituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl aryl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or amino-protected group, where R 38 At least one of is not hydrogen. For each R 38 are independently hydrogen, C 1 -C 8 Alkyl, C 3 -C 8 Alkenyl, C 3 -C 8 Alkynyl, C 6 -C 10 Aryl, 5-10 membered heteroaryl, 4-10 membered heteraryl Rocyclyl or C 3 -C 10 Cycloalkyl; or substituted with halo or hydroxy C 1 -C 8 Alkyl; halo or hydroxy substituted C 3 -C 8 Alkenyl ;Halo or hydroxy substituted C 3 -C 8 Alkynyl, or -(CH 2 ) t ( C 6 -C 10 Aryl), -(CH 2 ) t (5-10 membered heteroaryl), -(CH 2 ) t (C 3 -C 10 Cycloalkyl) or -(CH 2 ) t (4-10 membered heterocyclyl ), each of which is selected from unsubstituted C 1 - C 4 Alkyl, halo, unsubstituted C 1 -C 4 Alkoxy, unsubstituted C 1 -C 4 Haloalkyl, non substitution C 1 -C 4 Hydroxyalkyl or unsubstituted C 1 -C 4 Haloalkoxy or hydroxy or both R 38 The groups are joined to form an alkylene group. do.

[0082] Exemplary "substituted amino" groups include -NR 39 -C 1 -C 8 Alkyl, -NR 39 - (CH 2 ) t (C 6 -C 10 Aryl), -NR 39 -(CH 2 ) t (5-10 membered hetero Aryl), -NR 39 -(CH 2 ) t (C3 -C 10 Cycloalkyl) and -NR 3 9 -(CH 2 ) t (4-10 membered heterocyclyl) (where t is 0 to 4, e.g., 1 or or 2), each R 39 is independently H or C 1 -C 8 any alkyl groups present may themselves represent halo, Any aryl group present may be substituted by substituted or unsubstituted amino or hydroxy; The aryl, heteroaryl, cycloalkyl or heterocyclyl groups are themselves unsubstituted. C 1 -C 4 Alkyl, halo, unsubstituted C 1 -C 4 Alkoxy, unsubstituted C 1 -C 4 Hello Aruki le, unsubstituted C 1 -C 4 Hydroxyalkyl or unsubstituted C 1 -C 4 Haloalkoxy also may be substituted by hydroxy. For the avoidance of doubt, the term "substituted amino" is alkylamino, substituted alkylamino, alkylarylamino, as defined in Substituted alkylarylamino, arylamino, substituted arylamino, dialkylamino and substituted dialkylamino groups. Substituted amino includes mono- and di-substituted amino groups. The term "group" includes both aryl and non-aryl groups.

[0083] "Azide" is the radical -N 3 This refers to:

[0084] "Carbamoyl" or "amide" refers to the radical -C(O)NH2 This refers to:

[0085] "Substituted carbamoyl" or "substituted amide" refers to the radical -C(O)N(R 62 ) 2 Here, each R 62 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbazole bocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted or an unsubstituted heteroaryl or amino protecting group, where R 62 At least one of One of R is not hydrogen. 62 , H, C 1 -C 8 Alkyl , C 3 -C 10 Cycloalkyl, 4-10 membered heterocyclyl, C 6 -C 10 Aryl, A arylalkyl, 5-10 membered heteroaryl and heteroaralkyl; or halo or hydroxyl C substituted with oxy 1 -C 8 Alkyl; or C 3 -C 10 Cycloalkyl, 4-10 C 6 -C 10 Aryl, aralkyl, 5-10 membered heteroaryl or or heteroaralkyl, each of which is selected from unsubstituted C 1 -C 4 Alkyl, halo , unsubstituted C 1 -C 4 Alkoxy, unsubstituted C 1 -C 4 Haloalkyl, unsubstituted C 1 -C 4 Hide oxyalkyl or unsubstituted C1 -C 4 Substituted by haloalkoxy or hydroxy However, at least one R 62 is other than H.

[0086] Exemplary "substituted carbamoyl" groups include -C(O)NR 64 -C 1 -C 8 Alkyl , -C(O)NR 64 -(CH 2 ) t (C 6 -C 10 Aryl), -C(O)N 64 -( CH 2 ) t (5-10 membered heteroaryl), -C(O)NR 64 -(CH 2 ) t (C 3 - C 10 cycloalkyl) and -C(O)NR 64 -(CH 2 ) t (4-10 membered heterocyclic kryl) (wherein t is an integer of 0 to 4), Each R 64 are independently H or C 1 -C 8 represents alkyl, and any aryl present, The heteroaryl, cycloalkyl or heterocyclyl groups are themselves unsubstituted C 1 -C 4 Alkyl, halo, unsubstituted C 1 -C 4 Alkoxy, unsubstituted C 1 -C 4 Haloalkyl, unsubstituted C 1 -C 4 Hydroxyalkyl or unsubstituted C 1 -C 4 Haloalkoxy or hyaluronan It may be substituted by hydroxy.

[0087] "Carboxy" refers to the radical -C(O)OH.

[0088] "Cyano" refers to the radical -CN.

[0089] "Halo" or "halogen" means fluoro (F), chloro (Cl), bromo (Br) and iodo(I). In certain embodiments, a halo group is a fluoro or Or Chloro.

[0090] "Hydroxy" refers to the radical -OH.

[0091] "Nitro" means the radical -NO 2 This refers to:

[0092] "Cycloalkylalkyl" refers to an alkyl group in which the alkyl group is substituted with a cycloalkyl group. A typical cycloalkylalkyl group is cyclopropyl. Methyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylmethyl butylmethyl, cyclooctylmethyl, cyclopropylethyl, cyclobutylethyl, Cyclopentylethyl, cyclohexylethyl, cycloheptylethyl and cyclooctylethyl These include, but are not limited to, ethyl.

[0093] "Heterocyclylalkyl" refers to an alkyl group in which the alkyl group is substituted with a heterocyclyl group. A typical heterocyclylalkyl group is pyrrolidinylmethyl. Tyl, piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyrrolidinylmethyl ethyl, piperidinylethyl, piperazinylethyl, morpholinylethyl, etc. But not limited to these.

[0094] "Cycloalkenyl" means an alkyl group having 3 to 10 carbon atoms and a single cyclic ring or multiple cyclic rings. Containing fused rings (including fused and bridged ring systems), at least one, especially one ~ A substituted or unsubstituted carbocyclyl group having two sites of olefinic unsaturation Such cycloalkenyl groups include, by way of example, single ring structures (e.g., cyclohexenyl, Cyclohexyl, cyclopentenyl, cyclopropenyl, etc.

[0095] A "fused cycloalkenyl" refers to an alkenyl group having two of its ring carbon atoms fused to a second aliphatic ring. or aromatic ring and are arranged so as to impart aromaticity to the cycloalkenyl ring. It refers to a cycloalkenyl having olefinic unsaturation.

[0096] "Ethenyl" refers to a substituted or unsubstituted -(C=C)-.

[0097] "Ethylene" refers to a substituted or unsubstituted --(CC)--.

[0098] "Ethynyl" refers to --(C≡C)--.

[0099] A "nitrogen-containing heterocyclyl" group is a 4- to 7-membered non-aromatic heterocyclic ring system that contains at least one nitrogen atom. aromatic cyclic groups, such as, but not limited to, morpholine, piperidine (e.g., 2-piperidine, lysinyl, 3-piperidinyl and 4-piperidinyl), pyrrolidine (e.g., 2-pyrrolidine, lysinyl and 3-pyrrolidinyl), azetidine, pyrrolidone, imidazoline, imidazo Lisinones, 2-pyrazolines, pyrazolidines, piperazines and N-alkylpiperazines ( For example, N-methylpiperazine. Specific examples include azetidine, piperazine, These include peridolone and piperazone.

[0100] "Thioketo" refers to the group =S.

[0101] Alkyl, alkenyl, alkynyl, carbocyclyl, as defined herein The heterocyclyl, aryl and heteroaryl groups are optionally substituted (e.g., For example, "substituted" or "unsubstituted" alkyl, "substituted" or "unsubstituted" alkenyl, "substituted" or "unsubstituted" alkynyl, "substituted" or "unsubstituted" carbocyclyl, "Substituted" or "unsubstituted" heterocyclyl, "substituted" or "unsubstituted" aryl or "Substituted" or "unsubstituted" heteroaryl groups. In general, the term "substituted" refers to the term Whether or not preceded by "optionally", a group (e.g., a carbon atom or nitrogen atom) is replaced with an acceptable substituent, e.g., Upon reaction, a stable compound is obtained, for example, by rearrangement, cyclization, elimination or other reaction. It means that the substituents can be replaced with groups that do not spontaneously form compounds. Unless otherwise specified, a "substituted" group has substituents at one or more substitutable positions of the group. However, when more than one position in any given structure is substituted, the substituents may be substituted at each position. The term "substituted" refers to a group that is the same or different in position. Any of the permissible substituents of organic compounds are described herein. The present invention contemplates substitution with any of the above in order to arrive at a stable compound. Any and all such combinations are contemplated. For purposes of this invention, nitrogen, etc. The heteroatom may be substituted with a hydrogen atom, which satisfies the valence of the heteroatom and results in the formation of a stable moiety. The alkyl group may have any suitable substituents as described herein and / or as substituted groups.

[0102] Exemplary carbon atom substituents include halogen, -CN, -NO 2 , -N 3 , -SO 2 H , -SO 3 H, -OH, -OR aa , -ON(R bb ) 2 , -N(R bb ) 2 , -N(R bb ) 3 + X - , -N(OR cc )R bb , -SH, -SR aa , -SSR cc , -C( =O)R aa , -CO 2 H, -CHO, -C(OR cc ) 2 , -CO 2 R aa , -OC( =O)R aa , -OCO 2 R aa , -C(=O)N(R bb ) 2 , -OC(=O)N(R bb ) 2 , -NR bb C(=O)R aa , -NR bb CO 2 R aa , -NR bb C(=O )N(R bb ) 2 , -C(=NR bb )R aa , -C(=NR bb ) ORaa 、-OC( =NR bb )R aa 、-OC(=NR bb )OR aa 、-C(=NR bb )N(R bb ) 2 、-OC(=NR bb )N(R bb ) 2 、-NR bb C(=NR bb )N(R bb ) 2 、-C(=O)NR bb SO 2 R aa 、-NR bb SO 2 R aa 、-SO 2 N(R bb ) 2 、-SO 2 R aa 、-SO 2 OR aa 、-OSO 2 R aa 、-S(=O)R aa 、-O S(=O)R aa 、-Si(R aa ) 3 、-OSi(R aa ) 3 -C(=S)N(R b b ) 2 、-C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-S C(=O)SR aa 、-OC(=O)SR aa 、-SC(=O)OR aa 、-SC(=O )R aa 、-P(=O) 2 R aa 、-OP(=O) 2 R aa 、-P(=O)(Raa ) 2 , -OP(=O)(R aa ) 2 ,-OP(=O)(OR cc ) 2 , -P(=O) 2 N(R bb ) 2 , -OP(=O) 2 N(R bb ) 2 , -P(=O)(NR bb ) 2 , -OP(= O)(NR bb ) 2 , -NR bb P(=O)(OR cc ) 2 , -NR bb P(=O)(N R bb ) 2 , -P(R cc ) 2 , -P(R cc ) 3 , -OP(R cc ) 2 , -OP(R c c ) 3 , -B(R aa ) 2 , -B(OR cc ) 2 , -BR aa (OR cc ), C 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl , C 3-10 Carbocyclyl, 3-14 membered heterocyclyl, C 6-14 Aryl and 5 aryl, aryl, aryl-14 membered heteroaryl, Enyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl each independently represents 0, 1, 2, 3, 4 or 5 Rdd Is substituted with a group; or the two geminal hydrogens on a carbon atom are the groups =O, =S, =NN(R bb ) 2 , =N NR bb C(=O)R aa , =NNR bb C(=O)OR aa , =NNR bb S(=O) 2 R aa , =NR bb OR =NOR cc Replaced by; R aa Each instance of 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2 -10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3-14 membered heptane Rocyclyl, C 6-14 aryl and 5- to 14-membered heteroaryl; or two R aa The groups are connected to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heterocyclic ring. aryl ring, wherein alkyl, alkenyl, alkynyl, carbocyclyl, Each of heterocyclyl, aryl and heteroaryl is independently 0, 1, 2, 3, 4 or 5 R's dd substituted with a group; R bb Each instance of is independently hydrogen, -OH, -OR aa , -N(R cc ) 2 , -CN, -C(=O)R aa , -C(=O)N(R cc ) 2 , -CO 2 R aa , -SO 2 R aa , -C(=NR cc) OR aa , -C(=NR cc )N(R cc ) 2 , -SO 2 N(R cc ) 2 , -SO 2 R cc , -SO 2 OR cc , -SOR aa , -C(=S)N(R cc ) 2 , -C(=O)SR cc , -C(=S)SR cc , -P(=O) 2 R aa , -P(=O) (R aa ) 2 , -P(=O) 2 N(R cc ) 2 , -P(=O)(NR cc ) 2 ,C 1-1 0 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkini Lu, C 3-10 Carbocyclyl, 3-14 membered heterocyclyl, C 6-14 Aryl and 5-14 membered heteroaryl, or two R bb The group is connected to 3 Forms a 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and hetero Each aryl independently has 0, 1, 2, 3, 4 or 5 R dd substituted with a group; R cc Each instance of 1-10 Alkyl, C 1-10 Perhaloalkyl , C 2-10 Alkenyl, C2-10 Alkynyl, C 3-10 Carbocyclyl, 3-14 C 6-14 aryl and 5- to 14-membered heteroaryl or two R's cc The groups are joined to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heterocyclyl ring. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, Each of aryl, heterocyclyl, aryl and heteroaryl is independently 0, 1, 2 , 3, 4 or 5 R dd substituted with a group; R dd Each instance of is independently a halogen, -CN, -NO 2 , -N 3 , -SO 2 H, -S O 3 H, -OH, -OR ee , -ON(R ff ) 2 , -N(R ff ) 2 , -N(R ff ) 3 + X - , -N(OR ee )R ff , -SH, -SR ee , -SSR ee , -C(=O) R ee , -CO 2 H, -CO 2 R ee , -OC(=O)R ee , -OCO 2 R ee , -C (=O)N(R ff ) 2 , -OC(=O)N(R ff ) 2 , -NR ff C(=O)R ee , -NR ff CO 2 R ee、-NR ff C(=O)N(R ff ) 2 、-C(=NR ff ) OR ee 、-OC(=NR ff )R ee 、-OC(=NR ff )OR ee 、-C(=NR ff )N(R ff ) 2 、-OC(=NR ff )N(R ff ) 2 、-NR ff C(=NR f f )N(R ff ) 2 ,-NR ff SO 2 R ee 、-SO 2 N(R ff ) 2 、-SO 2 R e e 、-SO 2 OR ee 、-OSO 2 R ee 、-S(=O)R ee 、-Si(R ee ) 3 、 -OSi(R ee ) 3 、-C(=S)N(R ff ) 2 、-C(=O)SR ee 、-C(= S)SR ee 、-SC(=S)SR ee 、-P(=O) 2 R ee 、-P(=O)(R ee ) 2 、-OP(=O)(R ee ) 2 、-OP(=O)(OR ee ) 2 、C 1-6 アルキル , C 1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 mosquito Rubocyclyl, 3-10 membered heterocyclyl, C 6-10 Aryl, 5-10 membered heteroaryl wherein the alkyl, alkenyl, alkynyl, carbocyclyl, heptyl, Each of aryl, heteroaryl and heteroaryl may independently represent 0, 1, 2, 3, 4 or Or 5 R's gg substituted with a group or two geminal R dd The substituents are taken together to form =O or =S; R ee Each instance of 1-6 Alkyl, C 1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclyl, C 6-10 Aryl, 3 aryl, aryl- ... alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and hetero Each aryl independently has 0, 1, 2, 3, 4 or 5 R gg substituted with a group; R ff Each instance of 1-6 Alkyl, C 1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclyl, 3-10 membered hetero Cyclyl, C 6-10 aryl and 5-10 membered heteroaryl; There are two R ff The groups are connected to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered hetero aryl ring, wherein alkyl, alkenyl, alkynyl, carbocyclyl, hexyl, Each of tetracyclyl, aryl and heteroaryl is independently 0, 1, 2, 3, 4 or 5 R's gg substituted with a group; R gg Each instance of is independently a halogen, -CN, -NO 2 , -N 3 , -SO 2 H, -S O 3 H, -OH, -OC 1-6 Alkyl, -ON(C 1-6 Alkyl) 2 , -N(C 1- 6 Alkyl) 2 , -N(C 1-6 Alkyl) 3 + X - , -NH(C 1-6 Alkyl) 2 + X - , -NH 2 (C 1-6 Alkyl) + X - , -NH 3 + X - , -N(OC 1-6 Alki (C 1-6 alkyl), -N(OH)(C 1-6 alkyl), -NH(OH), -S H, -SC 1-6 Alkyl, -SS(C 1-6 alkyl), -C(=O)(C 1-6 Al Kill), -CO 2 H, -CO 2 (C 1-6 alkyl), -OC(=O)(C 1-6 Alki -OCO 2 (C 1-6 alkyl), -C(=O)NH 2, -C(=O)N(C 1- 6 Alkyl) 2 , -OC(=O)NH(C 1-6 alkyl), -NHC(=O)(C 1- 6 alkyl), -N(C 1-6 Alkyl)C(=O)(C 1-6 alkyl), -NHCO 2 (C 1-6 alkyl), -NHC(=O)N(C 1-6 Alkyl) 2 , -NHC(=O )NH(C 1-6 alkyl), -NHC(=O)NH 2 , -C(=NH)O(C 1-6 a Ru(=C)-OC(=NH)(C 1-6 alkyl), -OC(=NH)OC 1-6 Alki -C(=NH)N(C 1-6 Alkyl) 2 , -C(=NH)NH(C 1-6 Alkyl ), -C(=NH)NH 2 , -OC(=NH)N(C 1-6 Alkyl) 2 , -OC(NH )NH(C 1-6 alkyl), -OC(NH)NH 2 , -NHC(NH)N(C 1-6 a Rukill) 2 , -NHC(=NH)NH 2 , -NHSO 2 (C 1-6 Alkyl), -SO 2 N(C 1-6 Alkyl) 2 , -SO 2 NH(C 1-6 Alkyl), -SO 2 NH 2 ,-S O 2 C 1-6 Alkyl, -SO2 O.C. 1-6 Alkyl, -OSO 2 C 1-6 Alkyl, - SOC 1-6 Alkyl, -Si(C 1-6 Alkyl) 3 , -OSi(C 1-6 Alkyl) 3 -C(=S)N(C 1-6 Alkyl) 2 , C(=S)NH(C 1-6 Alkyl), C (=S)NH 2 , -C(=O)S(C 1-6 Alkyl), -C(=S)SC 1-6 Alki ru, -SC(=S)SC 1-6 Alkyl, -P(=O) 2 (C 1-6 Alkyl), -P( =O)(C 1-6 Alkyl) 2 , -OP(=O)(C 1-6 Alkyl) 2 , -OP(=O )(OC 1-6 Alkyl) 2 , C 1-6 Alkyl, C 1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclyl, C 6-10 Aryl, 3 10-membered heterocyclyl, 5-10-membered heteroaryl; or two geminal R gg The substituents may be taken together to form =O or =S; where X - is against Io It is.

[0103] A "counterion" or "anionic counterion" is a cation that maintains electrical neutrality. A counterion is a negatively charged group associated with a neutral quaternary amino group. Exemplary counterions include halo Genide ions (e.g., F - , Cl - , Br - , I-), NO 3 - , ClO 4 - , O.H. - , H 2 PO 4 - , HSO 4 - , sulfonate ions (e.g., methanesulfonate, trifluoromethanesulfonate, Fluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, 10-camphor naphthalene-2-sulfonic acid, naphthalene-1-sulfonic acid-5-sulfonic acid sulfonic acid, ethane-1-sulfonic acid-2-sulfonic acid, etc.) and carboxylate ions (e.g. For example, acetic acid, ethanoic acid, propanoic acid, benzoic acid, glyceric acid, lactic acid, tartaric acid, glycolic acid, Examples include carboxylic acid.

[0104] The nitrogen atom may be substituted or unsubstituted, as permitted by valence, and the nitrogen atom may include a first Exemplary nitrogen atom substituents include primary, secondary, tertiary and quaternary nitrogen atoms. Substitutents include hydrogen, -OH, -OR aa , -N(R cc ) 2 , -C N, -C(=O)R aa , -C(=O)N(R cc ) 2 , -CO 2 R aa , -SO 2 R a a , -C(=NR bb )R aa , -C(=NR cc ) OR aa , -C(=NR cc )N( R cc ) 2, -SO 2 N(R cc ) 2 , -SO 2 R cc , -SO 2 OR cc , -SOR a a , -C(=S)N(R cc ) 2 , -C(=O)SR cc , -C(=S)SR cc , -P (=O) 2 R aa , -P(=O)(R aa ) 2 , -P(=O) 2 N(R cc ) 2 , -P( =O)(NR cc ) 2 , C 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3-14 membered heterocycle Lil, C 6-14 aryl and 5-14 membered heteroaryl, but are not limited to these or two R attached to the nitrogen atom cc The group is connected to 3 to 14 membered heterocyclic rings. Forms a cyclocyclyl ring or a 5- to 14-membered heteroaryl ring, in which alkyl, alkoxy, Nyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl each independently represents 0, 1, 2, 3, 4 or 5 R dd is substituted with a R aa , R b b , R cc and R dd is as defined above.

[0105] In certain embodiments, the substituent present on the nitrogen atom is an amino protecting group (see herein). (also referred to as nitrogen protecting groups in the text). Amino protecting groups include -OH, -OR aa , -N(R cc ) 2 , -C(=O)R aa , -C(=O)N(R cc ) 2 , -CO 2 R aa , -SO 2 R aa , -C(=NR cc )R aa , -C(=NR cc ) OR aa , -C(= NR cc )N(R cc ) 2 , -SO 2 N(R cc ) 2 , -SO 2 R cc , -SO 2 OR c c , -SOR aa , -C(=S)N(R cc ) 2 , -C(=O)SR cc , -C(=S) S.R. cc , C 1-10 Alkyl (e.g., aralkyl, heteroaralkyl), C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3-14 membered heterocycle Lil, C 6-14 aryl and 5- to 14-membered heteroaryl groups; Without being limited thereto, alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, Each of aryl, aralkyl, aryl and heteroaryl is independently 0, 1, 2, 3 , 4 or 5 R dd is substituted with a Raa , R bb , R cc and R dd This specification Amino protecting groups are well known in the art and are as defined herein. Protecting Groups in Organic Synthesis s,TWGreene and PGMWuts,3 rd edition, John Wiley & Sons, 1999 (incorporated herein by reference) These include those described in detail in.

[0106] For example, an amino protecting group such as an amide group (e.g., -C(=O)R aa ) as a Acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide Acetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamides, N-benzoylphenylalanyl derivatives, benzamides, p-Phenylbenzamide, o-Nitrophenylacetamide cetamide), o-nitrophenoxyacetamide, acetoacetamide, (N' -Dithiobenzyloxyacylamino)acetamide, 3-(p-hydroxyphenyl) Propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o- nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy) Propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o- Nitrocinnamide, N-acetylmethionine derivatives, o-nitrobenzamide and o- (benzoyloxymethyl)benzamide.

[0107] Amino protecting groups such as carbamate groups (e.g., -C(=O)OR aa ) is Methionine ethyl carbamante, 9-flurocarbamate fluorenylmethylcarbamate (Fmoc), 9-(2-sulfo)fluorenylmethylcarbamate Bamate, 9-(2,7-dibromo)fluoroenylmethylcarbamate, 2,7-di- t-Butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothio oxanthryl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl Carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc) , 2-trimethylsilylethylcarbamate (Teoc), 2-phenylethylcarbamate 1-(1-adamantyl)-1-methylethyl carbamate (Adpoc ), 1,1-dimethyl-2-haloethylcarbamate, 1,1-dimethyl-2,2-dibutyl Bromoethyl carbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trimethyl Carbamate (TCBOC), 1-methyl-1-(4-biphenylyl)ethyl Carbamate (Bpoc), 1-(3,5-di-t-butylphenyl)-1-methylethyl Carbamate (t-Bumeoc), 2-(2'- and 4'-pyridyl)ethylcarbamate Bamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethylcarbamate mate, t-butyl carbamate (BOC), 1-adamantyl carbamate (Adoc ), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropanol Pyraryl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitro Rosinamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidine Lysinyl carbamate, alkyl dithiocarbamate, benzyl carbamate (Cbz) , p-Methoxybenzyl carbamate (Moz), p-Nitrobenzyl (nitoben zyl) carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate 2,4-Dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate Mate (Msz), 9-anthrylmethylcarbamate, diphenylmethylcarbamate , 2-Methylthioethyl carbamate, 2-Methylsulfonylethyl carbamate, 2- (p-Toluenesulfonyl)ethylcarbamate, [2-(1,3-dithianyl)]methyl Dimethylcarbamate (Dmoc), 4-methylthiophenylcarbamate (Mtpc), 2, 4-Dimethylthiophenylcarbamate (Bmpc), 2-phosphonioethylcarbamate 2-triphenylphosphonioisopropylcarbamate (Peoc), 2-triphenylphosphonioisopropylcarbamate (Ppoc), 1,1-Dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzene Dicarbamate, p-(dihydroxyboryl)benzylcarbamate, 5-benzoiso Oxazolylmethylcarbamate, 2-(trifluoromethyl)-6-chromonylmethyl Carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxyphenyl o-Nitrobenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitro phenyl(o-nitrophenyl)methylcarbamate, t-nitrophenyl Milcarbamate, S-benzylthiocarbamate, p-cyanobenzylcarbamate, Cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate , cyclopropylmethylcarbamate, p-decyloxybenzylcarbamate, 2,2 -Dimethoxyacylvinylcarbamate, o-(N,N-dimethylcarboxamide)benzene Dicarbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propionate Dicarbamate, 1,1-dimethylpropynylcarbamate, di(2-pyridyl)methyl Carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, iso Bornyl carbamate, isobutyl carbamate, isonicotinic acid p-(p'-methoxyphenylazo)benzyl carbamate, 1-methyl 1-Methylcyclohexylcarbamate, 1-methyl-1 -Cyclopropyl methyl carbamate, 1-methyl-1-(3,5-dimethoxyphenyl ) Ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate 1-Methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl ) Ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate 2,4,6-tri-t-butylphenylcarbamate, 4-(trimethylammonium Examples include 2,4,6-trimethylbenzyl carbamate and 2,4,6-trimethylbenzyl carbamate. These include, but are not limited to:

[0108] Amino protecting groups such as sulfonamide groups (e.g., -S(=O) 2 R aa ) is p -Toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6,-trimethyl 4-Methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzene Benzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (M te), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzene benzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide iMds, 2,2,5,7,8-pentamethylchroman-6-sulfonamide (P mc), methanesulfonamide (Ms), β-trimethylsilylethanesulfonamide ( SES), 9-anthracenesulfonamide, 4-(4',8'-dimethoxynaphthyl methyl Benzylsulfonamide (DNMBS), trifluoro These include, but are not limited to, methylsulfonamides and phenacylsulfonamides. do not have.

[0109] Other amino protecting groups include phenothiazinyl-(10)-acyl derivatives, N'-p- Toluenesulfonylaminoacyl derivatives, N'-phenylaminothioacyl derivatives, N- Benzoylphenylalanyl derivatives, N-acetylmethionine derivatives, 4,5-diphenyl 3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dt s), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1 ,4,4-Tetramethyldisilylazacyclopentane adduct (STABASE), 5-position Substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3 -Dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted 3,5-diphenyl 4-Pyridone, N-Methylamine, N-Allylamine, N-[2-(trimethylsilyl) N-3-acetoxypropylamine, N-( 1-isopropyl-4-nitro-2-oxo-3-pyrrololine-3-ylamine, quaternary Ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine , N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[( 4-Methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluoro PhF, N-2,7-dichloro-9-fluorenylmethyleneamine, N-Ferrocenylmethylamino (Fcm), N-2-picolylamino N'-oxide, N -1,1-Dimethylthiomethyleneamine, N-benzylideneamine, Np-methoxybenzylamine N-phenylenediamine, N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl] Methyleneamine, N-(N',N'-dimethylaminomethylene)amine, N,N'-iso Propylidenediamines, Np-nitrobenzylideneamines, N-salicylideneamines, N-5-Chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenyl Nylmethyleneamine, N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxopropylamine) (xo-1-cyclohexenyl)amine, N-borane derivatives, N-diphenylborinic acid derivatives N-[phenyl(pentaacylchromium or tungsten) acyl]amine, N- Copper chelate, N-zinc chelate, N-nitroamine, N-nitrosamine, amine N-o oxide, diphenylphosphine amide (Dpp), dimethylthiophosphine amide (Mp t), diphenylthiophosphine amide (Ppt), dialkyl phosphoramidate, di Benzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamidate , o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulf benzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzene phenylsulfenamide, triphenylmethylsulfenamide and 3-nitropyridine These include, but are not limited to, phenylamide (Npys).

[0110] In certain embodiments, the substituent present on the oxygen atom is an oxygen protecting group (hydroxyl group). The oxygen protecting group is -R aa , -N(R bb ) 2 , -C(=O)SR aa , -C(=O)R aa , -CO 2 R aa , -C(=O)N(R bb ) 2 , -C(=NR bb )R aa , -C(=NR bb ) OR aa , -C(=NR bb )N (R bb ) 2 , -S(=O)R aa , -SO 2 R aa , -Si(R aa ) 3、 -P(R c c ) 2 , -P(R cc ) 3 , -P(=O) 2 R aa , -P(=O)(R aa ) 2 , -P( =O)(OR cc ) 2 , -P(=O) 2 N(R bb ) 2 , and -P(=O)(NRbb ) 2 In particular, but not limited to, R aa , R bb and R cc This is As defined herein. Oxygen protecting groups are well known in the art and include , Protecting Groups in Organic Synthesis, T.W. Greene and P.G. M. Huts, 3 rd edition, Jo Wiley & Sons, 1999, incorporated herein by reference. This includes those described in detail.

[0111] Exemplary oxygen protecting groups include methyl, methoxymethyl (MOM), methylthiomethyl, (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (S MOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PM BM), (4-methoxyphenoxy)methyl (p-AOM), guaiacol methyl (G UM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl , 2-Methoxyethoxymethyl (MEM), 2,2,2-Trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl (SEMO R), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydro Rothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (M THP), 4-Methoxytetrahydrothiopyranyl, 4-Methoxytetrahydrothiopyran Nyl S,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4-methoxy Piperidin-4-yl (CTMP), 1,4-dioxan-2-yl, tetrahydrofuranic acid tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro -7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl -1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-Trichloroethyl, 2-Trimethylsilylethyl, 2-(phenylselenyl ) Ethyl, t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4- Dinitrophenyl, benzyl (Bn), p-methoxybenzyl, 3,4-dimethoxybenzyl o-Nitrobenzyl, p-Nitrobenzyl, p-Halobenzyl, 2,6-Dichloro Benzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-Methyl-2-picolyl N-oxide, diphenylmethyl, p,p'-dinitrobenz hydryl, 5-dibenzosuberyl, triphenylmethyl, α-naphthyldiphenylmethyl , p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl , tri(p-methoxyphenyl)methyl, 4-(4'-bromophenacyloxyphenyl )diphenylmethyl, 4,4',4”-tris(4,5-dichlorophthalimidophenyl )methyl, 4,4',4”-tris(levulinoyloxyphenyl)methyl, 4,4', 4"-Tris(benzoyloxyphenyl)methyl, 3-(imidazol-1-yl)biphenyl Bis(4',4”-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl) -1'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-( 9-Phenyl-10-oxo)anthryl, 1,3-benzodisulfuran-2-yl, Benzoisothiazolyl S,S-dioxide, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (I PDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t -Butyldimethylsilyl (TBDMS), t-Butyldiphenylsilyl (TBDPS), Tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethyl tert-butyl methoxyphenyl silyl (DPMS), tert-butyl methoxyphenyl silyl (TBMPS), formate , benzoyl formate, acetate, chloroacetate, dichloroacetate, trichloroacetate doloacetate, trifluoroacetate, methoxyacetate, triphenylmethoxy Acetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropane Lopionate, 4-oxopentanoate (levulinate), 4,4-(ethylenedithio ) Pentanoate (levulinoyl dithioacetal), pivaloate, adamantoate , Crotonate, 4-methoxycrotonate, Benzoate, p-phenylbenzoate , 2,4,6-trimethylbenzoate (mesitoate), alkyl methyl carbonate , 9-fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, Alkyl 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl 2-(phenylsulfonyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl)ethyl carbonate (Psec), 2-(triphenylphosphonio)ethyl carbonate (Peoc), Alkyl isobutyl carbonate, alkyl vinyl carbonate, alkyl allyl carbonate , alkyl p-nitrophenyl carbonate, alkyl benzyl carbonate, alkyl p-Methoxybenzyl carbonate, alkyl 3,4-dimethoxybenzyl carbonate , alkyl o-nitrobenzyl carbonate, alkyl p-nitrobenzyl carbonate , alkyl S-benzyl thiocarbonate, 4-ethoxy-1-naphthyl (napth thyl) carbonate, methyldithiocarbonate, 2-iodobenzoate, 4-a dihydrobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzene Zoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl, 4 -(Methylthiomethoxy)butyrate, 2-(Methylthiomethoxymethyl)benzoate , 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1, 1,3,3-Tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethyl ethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, Monosuccinoate, (E)-2-methyl-2-butenoate, o-(methoxyacyl) Benzoate, α-naphthoate, nitrate, alkyl N,N,N',N'-tetramethyl ethyl phosphorodiamidate, alkyl N-phenylcarbamate, borate, dimethyl phosphatide Sphinothiol, Alkyl 2,4-dinitrophenylsulfenate, Sulfate, Methanesulfonate (mesylate), benzylsulfonate and tosylate (Ts) These include, but are not limited to:

[0112] In certain embodiments, the substituent present on the sulfur atom is a sulfur protecting group (thiol The sulfur protecting group is -R aa , -N(R bb ) 2 , -C (=O)SR aa , -C(=O)R aa , -CO 2 R aa , -C(=O)N(R bb ) 2 , -C(=NR bb )R aa , -C(=NR bb ) OR aa , -C(=NR bb )N(R bb ) 2 , -S(=O)R aa , -SO 2 R aa , -Si(R aa ) 3、 -P(R cc ) 2 , -P(R cc ) 3 , -P(=O) 2 R aa , -P(=O)(R aa ) 2 , -P(=O )(OR cc ) 2 , -P(=O) 2 N(R bb ) 2 , and -P(=O)(NR bb ) 2 In particular, but not limited to, R aa , R bb and R cc This specification Sulfur protecting groups are well known in the art and include, for example, P rotecting Groups in Organic Synthesis,T. W. Greene and P.G.M. Huts, 3 rd edition,John Wiley & Sons, 1999, incorporated herein by reference. Includes what is stated.

[0113] "Compounds of the invention" and equivalent expressions refer to compounds as described herein above, In particular, compounds according to any of the formulae listed and / or described herein are included. This expression is intended to include, where the context so permits, prodrugs, pharma- ceutically acceptable This includes acceptable salts and solvates, for example hydrates. Similarly, references to intermediates include Their salts, where the context so permits, whether or not they are themselves claimed. and solvates.

[0114] These and other exemplary substituents are more particularly described in the detailed description, examples, and claims. The present invention is not to be construed in any manner whatsoever in accordance with the above exemplary enumeration of substituents. It is not intended to be limiting.

[0115] Other definitions "Pharmaceutically acceptable" means any product approved by a federal or state government regulatory agency or in a country other than the United States. or The United States Pharmacopoeia or other generally accepted standards for use in animals, and more particularly in humans, are This means that it is listed in the Pharmacopoeia.

[0116] A "pharmaceutically acceptable salt" refers to a compound that is pharmaceutically acceptable and that has the desired pharmacological effect as the parent compound. In particular, such salts are non-toxic. and inorganic or organic acid addition salts and inorganic or organic base addition salts. Specifically, such salts include: (1) salts obtained from inorganic acids (e.g., hydrochloric acid, hydrobromic acid, acid addition salts formed with organic acids (e.g., acetic acid, protons, etc.); Pionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid , malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid , 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid , ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid , benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4 -Toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-o 2-Cu-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, tri Methyl acetate, tertiary butyl acetate, lauryl sulfate, gluconic acid, glutamic acid, hydroxy Naphthoic acid, salicylic acid, stearic acid, muconic acid, etc.); or (2) The acidic protons present in the parent compound are converted to metal ions, e.g., alkali metal ions. , replaced by alkaline earth ions or aluminum ions; or Synthetic bases (e.g., ethanolamine, diethanolamine, triethanolamine, N- methylglucamine, etc. By way of example only, sodium, potassium, calcium, magnesium, ammonium, trialkylammonium etc.; and when the compound contains a basic functional group, non-toxic organic Salts of acids or inorganic acids (e.g., hydrochlorides, hydrobromides, tartrates, mesylates, acetates, Maleate, oxalate, etc. The term "Pharmaceutically acceptable cation" refers to an acceptable cationic counterion of an acidic functional group. are sodium, potassium, calcium, magnesium, ammonium, tetraalkyl ammonium cation and the like (see, for example, Berge, et al., J. Phar m.Sci.66(1):1-79 (see Jan.”77).

[0117] A "pharmaceutical acceptable vehicle" refers to a diluent with which a compound of the present invention is administered. , adjuvant, excipient or carrier.

[0118] A "pharmaceutically acceptable metabolically cleavable group" refers to a group that is cleaved in vivo to produce a medicament as described herein. The term refers to a group that provides a parent molecule with a structural formula shown in the document. Examples of metabolically cleavable groups are For -COR, -COOR, -CONRR and -CH 2 The OR radical is wherein R, at each occurrence, is alkyl, trialkylsilyl, carbocyclic aryl, or is one or more of alkyl, halogen, hydroxy or alkoxy; Representative metabolically cleavable aryls are independently selected from carbocyclic aryls substituted with a group Specific examples of such groups include acetyl, methoxycarbonyl, benzoyl, and methoxymethyl. Examples of such groups include methylsilyl and trimethylsilyl groups.

[0119] A "prodrug" is a drug that has a cleavable group and is capable of being degraded by solvolysis or under physiological conditions. In the present invention, the compound is a compound of the present invention that is pharma- ceutical active in vivo. Examples of such compounds include choline ester derivatives, N- These include, but are not limited to, alkyl morpholine esters. Other derivatives of are active in both their acid and acid derivative forms, but often have an acid sensitivity. Insoluble forms offer the advantages of solubility, tissue compatibility or delayed release in the mammalian organism. (Bundgard, H., Design of Prodrugs, pp. 7-9 , 21-24, Elsevier, Amsterdam 1985). The drugs include acid derivatives well known to those skilled in the art, such as those obtained by reaction of the parent acid with a suitable alcohol. or an ester prepared by reacting the parent acid with a substituted or unsubstituted amine or anhydride. The compounds of the present invention include amides prepared by reaction with an amide or mixed anhydride. Simple aliphatic or aromatic esters, amides and derivatives derived from the pendant acidic groups of Anhydrides are a special class of prodrugs. In some cases, double ester type prodrugs are also used. (e.g., (acyloxy) alkyl esters or ((alkoxycarbonyl) aryl esters) It is desirable to prepare the C(oxy)alkyl esters of the compounds of the present invention. 1 ~C 8 Alkyl, C 2 -C 8 Alkenyl, C 2 -C 8 Alkynyl, Aryl, C 7 -C 1 2 Substituted Aryl and C 7 -C 12 Aryl alkyl esters.

[0120] "Solvate" refers to a compound that is associated with a solvent, usually by a solvolysis reaction. This refers to the form of the compound in which it is combined with water (also called a "hydrate"). The physical associations of the solvents include hydrogen bonds. Conventional solvents include water, ethanol, and acetic acid. The compounds of the invention may be prepared, for example, in crystalline form and may be solvated. Suitable solvates include pharma- ceutically acceptable solvates (e.g., For example, hydrates), including both stoichiometric and non-stoichiometric solvates. In certain cases, the solvate may further include, for example, one or more Isolation may be possible when solvent molecules are incorporated into the crystal lattice of the crystalline solid. "Solvates" encompass both solution-phase and isolatable solvates. Compounds include hydrates, ethanolates, and methanolates.

[0121] The "subject" to which administration is contemplated includes humans (i.e., male or female of any age group). Gender, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., juveniles, adult, middle-aged adult or elderly) and / or non-human animals, e.g., mammals (e.g., Primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, In certain embodiments, the mammalian animal may be a rodent, cat, or dog. In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human The terms "human," "patient," and "subject" are used interchangeably herein. will be done.

[0122] An "effective amount" is an amount that, when administered to a subject to treat or prevent a disease, "Effective amount" refers to that amount of a compound sufficient to effect such treatment or prevention. Varies depending on the compound, the disease and its severity, and the age, weight, etc. of the subject being treated. A "therapeutically effective amount" refers to an amount effective for therapeutic treatment. A "prophylactically effective amount" refers to an amount effective for therapeutic treatment. , refers to an amount effective for prophylactic treatment.

[0123] "Prevent" or "prevention" or "prophylactic treatment" refers to treating a disease or disorder before it is acquired. or reducing the risk of developing (i.e., reducing at least one clinical sign of disease by a pathogen) in subjects who have not been exposed or who have a predisposition to the disease prior to disease onset. This refers to preventing the onset of the disease.

[0124] The term "prophylaxis" is related to "prevention" and refers to a method for preventing a disease, rather than treating or curing the disease. Non-limiting examples of preventive measures include vaccination. Administration of low molecular weight heparin to hospitalized patients who are at risk for thrombosis due to restraints, for example administration; and in geographical areas where malaria is endemic or in contact with malaria (contr Antimalarial drugs such as chloroquine prior to travel to high-risk geographic areas This may include administration of a drug.

[0125] "Treatment" of any disease or disorder In one embodiment, "therapeutic treatment" refers to reversing (or improving) the disease or disorder. That is, to halt the disease or to reduce the manifestation or severity of at least one of its clinical signs. In another embodiment, "treat" or "reduce the severity of "Treatment" refers to ameliorating at least one physical parameter, which amelioration is achieved by: In yet another embodiment, "treat" or " "Treatment" refers to physically modulating a disease or disorder (e.g., stabilizing discernible symptoms). ), physiological regulation (e.g., stabilization of physiological parameters) or In a further embodiment, "treat" or "treatment" refers to the treatment of a disease. Concerning slowing progression.

[0126] As used herein, the term "isotopic variant" refers to a compound that is Such compounds may contain unnatural proportions of isotopes at one or more of the atoms that constitute them. For example, an "isotopic variant" of a compound is one or more Non-radioactive isotopes that can be used, such as deuterium ( 2 H or D), carbon-13 ( 13 C) , Nitrogen-15( 15 N) and the like. In the following atoms, if present, for example, any hydrogen 2 Can it be H / D? The carbon of interest 13 C or any nitrogen 15 N can vary The presence and location of such atoms is within the skill of the art. It will be understood that the present invention may also be used in conjunction with isotopic ballasts having radioisotopes. This may include the preparation of compounds, for example, in which the resulting compounds are drugs and / or substrates. It can be used in tissue distribution studies of the radioisotope tritium, i.e. 3 H, and and carbon-14, i.e. 14 C is available due to their ease of incorporation and detection means. In view of the fact that positron-emitting isotopes (e.g. For example, 11 C. 18 F, 15 O and13 N) substituted compounds can be prepared, The compounds were subjected to positron emission tomography (PET) studies to examine substrate receptor occupancy. The compounds provided herein, whether radioactive or not, may be useful in All isotopic variants of are intended to be encompassed within the scope of the present invention.

[0127] have the same molecular formula but differ in the nature or sequence of bonding of their atoms or in the spatial arrangement of their atoms It should also be understood that compounds that have different spatial arrangements of the atoms are referred to as "isomers." Such isomers are called "stereoisomers."

[0128] Stereoisomers that are not mirror images of each other are called "diastereomers" and are superimposable on top of each other. When a compound has an asymmetric center, it is called an "enantiomer." When it is bonded to four different groups, for example, a pair of enantiomers exists. Enantiomers may be characterized by the absolute configuration of their chiral centers, as described by Cahn and and Prelog's R- and S-sequencing rules. or by the way that its molecules rotate the plane of polarized light, either dextrorotatory or are often designated as levorotatory (i.e., as (+) or (-)-isomers, respectively). Chiral compounds can exist as individual enantiomers or as mixtures thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture."

[0129] "Tautomers" are interchangeable forms of a particular compound structure in which hydrogen and The term refers to compounds in which the electron displacement is different. The structure can be in equilibrium with the movement of π electrons and atoms (usually H). For example, Nols and ketones are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the isomerism that occurs when the compound is treated with acid or base. The tautomers are the aci- and nitro- forms of phenylnitromethane, This can be beneficial in achieving optimal chemical reactivity and biological activity of the compound of interest.

[0130] As used herein, a pure enantiomer of a compound is a compound that is enantiomerically pure relative to the other enantiomer of that compound. or substantially free of stereoisomers (i.e., in enantiomeric excess). The "S" forms of the compounds are substantially free of the "R" forms of the compounds and therefore have the mirror image form, The term "enantiomerically pure" or "pure enantiomer" refers to a compound that is More than 75% by weight, more than 80% by weight, more than 85% by weight, more than 90% by weight, more than 91% by weight, 92% by weight Super, more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, 98% by weight More than 98.5% by weight, more than 99% by weight, more than 99.2% by weight, more than 99.5% by weight, 99 More than 0.6%, more than 99.7%, more than 99.8% or more than 99.9% by weight enantiomeric In certain embodiments, the weight includes all enantiomeric forms of the compound. Based on the total weight of the compound or stereoisomer.

[0131] As used herein, unless otherwise indicated, the term "enantiomerically pure R-form "Compound" refers to a mixture of at least about 80% by weight of an R-compound and at most about 20% by weight of an S-compound. a mixture of at least about 90% by weight of an R-compound and at most about 10% by weight of an S-compound; At least about 95% by weight of R-compounds and at most about 5% by weight of S-compounds, At least about 99% by weight of R-compounds and at most about 1% by weight of S-compounds, 0.9% by weight of R-compounds or at most about 0.1% by weight of S-compounds. In certain embodiments, the weights are based on the total weight of the compound.

[0132] As used herein, unless otherwise indicated, the term "enantiomerically pure S-form "S-compound" or "S-compound" means a mixture of at least about 80% by weight of S-compound and at most About 20% by weight of the R-compound, at least about 90% by weight of the S-compound and at most about 10 % by weight of the R-compound, at least about 95% by weight of the S-compound, and at most about 5% by weight of R-compounds, at least about 99% by weight of S-compounds and at most about 1% by weight of R-compounds or at least about 99.9% by weight of S-compounds and at most about 0.1% by weight of R- In certain embodiments, the weight is based on the total weight of the compound.

[0133] In the compositions provided herein, enantiomerically pure compounds or their pharmaceutical equivalents are The acceptable salts, solvates, hydrates or prodrugs of For example, a pharmaceutical composition containing an enantiomerically pure R-compound may be present together with an inactive ingredient. The composition may, for example, contain about 90% excipients and about 10% enantiomerically pure R-compound. In certain embodiments, the enantiomerically pure R The compound may, for example, be at least about 95% by weight of an R-compound, based on the total weight of the compound. and at most about 5% by weight of S-compound. A pharmaceutical composition containing the compound may, for example, be about 90% excipient and about 10% enantiomerically pure glycerol. In certain embodiments, the mirror-imageable S-compounds in such compositions may include An enantiomerically pure S-compound may, for example, have an isomerization ratio of at least about 95%, based on the total weight of the compound. % by weight of S-compounds and at most about 5% by weight of R-compounds. In the formulation, the active ingredient is formulated with little or no excipients or carriers. It can be formulated as a drug.

[0134] The compounds of the present invention may have one or more asymmetric centers; Such compounds may be present as individual (R)- or (S)-stereoisomers or mixtures thereof. It can be generated as follows.

[0135] Unless otherwise indicated, the description or designation of a particular compound in the specification and claims is intended to include both the individual enantiomers and mixtures thereof, racemic or not. Methods for determining stereochemistry and for separating stereoisomers are shown in the figures. , are well known in the art.

[0136] The maximum number of heteroatoms in a stable, chemically feasible heterocyclic ring is the maximum number of heteroatoms that can be The ring size, degree of unsaturation and heterocyclic groups, whether aromatic or non-aromatic, It will be recognized by those skilled in the art of organic synthesis that the valence of the atoms is a determining factor. The heterocyclic ring may be any aromatic ring, as long as the aromatic ring is chemically feasible and stable. It may have up to 4 heteroatoms. Detailed Description of Certain Embodiments of the Invention

[0137] In certain embodiments, as NMDA receptor modulators, A wide range of CNS conditions, particularly schizophrenia, depression, bipolar disorder (e.g., I and / or or II), schizoaffective disorder, mood disorder, anxiety disorder, personality disorder, psychosis, or obsessive-compulsive disorder. , Post-Traumatic Stress Disorder (PTSD), Autism Spectrum Disorder (ASD), Dysthymia (Mild Depression) , social anxiety disorder, obsessive-compulsive disorder (OCD), pain (e.g., painful syndrome or disorder), sleep Sleep disorders, memory disorders, dementia, Alzheimer's disease, seizure disorders (e.g., epilepsy), traumatic brain injury injury, stroke, addictive disorders (e.g., opiates, cocaine and / or alcohol) addiction to drugs), autism, Huntington's disease, insomnia, Parkinson's disease, withdrawal syndrome or tinnitus 3-α and 3β-hydroxysteroid compounds useful for the prevention and / or treatment of These compounds have improved in vivo efficacy, pharmacokinetic properties, and PK properties, oral bioavailability, suitability for formulation, stability and / or safety It is expected to show

[0138] compound Exemplary compounds described herein include agonists of NMDAR or NMDAR antagonists. Positive allosteric modulators (PAMs) of the DAR are also included. In some embodiments, the compounds described herein act as NMDAR antagonists or NA The compounds described herein include naturally occurring and non-naturally occurring s Includes steroids and sterols (e.g., 24(S)-hydroxycholesterol). In some embodiments, the compound is an oxysterol. In the form, the compound has a C-17β end group as shown in the compound of formula (I). 3-β-hydroxyl groups with alkyl side chains and optional substitutions at various positions on the steroid skeleton Further exemplary compounds include 24(s)-hydroxycholesterol steroids. Compounds that enhance (e.g., increase) the endogenous activity or amount of terol (e.g., 2 Compounds that inhibit the enzyme that metabolizes 4(s)-hydroxycholesterol, e.g., 24- Compounds that inhibit hydroxycholesterol 7 alpha-hydroxylase (CYP39) or 24(s)-hydroxycholesterol. Compounds that activate the enzyme that produces 24(s)-hydroxycholesterol Compounds that activate cholesterol 24(S)-hydroxylase (CYP46), e.g. Compounds that

[0139] In some embodiments, the compound used in the methods described herein, e.g., the methods of evaluation or treatment described herein, is a compound according to formula (I): [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer, isotopic variant, or N-oxide thereof, or any combination thereof; During the ceremony: Z is a group of formula (i), (ii), (iii), (iv) or (v): [ka] L 1 and L 2 is a bond, substituted or unsubstituted C 1 -C 6Alkylene, substituted or unsubstituted C 2 -C 6 Alkenylene, substituted or unsubstituted C 2 -C 6 Alkynylene, substituted or unsubstituted hetero C 1 -C 6 Alkylene, substituted or unsubstituted hetero C 2 -C 6 Alkenylene and substituted or unsubstituted heteroC 2 -C 6 alkynylene; L 3 is a substituted or unsubstituted C 1 -C 6 Alkylene, substituted or unsubstituted C 2 -C 6 Alkenylene, substituted or unsubstituted C 2 -C 6 Alkynylene, substituted or unsubstituted hetero C 1 -C 6 Alkylene, substituted or unsubstituted hetero C 2 -C 6 Alkenylene or substituted or unsubstituted hetero C 2 -C 6 alkynylene; X 1 and X 2 Each instance of is independently -O-, -S-, -N(R X )-, where R X each instance of is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, or an amino protecting group; R 1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, -N 3 , -NO 2 , -SCN, -CN, -ORA1 、-SR A1 、-N(R A1 ) 2 、-N=NR A1 、-N=C(R A1 ) 2 、-N(OR A1 )(R A1 )、-C(=O)R A1 、-C(=O)OR A1 、-C(=O)SR A1 、-C(=O)N(R A1 ) 2 、-C(=O)N(OR A1 )(R A1 )、-OC(=O)R A1 、-OC(=O)OR A1 、-OC(=O)SR A1 、-OC(=O)N(R A1 ) 2 、-NR A1 C(=O)R A1 、-NR A1 C(=O)OR A1 、-NR A1 C(=O)SR A1 、-NR A1 C(=O)N(R A1 ) 2 、-SC(=O)R A2 、-SC(=O)OR A1 、-SC(=O)SR A1 、-SC(=O)N(R A1 ) 2 、-OS(=O) 2 R A2 、-OS(=O) 2 OR A1 、-S-S(=O) 2 R A2 、-S-S(=O) 2 OR A1 、-S(=O)R A2 、-SO 2 R A2 、-NR A1 SO 2 R A2 、または-SO 2 N(R A1 ) 2 であり、ここで、R A1is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R A1 The groups are joined to form a substituted or unsubstituted heterocyclic ring; R A2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, or R A1 Groups and R A2 the groups are joined to form a substituted or unsubstituted heterocyclic ring; R 2 , R 4a , R 4b , R 7a , R 7b , R 11a and R 11b Each instance of is independently selected from hydrogen, -OH, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N 3 , -NO 2 , -SCN, -CN, -OR B1 , -SR B1 , -N(R B1 ) 2 , -N=NR B1 , -N=C(R B1 ) 2 , -N(OR B1 )(R B1 ), -C(=O)R B1 , -C(=O)OR B1 , -C(=O)SR B1 , -C(=O)N(R b1 ) 2 , -C(=O)N(OR B1 )(RB1 ), -OC(=O)R B1 , -OC(=O)OR B1 , -OC(=O)SR B1 , -OC(=O)N(R B1 ) 2 , -NR B1 C(=O)R B1 , -NR B1 C(=O)OR B1 , -NR B1 C(=O)SR B1 , -NR B1 C(=O)N(R B1 ) 2 , -SC(=O)R B2 , -SC(=O)OR B1 , -SC(=O)SR B1 , -SC(=O)N(R B1 ) 2 , -OS(=O) 2 R B2 , -OS(=O) 2 OR B1 , -SS(=O) 2 R B2 , -SS(=O) 2 OR B1 , -S(=O)R B2 , -SO 2 R B2 , -NR B1 SO 2 R B2 , or -SO 2 N(R B1 ) 2 where R B1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R B1 The groups are joined to form a substituted or unsubstituted heterocyclic ring; R B2is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, or R B1 Groups and R B2 The groups may be joined to form a substituted or unsubstituted heterocyclic ring; or optionally, R 4a and R 4b and / or R 7a and R 7b and / or R 11a and R 11b each taken together form an oxo (=O) group; R 3a is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 3b is hydrogen, -C(=O)R C1 , -C(=O)OR C1 , -C(=O)SR C1 , -C(=O)N(R C1 ) 2 , -S(=O) 2 R C2 , -S(=O) 2 OR C1 , -P(=O) 2 R C2 , -P(=O) 2 OR C1 , -P(=O)(OR C1 ) 2 , -P(=O)(R C2 ) 2 , or -P(=O)(R C2 )(OR C1 ), where R C1is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R C1 The groups are joined to form a substituted or unsubstituted heterocyclic ring; R C2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 6a and R 6b each is independently hydrogen, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; [ka] represents a single bond or a double bond, provided that when a double bond is present in ring B, R 6a or R 6b is absent and a single bond is present in ring B, then the hydrogen at C5 is in the alpha or beta position; R 14 is hydrogen or substituted or unsubstituted alkyl; R 17 is hydrogen, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or -OR D1 where R D1is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; R 18 , R 19 and R 20 Each instance of is independently hydrogen or substituted or unsubstituted alkyl; R 23a and R 23b Each instance of is independently hydrogen, halogen, or substituted or unsubstituted alkyl, or R 23a and R 23b are connected together to form substituted or unsubstituted C 3 -C 6 Forming a cycloalkyl; R 24 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C(=O)R E1 , -C(=O)OR E1 , -C(=O)SR E1 , -C(=O)N(R E1 ) 2 , -S(=O) 2 R E2 , -S(=O) 2 OR E1 , -P(=O) 2 R E2 , -P(=O) 2 OR E1 , -P(=O)(OR E1 ) 2 , -P(=O)(R E2 ) 2 , or -P(=O)(R E2 )(OR E1 ), where R E1is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R E1 The groups are joined to form a substituted or unsubstituted heterocyclic ring; R E2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; Y is -O-, -S- or -NR Z5 - and; R Z4 are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -OR Z5 , -SR Z5 or -N(R Z5 ) 2 and; R Z5 Each instance of is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R Z5 the groups are joined to form a substituted or unsubstituted heterocyclic ring; R Z6 Each instance of is independently hydrogen or substituted or unsubstituted alkyl, or two R Z6 The group is connected, C 3-6 Forming a carbocyclic ring; The subscript n is 0, 1, 2 or 3.

[0140] In certain embodiments, R 3a is H, n is 1, and R 19 But, Me When R 1 is other than H, alkyl, alkenyl or alkynyl. In the embodiment, R 3a is H and R 3b is -COMe, and R 19 But, M e and n is 0; R 1 is OH. In certain embodiments, R 3a is H, n is 0, and R 20 is alkyl; R 1 is other than OH In certain embodiments, R 19 When Me is;R 1 H, Alki In certain embodiments, R is other than aryl, alkenyl, or alkynyl. 1 is H ;R 19 is other than Me. In certain embodiments, R 1 and R 3a of Each is H;R 19 is other than Me.

[0141] In certain embodiments, R 3a When H, R 1 is other than H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl. 3a When H, R 1 is a substituted or unsubstituted carbocyclyl, a substituted or unsubstituted heterocyclyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a halo, -N 3 , -NO2 、-SCN、-CN、-OR A1 、-SR A1 、-N(R A1 ) 2 、-N=NR A1 、-N=C(R A1 ) 2 、-N(OR A1 )(R A1 )、-C(=O)R A1 、-C(=O)OR A1 、-C(=O)SR A1 、-C(=O)N(R A1 ) 2 、-C(=O)N(OR A1 )(R A1 )、-OC(=O)R A1 、-OC(=O)OR A1 、-OC(=O)SR A1 、-OC(=O)N(R A1 ) 2 、-NR A1 C(=O)R A1 、-NR A1 C(=O)OR A1 、-NR A1 C(=O)SR A1 、-NR A1 C(=O)N(R A1 ) 2 、-SC(=O)R A2 、-SC(=O)OR A1 、-SC(=O)SR A1 、-SC(=O)N(R A1 ) 2 、-OS(=O) 2 R A2 、-OS(=O) 2 OR A1 、-S-S(=O) 2 R A2 、-S-S(=O) 2 OR A1 、-S(=O)R A2 、-SO 2 R A2 、-NR A1 SO 2 R A2 、または-SO 2 N(R A1 ) 2 である。

[0142] In certain further embodiments, the following compound: [ka] and pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers thereof, Tautomers, isotopic variants or N-oxides or combinations thereof are expressly intended to be included herein. are excluded.

[0143] R 3a Various embodiments of the present invention As generally defined above, R 3a is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carboxyl aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted aryl; or unsubstituted heteroaryl. 3a is alpha (lower) or beta (upper) It is broadly understood that R 3a Alf In certain embodiments, R 3a is beta.

[0144] In certain embodiments, R 3a is hydrogen.

[0145] In certain embodiments, R 3a is a substituted or unsubstituted alkyl, e.g., or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted substitution C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4 -5 Alkyl or substituted or unsubstituted C 5-6 An exemplary R is an alkyl group. 3a C 1- 6 The alkyl group may be substituted or unsubstituted, such as methyl (C 1 ), ethyl (C 2 ), n-p Ropil (C 3 ), isopropyl (C 3 ), n-Butyl (C 4 ), tert-Butyl (C 4 ), sec-Butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-P Ntanil (C 5 ), Amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), n-hexyl (C 6 ), 1, 2, 3, 4, 5, 6, 7 , 8, 9, 10 or more fluoro-substituted C 1-6 Alkyl (e.g. , -CF 3 , -CH 2 F, -CHF 2 , difluoroethyl and 2,2,2-trifluoro b-1,1-dimethyl-ethyl), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or More than one chloro-substituted C 1-6 Alkyl (e.g., -CH 2 Cl, -CHC l 2 ) and alkoxy-substituted C 1-6 Alkyl (e.g., -CH 2 OCH 3 oh Yobi-CH 2 OCH 2 CH 3) are included, but are not limited to. In this state, R 3a is a substituted alkyl, e.g., R 3a is haloalkyl, alkoxy In certain embodiments, R 3a is M e, Et, n-Pr, n-Bu, i-Bu, fluoromethyl, chloromethyl, difluoro Methyl, trifluoromethyl, trifluoroethyl, difluoroethyl, 2,2,2-trifluoroethyl Trifluoro-1,1-dimethyl-ethyl, methoxymethyl, methoxyethyl or ethoxy In certain embodiments, R 3a Me, Et, n-Pr, n- In certain embodiments, R 3a is methoxymethyl, ethoxymethyl, propoxymethyl, methoxyethyl or ethoxyethyl. In certain embodiments, R 3a is trifluoromethoxymethyl. In the embodiment, R 3a are fluoromethyl, chloromethyl, difluoromethyl, trifluoromethyl, Fluoromethyl, difluoroethyl, trifluoroethyl or 2,2,2-trifluoro -1,1-dimethyl-ethyl. In certain embodiments, R 3a is a trifle It is oromethyl.

[0146] In certain embodiments, R 3a is a substituted or unsubstituted alkenyl, e.g., substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-3 Alkenyl, optionally substituted or unsubstituted C 3-4 Alkenyl, substituted or unsubstituted C 4-5Alkenyl or substituted or unsubstituted or unsubstituted C 5-6 alkenyl. In certain embodiments, R 3a is a non-permutation or alkyl, halo, haloalkyl, alkoxyalkyl or hydroxyl ethenyl (C 2 ), propenyl (C 3 ) or butenyl (C 4 In certain embodiments, R 3a is unsubstituted or alkyl, halo, haloalkyl, alkoxyalkyl or is ethenyl, propenyl or butenyl substituted with hydroxy. In the embodiment, R 3a is ethenyl.

[0147] In certain embodiments, R 3a is a substituted or unsubstituted alkynyl, e.g., substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 2-3 Alkynyl, optionally substituted or unsubstituted C 3-4 Alkynyl, substituted or unsubstituted C 4-5 Alkynyl or optionally substituted or unsubstituted C 5-6 alkynyl. Exemplary substituted or unsubstituted R 3a Alkynyl groups The alkyl, halo, haloalkyl (e.g., CF 3 ), Alcoki cycloalkyl (e.g., cyclopropyl or cyclobutyl) or hydoalkyl hydroxyl-substituted ethynyl, propynyl or butynyl. Not limited thereto. In certain embodiments, R 3a is trifluoroethynyl, cyclo Propylethynyl, cyclobutylethynyl and propynyl, fluoropropynyl and In certain embodiments, R 3a is non Substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or from the group consisting of unsubstituted carbocyclyl and substituted or unsubstituted heterocyclyl Ethynyl (C 2 ), Propini Lu (C 3 ) or butynyl (C 4 In certain embodiments, R 3a Is, place Phenyl-substituted ethynyl (C 2 ), Propynyl (C 3 ) or butynyl (C 4 In certain embodiments, the phenyl substituten t) is halo, alkyl, trifluoroalkyl, alkoxy, acyl, amino or a and m is 0, 1 or 2. The alkyl group is further substituted with one or more substituents selected from the group consisting of: In certain embodiments, R 3a is a substituted or unsubstituted pyrrolyl, imidazolyl, Pyrazolyl, oxazolyl, thiazolyl, isoxazolyl, 1,2,3-triazolyl , 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl or tetrazolyl substituted with ethynyl (C 2 ), Propynyl (C 3 ) or butynyl (C 4 ).

[0148] In certain embodiments, R 3a is unsubstituted or alkyl, halo, haloal ethynyl, propynyl or substituted with alkyl, alkoxyalkyl or hydroxyl; or butynyl. In certain embodiments, R 3a is a substituted or unsubstituted ary In certain embodiments, R is ethynyl or propynyl substituted with aryl. 3 a is unsubstituted phenyl or halo, alkyl, alkoxy, haloalkyl, trihaloa phenyl substituted with alkyl or acyl; In certain embodiments, R 3a is substituted or unsubstituted carbocyclyl In certain embodiments, R is substituted, ethynyl or propynyl. 3a teeth, Substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl In certain embodiments, R is ethynyl or propynyl substituted with sil. 3a is ethynyl or propynyl substituted with a substituted or unsubstituted heteroaryl; In certain embodiments, R 3a is a substituted or unsubstituted pyridinyl or pyridinyl group; In certain embodiments, the aryl group is ethynyl or propynyl substituted with rimidinyl. R 3a is a substituted or unsubstituted pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, isoxazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl substituted with aryl, oxadiazolyl, thiadiazolyl, tetrazolyl, ethynyl or In certain embodiments, R 3a is a substituted or unsubstituted heterocyclic In certain embodiments, the aryl group is ethynyl or propynyl substituted with aryl. R 3a is a substituted or unsubstituted pyrrolidinyl, piperidinyl, piperazinyl or molar ethynyl or propynyl substituted with mopholinyl. In certain embodiments, R 3a is a hydroxyl or alkoxy substituted proline. In certain embodiments, R 3a Methoxy or is propynyl or butynyl substituted with ethoxy. R 3a is ethynyl or propynyl substituted with Cl. In this state, R 3a is ethynyl or propynyl substituted with trifluoromethyl; be.

[0149] In certain embodiments, R 3a is a substituted or unsubstituted carbocyclyl, for example Substituted or unsubstituted C 3-6 Carbocyclyl, substituted or unsubstituted C 3-4 Carbocycli , substituted or unsubstituted C 4-5 Carbocyclyl or substituted or unsubstituted C 5-6 Cal It is bocyclyl.

[0150] In certain embodiments, R 3a is a substituted or unsubstituted heterocyclyl, for example Substituted or unsubstituted 3- to 6-membered heterocyclyl, substituted or unsubstituted 3- to 4-membered heterocyclyl substituted or unsubstituted 4- to 5-membered heterocyclyl or substituted or unsubstituted 5- to 6-membered heterocyclic It is Rocyclyl.

[0151] In certain embodiments, R 3a is substituted or unsubstituted aryl. In the embodiment, R 3a is substituted or unsubstituted phenyl.

[0152] In certain embodiments, R 3a is a substituted or unsubstituted heteroaryl, for example It is an optionally substituted 5-6 membered heteroaryl.

[0153] R 3a Further embodiments of the invention include substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, As substituted or unsubstituted alkynyl groups, the following are examples: [ka] where R 3c Each instance of -OR is hydrogen, halo, or -OR. F1 where R F1 is substituted or unsubstituted alkyl; R 3d Each instance of or unsubstituted alkyl, substituted or unsubstituted carbocyclyl or substituted or unsubstituted It is a heterocyclyl.

[0154] In certain embodiments, at least one R 3c is hydrogen. In an embodiment, at least two R 3c is hydrogen. In certain embodiments, , each R 3c is hydrogen. In certain embodiments, at least one R 3c teeth, Halogen (e.g., fluoro, chloro, bromo, iodo). In this case, at least two R 3c is a halogen (e.g., fluoro, chloro, bromo, iodine). In certain embodiments, each R 3cis a halogen (e.g., the group -CF 3 In certain embodiments, at least one R 3c -OR F1 (e.g., OMe or OEt). In certain embodiments, At least two R 3c -OR F1 (e.g., OMe or OEt). In certain embodiments, at least one R 3c is hydrogen, F, -OMe or -OEt In certain embodiments, R 3c One of the is F, -OMe or OEt. the remainder is H.

[0155] In certain embodiments, at least one R 3d is hydrogen. In the embodiment, each R 2c is hydrogen. In certain embodiments, at least one R 3d is halogen (e.g., fluoro, chloro, bromo, iodo). In certain embodiments, each R 3d is a halogen (e.g., fluoro, chloro, bromo, iodine). In certain embodiments, each R 3d is alkyl, for example, each R 2c is Me. In certain embodiments, one R 3d is an alkyl the other is hydrogen, e.g., one R 3d is Me; the other is hydrogen. In certain embodiments, one R 3d is a substituted or unsubstituted carbocyclyl, e.g. , cyclopropyl or cyclobutyl, and the other is hydrogen. In the 3d is hydrogen, -F, -Br, -Cl, -I, -CH 3 , -CF 3 , cyclopropyl or cyclobutyl. 3d Each instance of R is H. In certain embodiments, R 3d Each example is a halogen (e.g., fluoro, chloro, bromo, iodo). In certain embodiments, R 3d Each example of is alkyl, e.g., -CH 3 , -CF 3 , -CH 2 CH 2 Cl In certain embodiments, R 3d Each example of the formula is a substituted or unsubstituted carbocyclyl, For example, cyclopropyl or cyclobutyl. In certain embodiments, R 3 d is substituted or unsubstituted cyclopropyl. In certain embodiments, R 3d of Examples are hydrogen, -F, -Br, -Cl, -I, -CH 3 , -CF 3 , -CH 2 CH 2 C l, cyclopropyl or cyclobutyl. 3d teeth , Me or Cl. In certain embodiments, R 3d can be used to It is a terocyclic.

[0156] -X 1 -R 3b Various embodiments of the present invention As generally defined above, the group -X 1 R 3b For X 1 are independently -O-, -S- or -N(RX )-, where R X Each instance of is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, or an amino protecting group; 3b is hydrogen, -C(=O)R C1 , -C(=O)OR C1 , -C(=O)SR C1 , -C(=O)N(R C1 ) 2 , -S(=O) 2 R C1 , -S(=O) 2 OR C1 , -P(=O) 2 R C1 , -P(=O) 2 OR C1 , -P(=O)(OR C1 ) 2 , -P(=O)(R C1 ) 2 , or -P(=O)(R C1 )(OR C1 ), where R C1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R C1 The groups may be joined to form a substituted or unsubstituted heterocyclic ring. 1 -R 3b It is broadly understood that may be at the alpha position (down) or the beta position (up). In certain embodiments, the group -X 1 -R 3b is alpha. In certain embodiments, the group -X 1 -R 3b is beta.

[0157] In certain embodiments, X 1 is -O-. In certain embodiments, X 1 In certain embodiments, X is -S-. 1 is -N(R X )-. In certain embodiments, R X is alkyl. In certain embodiments, R X is Me, Et or i-Pr. In certain embodiments, R X is H Yes, i.e., X 1 is -NH-.

[0158] In certain embodiments, R 3b is hydrogen. For example, in certain embodiments In the above, the group -X 1 R 3b is -OH. In certain embodiments, the group -X 1 R 3 b is -SH. In certain embodiments, the group -X 1 R 3b is -NH 2 or -NHR X It is.

[0159] In certain embodiments, R 3b is -C(=O)R C1 , -C(=O)OR C1 , -C(=O)SR C1 , -C(=O)N(R C1 ) 2 , -S(=O) 2 R C1 , -S(=O) 2 OR C1 , -P(=O) 2 R C1 , -P(=O) 2 OR C1 , -P(=O)(OR C1 )2 , -P(=O)(R C1 ) 2 , or -P(=O)(R C1 )(OR C1 ).

[0160] In certain embodiments, R C1 At least one instance of is hydrogen or a protecting group, That is, when attached to an oxygen atom, it is an oxygen protecting group, and when attached to a sulfur atom, it is an oxygen protecting group. is a sulfur protecting group or, when attached to a nitrogen atom, a nitrogen protecting group. In terms of form, R C1 At least one instance of is hydrogen.

[0161] In certain embodiments, R C1 At least one instance of alkyl, e.g., substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 a , substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, Substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 Alkyl . An example R C1 C 1-6 The alkyl group may be substituted or unsubstituted, such as methyl (C 1 ), Ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-Butyl (C 4 ), tert-Butyl (C 4 ), sec-Butyl (C 4 ), iso-butyl (C 4 ), n-pe Ntil (C 5 ), 3-pentanyl (C 5 ), Amyl (C 5), neopentyl (C 5 ), 3 -Methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), n-hexyl (C 6 ), 1, C substituted with 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fluoro groups 1-6 Alkyl (e.g., -CF 3 , -CH 2 F, -CHF 2 , difluoroethyl and 2,2,2-trifluoro-1,1-dimethyl-ethyl), 1, 2, 3, 4, 5, 6, 7 , 8, 9, 10 or more chloro groups substituted C 1-6 Alkyl (e.g. -CH 2 Cl, -CHCl 2 ) and alkoxy-substituted C 1-6 Alkyl (e.g. For example, -CH 2 OCH 3 and -CH 2 OCH 2 CH 3 ) but are not limited to these do not have.

[0162] In certain embodiments, R C1 At least one instance of Alkenyl, for example, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2- 3 Alkenyl, substituted or unsubstituted C 3-4 Alkenyl, substituted or unsubstituted C 4-5 a Alkenyl or substituted or unsubstituted C 5-6 It is alkenyl.

[0163] In certain embodiments, R C1 At least one instance of Alkynyl, for example, substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 2- 3 Alkynyl, substituted or unsubstituted C 3-4 Alkynyl, substituted or unsubstituted C 4-5 a Rucynyl or substituted or unsubstituted C 5-6 It is alkynyl.

[0164] In certain embodiments, R C1 At least one instance of Rubocyclyl, e.g., substituted or unsubstituted C 3-6 Carbocyclyl, substituted or unsubstituted exchange C 3-4 Carbocyclyl, substituted or unsubstituted C 4-5 Carbocyclyl or substituted or unsubstituted C 5-6 It is a carbocyclyl.

[0165] In certain embodiments, R C1 At least one instance of Heterocyclyl, for example, substituted or unsubstituted 3- to 6-membered heterocyclyl, substituted or unsubstituted substituted 3-4 membered heterocyclyl, substituted or unsubstituted 4-5 membered heterocyclyl or substituted or More preferably, it is unsubstituted 5- or 6-membered heterocyclyl.

[0166] In certain embodiments, R C1 At least one instance of Aryl is, for example, substituted or unsubstituted phenyl.

[0167] In certain embodiments, R C1 At least one instance of Heteroaryl, for example, optionally substituted 5-6 membered heteroaryl.

[0168] In certain embodiments, two R C1 The group is connected to a substituted or unsubstituted heterocyclic Cyclic rings, such as substituted or unsubstituted piperidinyl rings, substituted or unsubstituted piperazinyl The aryl group forms a substituted or unsubstituted morpholinyl ring.

[0169] In certain embodiments, R 3b is -C(=O)R C1 , -C(=O)OR C1 , -C(=O)N(R C1 ) 2 or -C(=O)N(OR C1 )(R C1 ) and So, R C1 is as defined herein.

[0170] In certain embodiments, R 3b is -C(=O)R C1 For example, R C1 is, for example, a substituted or unsubstituted methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-Butyl (C 4 ), tert-Butyl (C 4 ), sec -Butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl ( C 5 ), Amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), Tertiary amyl (C 5 ) or n-hexyl (C 6 In certain embodiments, , R 3b is -C(=O)CH3 In certain embodiments, R 3b -C (=O)(CH 2 ) m CO 2 H, where m is an integer between 2 and 5. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 4. In certain embodiments, m is , 5. In certain embodiments, R 3b is -C(=O)CH 2 CH 2 C(= O)OH.

[0171] In certain embodiments, R 3b is -C(=O)OR C1 For example, R C 1 is, for example, a substituted or unsubstituted methyl (C 1 ), ethyl (C 2 ), n-propyl ( C 3 ), isopropyl (C 3 ), n-Butyl (C 4 ), tert-Butyl (C 4 ), se c-Butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), Amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ) , tertiary amyl (C 5 ) or n-hexyl (C 6 ).

[0172] In certain embodiments, R 3b is -C(=O)SR C1For example, R C 1 is, for example, a substituted or unsubstituted methyl (C 1 ), ethyl (C 2 ), n-propyl ( C 3 ), isopropyl (C 3 ), n-Butyl (C 4 ), tert-Butyl (C 4 ), se c-Butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), Amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ) , tertiary amyl (C 5 ) or n-hexyl (C 6 ).

[0173] In certain embodiments, R 3b is -C(=O)N(R C1 ) 2 , e.g., -C (=O)NH 2 or -C(=O)NHR C1 where R C1 For example, the substitution or unsubstituted methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), isopropanol Pill (C 3 ), n-Butyl (C 4 ), tert-Butyl (C 4 ), sec-Butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), Amyl (C 5 ), neopentyl (C 5), 3-methyl-2-butanyl (C 5 ), tertiary amyl ( C 5 ) or n-hexyl (C 6 ) or R 1 is -C(=O)N(R C1 ) 2 where the two R C1 The group is connected to a substituted or unsubstituted heterocyclic ring For example, a substituted or unsubstituted piperidinyl ring, a substituted or unsubstituted piperazinyl ring or forms a substituted or unsubstituted morpholinyl ring.

[0174] In certain embodiments, R 3b is -S(=O) 2 R C1 or -S(=O) 2 OR C1 where R C1 is, for example, hydrogen or a substituted or unsubstituted methyl Lu (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-Butyl Lu (C 4 ), tert-Butyl (C 4 ), sec-Butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), Amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ) or n-hex Sil (C 6 ), or substituted or unsubstituted phenyl. , R 3b is -S(=O) 2 RC1 In certain embodiments, R 3b teeth,- S(=O) 2 OR C1 , e.g., -SO 3 It's H.

[0175] In certain embodiments, R 3b is -P(=O) 2 R C1 , -P(=O) 2 OR C1 , -P(=O)(OR C1 ) 2 , -P(=O)(R C1 ) 2 or -P(=O)(R C1 )(OR C1 ), where each R C1 are, for example, independently hydrogen, a substitution or Unsubstituted methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-Butyl (C 4 ), tert-Butyl (C 4 ), sec-Butyl (C 4 ), is o-Butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), Amyl (C 5 ) , neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 )too or n-hexyl (C 6 ) or substituted or unsubstituted phenyl. In terms of form, R 3b is -P(=O) 2 R C1 In certain embodiments, R 1is -P(=O) 2 OR C1 In certain embodiments, R 3b -P (=O)(OR C1 ) 2 In certain embodiments, R 1 is -P(=O)( R C1 ) 2 In certain embodiments, R 3b is -P(=O)(R C1 )( OR C1 ).

[0176] Various embodiments in which Z is a group of formula (i) or (ii) In certain embodiments, Z is a group of formula (i): [ka]

[0177] In other embodiments, Z is a group of formula (ii): [ka]

[0178] As generally defined above, L 1 and L 2 is a bond (i.e., in other words , absent) or substituted or unsubstituted C 1 -C 6 Alkylene, substituted or unsubstituted substitution C 2 -C 6 Alkenylene, substituted or unsubstituted C 2 -C 6 Alkynylene, substituted or is unsubstituted heterocyclic C 1 -C 6 Alkylene, substituted or unsubstituted hetero C 2 -C 6 Alkenira or substituted or unsubstituted heterocyclic 2 -C 6 It is alkynylene.

[0179] In certain embodiments, L 1 or L 2 is a bond.

[0180] In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C 1 -C 6 Alki In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C 1 - C 4 In certain embodiments, L 1 or L 2 is a replacement or non-replacement substitution C 1 -C 3 In certain embodiments, L 1 or L 2 Is, place Substituted or unsubstituted C 1 -C 2 In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C 1 In certain embodiments, L 1 Ma Or L 2 is a substituted or unsubstituted C 2 In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C 3 In certain embodiments, the alkylene is , L 1 or L 2 is a substituted or unsubstituted C 4 In certain embodiments, the alkylene is L 1 or L 2 is a substituted or unsubstituted C 5 In certain embodiments, the alkylene is an alkylene. In L 1 or L 2 is a substituted or unsubstituted C 6 In certain embodiments, the alkylene is In terms of shape, L 1 or L 2 is selected from the group consisting of substituted or unsubstituted alkyl and halo. Alkyl groups as described above substituted with one or more selected substituents. In certain embodiments, L 1 or L 2 is -CH 2 -,-CHMe -, -CMe 2 -, -CH 2 -CH 2 -, -CF 2 -CH 2 -, -CH 2 -CMe 2 -, -CH 2 -CH 2 -CH 2 -or-CH 2 -CH 2 -CMe 2 -It is.

[0181] In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C 2 -C 6 Arke In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C 2 -C 5 In certain embodiments, L 1 or L 2 is replaced or is unsubstituted C 2 -C 4In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C 2 -C 3 In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C 2 In certain embodiments, the alkenylene is L 1 or L 2 is a substituted or unsubstituted C 3 alkenylene. In L 1 or L 2 is a substituted or unsubstituted C 4 It is an alkenylene. In the embodiment, L 1 or L 2 is a substituted or unsubstituted C 5 Alkenylene. In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C 6 It is alkenylene. In certain embodiments, L 1 or L 2 is a substituted or unsubstituted alkyl and halo substituted with one or more substituents selected from the group consisting of Such an alkenylene group is

[0182] In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C 2 -C 6 Alki In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C 2 -C 5In certain embodiments, L 1 or L 2 is replaced or is unsubstituted C 2 -C 4 In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C 2 -C 3 In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C 2 In certain embodiments, L 1 or L 2 is a substituted or unsubstituted C 3 Alkynylene. In L 1 or L 2 is a substituted or unsubstituted C 4 Alkynylene. In the embodiment, L 1 is a substituted or unsubstituted C 5 Alkynylene. In this state, L 1 or L 2 is a substituted or unsubstituted C 6 Alkynylene. In an embodiment, L 1 or L 2 is the group consisting of substituted or unsubstituted alkyl and halo. aryl, as described above, substituted with one or more substituents selected from It is a quinylene group.

[0183] Furthermore, in certain embodiments, L 1 or L 2 is a substituted or unsubstituted heterocyclic C 1-6 Alkylene, for example, substituted or unsubstituted hetero C 1-2 Alkylene, substituted or unsubstituted is unsubstituted heterocyclic C 2-3 Alkylene, substituted or unsubstituted hetero C 3-4 Alkylene, Substituted or unsubstituted hetero C 4-5 Alkylene or substituted or unsubstituted hetero C 5-6 a In certain embodiments, L 1 or L 2 can be used to Terror C 2-6 Alkenylene, for example, substituted or unsubstituted heptylene RO C 2-3 Alkenylene, substituted or unsubstituted hetero C 3-4 Alkenylene, substituted or is unsubstituted heterocyclic C 4-5 Alkenylene or substituted or unsubstituted hetero C 5-6 Arken In certain embodiments, L 1 or L 2 is a substituted or unsubstituted heterocyclic C 2-6 Alkynylene, for example, substituted or unsubstituted hetero C 2-3 Alkynylene, Substituted or unsubstituted hetero C 3-4 Alkynylene, substituted or unsubstituted hetero C 4-5 Alki Nylene or substituted or unsubstituted hetero C 5-6 Any of the above examples is alkynylene. In certain embodiments, L 1 or L 2 is a non-substituted or ha B (e.g., fluoro) or substituted or unsubstituted C 1-6 Alkyl-substituted, heptane heteroalkylene, heteroalkenylene or heteroalkynylene.

[0184] As generally defined above, R 1is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, -N 3 , -NO 2 , -SCN, -CN, -OR A1 , -SR A1 , -N(R A1 ) 2 , -N=NR A1 , -N=C(R A1 ) 2 , -N(OR A1 )(R A1 ), -C(=O)R A1 , -C(=O)OR A1 , -C(=O)SR A1 , -C(=O)N(R A1 ) 2 , -C(=O)N(OR A1 )(R A1 ), -OC(=O)R A1 , -OC(=O)OR A1 , -OC(=O)SR A1 , -OC(=O)N(R A1 ) 2 , -NR A1 C(=O)R A1 , -NR A1 C(=O)OR A1 , -NR A1 C(=O)SR A1 , -NR A1 C(=O)N(R A1 ) 2 , -SC(=O)R A2 , -SC(=O)OR A1 , -SC(=O)SR A1 , -SC(=O)N(R A1 ) 2 , -OS(=O) 2 R A2 , -OS(=O) 2 OR A1 , -SS(=O) 2 R A2 , -SS(=O) 2 OR A1 , -S(=O)R A2 , -SO2 R A2 , -NR A1 SO 2 R A2 , or -SO 2 N(R A1 ) 2 where R A1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R A1 The groups are joined to form a substituted or unsubstituted heterocyclic ring; R A2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, or R A1 Groups and R A2 The groups are joined to form a substituted or unsubstituted heterocyclic ring.

[0185] In certain embodiments, R 1 is hydrogen.

[0186] In certain embodiments, R 1 is a substituted or unsubstituted alkyl, substituted or unsubstituted In certain embodiments, the alkynyl group is substituted or unsubstituted alkenyl. R 1 is substituted or unsubstituted alkyl, for example, Me, Et or i-Pr. In certain embodiments, R 1 is a substituted or unsubstituted alkenyl, e.g., substituted or In certain embodiments, the aryl group is unsubstituted ethenyl or substituted or unsubstituted propenyl. Hey, R 1is a substituted or unsubstituted alkynyl.

[0187] In certain embodiments, R 1 is a substituted or unsubstituted carbocyclyl or a substituted or unsubstituted heterocyclyl.

[0188] In certain embodiments, R 1 is a substituted or unsubstituted aryl, e.g., phenyl It is.

[0189] In certain embodiments, R 1 is a substituted or unsubstituted heteroaryl, e.g., aryl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, isoxazolyl, 1 ,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl quinazonyl, quinoxylinyl, naphthyridinyl, indolyl, indazolyl, benzo Imidazolyl (benzimidazloyl), pyrrolopyridinyl, pyrrolopyrimidinyl substituted or unsubstituted heteroaryl selected from pyridyl, pyridopyrimidinyl, and purinyl In certain embodiments, the heteroaryl group is a substituted or unsubstituted aryl group. alkyl, haloalkyl, alkenyl, substituted or unsubstituted alkynyl, oxo, hydroxy( hydroxy), halo, alkoxy, -S-alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted -SO-alkyl, substituted or unsubstituted - SO 2 -Alkyl, substituted or unsubstituted -SO-Aryl, substituted or unsubstituted -SO 2 -a Aryl, substituted or unsubstituted -SO-heteroaryl, substituted or unsubstituted -SO2 -Hetero Substituted with one or more groups selected from aryl, amino, cyano and acyl In certain embodiments, R 1 imidazolyl, pyrazolyl, 1,2,3 -triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl or tetrazolyl; each of which is unsubstituted or substituted with oxo, Me, F, Cl, -CN and And-CF 3 In a particular embodiment, the compound is substituted with one or two groups independently selected from the group consisting of In the embodiment, R 1 is quinolinyl, isoquinolinyl or purinyl; Substituted or oxo, Me, F, Cl, -CN and -CF 3 Selected independently from The ring is substituted with one or two groups.

[0190] In certain embodiments, R 1 -OR A1 In a particular embodiment, R 1 are -O-quinolinyl, -O-isoquinolinyl, and -O-purinyl, respectively. Unsubstituted or Me, F, Cl, -CN and -CF 3 are independently selected from In certain embodiments, R 1 is -OH or -O-CO-CH 2 -CH 2 -CO 2 It's H.

[0191] In certain embodiments, R 1 -SR A1 In a particular embodiment, R 1 are S-quinolinyl, -S-isoquinolinyl or -S-purinyl, respectively , unsubstituted or Me, F, Cl, -CN and -CF 3 are selected independently from In certain embodiments, R 1 is -SH be.

[0192] In certain embodiments, R 1 -OS(=O) 2 R A2 A certain In the embodiment, R 1 -OS(=O) 2 OR A1 ;For example, -O-SO 3 It's H. In certain embodiments, R 1 -SS(=O) 2 R A2 A certain In the embodiment, R 1 , -SS(=O) 2 OR A1 ;For example, -S-SO 3 H .

[0193] As generally defined above, R 20 are independently hydrogen or a substituted or unsubstituted alkyl group. In certain embodiments, R 20 is hydrogen. In this state, R 20 is a substituted or unsubstituted alkyl (e.g., -CH 3 ).

[0194] As generally defined above, R 23a and R 23b Each instance of is independently hydrogen, halogen or substituted or unsubstituted alkyl, or R 23a and R 23b can be connected together to form substituted or unsubstituted C 3-C 6 Form a cycloalkyl. In embodiments, R 23a and R 23b Each instance of is hydrogen. In this state, R 23a and R 23b is halogen, e.g., fluoro, and R 23a and R 23b The other is hydrogen, halogen, or substituted or unsubstituted alkyl. In certain embodiments, R 23a and R 23b Examples of halogens, e.g. For example, fluoro. 23a and R 23b Each example is , independently, substituted or unsubstituted alkyl. In certain embodiments, R 23a and R 23b Each of R is Me. 23a and R 23b is H. In certain embodiments, R 23a and R 23b One One is H; the other is substituted or unsubstituted alkyl. In certain embodiments, R 23a and R 23b One of is H; the other is Me or Et. In certain embodiments, R 23a and R 23b can be connected together to produce either replacement or non-replacement C 3 -C 6 In certain embodiments, R 23a and R 23b are connected together to form a substituted or unsubstituted cyclopropyl.

[0195] In certain embodiments, the group [ka] is the formula: [ka]

[0196] As generally defined above, X 2 are independently -O-, -S- or -N(R X ) where R X Each instance of is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbo cyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or or an unsubstituted heteroalkyl or amino protecting group.

[0197] In certain embodiments, X 2 is -O-. In certain embodiments, X 2 In certain embodiments, X is -S-. 2 is -N(R X )-. In certain embodiments, R X is alkyl. In certain embodiments, R X is Me, Et or i-Pr. In certain embodiments, R X is hydrogen It is.

[0198] In certain embodiments, X 1 is -O- and X 2 is -O-. In certain embodiments, X 1 is -O- and X 2is -S-. In terms of form, X 1 is -O- and X 2 is -N(R X )-. In a particular implementation In terms of form, X 1 is -S- and X 2 is -O-. In certain embodiments, And X 1 is -S- and X 2 In certain embodiments, X is -S-. 1 is -S- and X 2 is -N(R X In certain embodiments, X 1 is -N(R X )- and X 2 is -O-. In certain embodiments, X 1 is -N(R X )- and X 2 In certain embodiments, X is -S-. 1 is -N(R X )- and X 2 is -N(R X )-.

[0199] As generally defined above, R 24 is H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C(=O)R E1 , -C(=O)OR E1 , -C(=O)SR E1 , -C(=O)N(R E1 ) 2 , -S(=O) 2 R E2 , -S(=O) 2 OR E1 , -P(=O) 2 R E2, -P(=O) 2 OR E1 , -P(=O)(OR E1 ) 2 , -P(=O)(R E2 ) 2 , or -P(=O)(R E2 )(OR E1 ).

[0200] In certain embodiments, R 24 is hydrogen.

[0201] In certain embodiments, R 24 is substituted or unsubstituted alkyl. In the embodiment, R 24 is unsubstituted, or halo and (or and) hydroxy alkyl substituted with one or more substituents selected from the group consisting of sil In certain embodiments, R 24 is a substituted or unsubstituted alkenyl. In certain embodiments, R 24 is substituted or unsubstituted alkynyl. In the embodiment, R 24 is a substituted or unsubstituted carbocyclyl. In the embodiment, R 24 is substituted or unsubstituted heterocyclyl. In this state, R 24 is substituted or unsubstituted aryl. In certain embodiments, R 24 is a substituted or unsubstituted heteroaryl.

[0202] In certain embodiments, R 24 is -C(=O)R E1 For example, R 24 is -C(=O)(CH 2 ) p CO 2H, where p is an integer between 2 and 5. In certain embodiments, p is 2. In certain embodiments, p is In certain embodiments, p is 3. In certain embodiments, p is 4. and p is 5. In certain embodiments, R 24 is -C(=O)OR E1 in In certain embodiments, R 24 is -C(=O)SR E1 It is a certain In the embodiment, R 24 is -C(=O)N(R E1 ) 2 In a particular embodiment: In this state, R 24 is -S(=O) 2 R E2 In certain embodiments, R 24 is -S(=O) 2 OR E1 ;For example, -SO 3 In certain embodiments, And R 24 is -P(=O) 2 R E2 In certain embodiments, R 24 teeth , -P(=O) 2 OR E1 In certain embodiments, R 24 is -P(=O )(OR E1 ) 2 In certain embodiments, R 24 is -P(=O)(R E 2 ) 2 In certain embodiments, R 24 is -P(=O)(R E2 )(OR E1 ).

[0203] As generally defined above, the subscript n is 0, 1, 2 or 3. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. It is. Various embodiments in which Z is a group of formula (iii), (iv) or (v)

[0204] In certain embodiments, Z is a group of formula (iii), (iv) or (v) : [ka]

[0205] In certain embodiments, L 3 is a substituted or unsubstituted C 1-6 Alkylene, e.g. , substituted or unsubstituted C 1-2 Alkylene, substituted or unsubstituted C 2-3 Alkylene, Substituted or unsubstituted C 3-4 Alkylene, substituted or unsubstituted C 4-5 Alkylene or substituted Substituted or unsubstituted C 5-6 In certain embodiments, L 3 Is, place Substituted or unsubstituted C 2-6 Alkenylene, for example, substituted or unsubstituted C 2-3 Alkenile , substituted or unsubstituted C 3-4 Alkenylene, substituted or unsubstituted C 4-5 Alkenile or substituted or unsubstituted C 5-6 In certain embodiments, the alkenylene is , L 3 is a substituted or unsubstituted C 2-6 Alkynylene, for example, substituted or unsubstituted C 2- 3 Alkynylene, substituted or unsubstituted C 3-4 Alkynylene, substituted or unsubstituted C 4- 5 Alkynylene or substituted or unsubstituted C 5-6 Alkynylene. In any one of the above, in certain embodiments, L 3 is unsubstituted or halo (e.g. (e.g., fluoro), substituted or unsubstituted C 1-6 Alkyl and / or -OR Z5 Replace with In particular, the aryl group is alkylene, alkenylene or alkynylene.

[0206] Furthermore, in certain embodiments, L 3 is a substituted or unsubstituted heterocyclic C 1-6 Al Xylene, e.g., substituted or unsubstituted hetero C 1-2 Alkylene, substituted or unsubstituted Terror C 2-3 Alkylene, substituted or unsubstituted hetero C 3-4 Alkylene, substituted or Unsubstituted Hetero C 4-5 Alkylene or substituted or unsubstituted hetero C 5-6 In alkylene In certain embodiments, L 3 is a substituted or unsubstituted heterocyclic C 2-6 Arken cyclohexane, e.g., substituted or unsubstituted heterocyclohexane 2-3 Alkenylene, substituted or unsubstituted Terror C 3-4 Alkenylene, substituted or unsubstituted hetero C 4-5 Alkenylene or substituted or unsubstituted hetero C 5-6 In certain embodiments, L 3 is a substituted or unsubstituted heterocyclic C 2-6 Alkynylene, for example, substituted or unsubstituted hetero C 2-3 Alkynylene, substituted or unsubstituted hetero C 3-4 Alkynylene, substituted or Unsubstituted Hetero C 4-5 Alkynylene or substituted or unsubstituted hetero C 5-6 Alkina In any of the above examples, in certain embodiments, L 3 is non-placed substituted or halo (e.g., fluoro), substituted or unsubstituted C 1-6 Alkyl and / OR -OR Z5 Heteroalkylene, heteroalkenylene or hetero It is alkynylene.

[0207] In any of the above or below examples, in certain embodiments, at least One R Z5 is hydrogen.

[0208] In any of the above or below examples, in certain embodiments, R Z5 Few At least one example is a substituted or unsubstituted alkyl, such as substituted or unsubstituted C 1- 6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alki , substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or Substituted or unsubstituted C 5-6 An exemplary R is an alkyl group. Z5 C 1-6 As an alkyl group is a substituted or unsubstituted methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ),stomach Sopropyl (C 3 ), n-Butyl (C4 ), tert-Butyl (C 4 ), sec-Butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), Amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), 3rd grade A Mill (C 5 ), n-hexyl (C 6 ), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fluoro-substituted C 1-6 Alkyl (e.g., -CF 3 , -CH 2 F, -CHF 2 , difluoroethyl and 2,2,2-trifluoro-1,1-dimethyl 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more chloro C substituted with a group 1-6 Alkyl (e.g., -CH 2 Cl, -CHCl 2 ) and Arco C substituted with oxy group 1-6 Alkyl (e.g., -CH 2 OCH 3 and -CH 2 OCH 2 CH 3 ) are included, but are not limited to these.

[0209] In any of the above or below examples, in certain embodiments, R Z5 Few At least one example is a substituted or unsubstituted alkenyl, such as a substituted or unsubstituted C 2 -6 Alkenyl, substituted or unsubstituted C 2-3 Alkenyl, substituted or unsubstituted C 3-4 Alkenyl, substituted or unsubstituted C 4-5 Alkenyl or substituted or unsubstituted C 5-6 It is alkenyl.

[0210] In any of the above or below examples, in certain embodiments, R Z5 Few At least one example is a substituted or unsubstituted alkynyl, such as a substituted or unsubstituted C 2 -6 Alkynyl, substituted or unsubstituted C 2-3 Alkynyl, substituted or unsubstituted C 3-4 Alkynyl, substituted or unsubstituted C 4-5 Alkynyl or substituted or unsubstituted C 5-6 It is alkynyl.

[0211] In any of the above or below examples, in certain embodiments, R Z5 Few At least one example is a substituted or unsubstituted carbocyclyl, e.g., a substituted or unsubstituted C 3-6 Carbocyclyl, substituted or unsubstituted C 3-4 Carbocyclyl, substituted or unsubstituted substitution C 4-5 Carbocyclyl or substituted or unsubstituted C 5-6 It is a carbocyclyl.

[0212] In any of the above or below examples, in certain embodiments, R Z5 Few At least one example is a substituted or unsubstituted heterocyclyl, e.g., a substituted or unsubstituted 3-6 membered heterocyclyl, substituted or unsubstituted 3-4 membered heterocyclyl, substituted or unsubstituted It is a substituted 4- to 5-membered heterocyclyl or a substituted or unsubstituted 5- to 6-membered heterocyclyl.

[0213] In any of the above or below examples, in certain embodiments, R Z5 Few At least one example is a substituted or unsubstituted aryl, such as a substituted or unsubstituted phenyl. It is.

[0214] In any of the above or below examples, in certain embodiments, R Z5 Few At least one example is a substituted or unsubstituted heteroaryl, e.g., optionally substituted It is a 5-6 membered heteroaryl.

[0215] In any of the above or below examples, in certain embodiments, R Z5 teeth, Protective groups, e.g., oxygen protecting groups when attached to an oxygen atom, and sulfur protecting groups when attached to a sulfur atom. when attached to a nitrogen atom it is a nitrogen protecting group.

[0216] The Two R's Z5 In certain embodiments where R is attached to a nitrogen atom, the two R Z5 The group is attached to a substituted or unsubstituted heterocyclic ring, e.g., a substituted or unsubstituted pipet a lysinyl ring, a substituted or unsubstituted piperazinyl ring, or a substituted or unsubstituted morpholinyl ring It forms a ring.

[0217] Further, in certain embodiments of any of the above or below examples, R Z6 Each instance of is independently hydrogen, substituted or unsubstituted alkyl, or two R Z6 The group is connected, C 3-6 It forms a carbocyclic ring.

[0218] In certain embodiments, R Z6 At least one instance of is hydrogen.

[0219] In certain embodiments, R Z6 At least one instance of alkyl, e.g., substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 a , substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, Substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 Alkyl . An example R Z4 C 1-6 The alkyl group may be substituted or unsubstituted, such as methyl (C 1 ), Ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-Butyl (C 4 ), tert-Butyl (C 4 ), sec-Butyl (C 4 ), iso-butyl (C 4 ), n-pe Ntil (C 5 ), 3-pentanyl (C 5 ), Amyl (C 5 ), neopentyl (C 5 ), 3 -Methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), n-hexyl (C 6 ), 1, C substituted with 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fluoro groups 1-6 Alkyl (e.g., -CF 3 , -CH 2 F, -CHF 2 , difluoroethyl and 2,2,2-trifluoro-1,1-dimethyl-ethyl), 1, 2, 3, 4, 5, 6, 7 , 8, 9, 10 or more chloro groups substituted C 1-6 Alkyl (e.g., -CH 2 Cl, -CHCl 2 ) and alkoxy-substituted C 1-6 Alkyl (e.g. For example, -CH 2 OCH 3 and -CH 2 OCH 2 CH 3 ) but are not limited to do not have.

[0220] In certain embodiments, two R Z6 The group is connected, C 3-6 Carbocycles, e.g. , a substituted or unsubstituted cyclopropyl ring, a substituted or unsubstituted cyclobutyl ring, a substituted or unsubstituted or an unsubstituted cyclopentyl ring or a substituted or unsubstituted cyclohexyl ring.

[0221] In certain embodiments, R Z4 is a substituted or unsubstituted alkyl, e.g., or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted substitution C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4 -5 Alkyl or substituted or unsubstituted C 5-6 An exemplary R is an alkyl group. Z4 C 1- 6 The alkyl group may be substituted or unsubstituted, such as methyl (C 1 ), ethyl (C 2 ), n-p Ropil (C 3 ), isopropyl (C 3 ), n-Butyl (C 4 ), tert-Butyl (C 4 ), sec-Butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-P Ntanil (C 5 ), Amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), n-hexyl (C 6 ), 1, 2, 3, 4, 5, 6, 7 , 8, 9, 10 or more fluoro-substituted C 1-6 Alkyl (e.g. , -CF 3 , -CH 2 F, -CHF 2 , difluoroethyl and 2,2,2-trifluoro b-1,1-dimethyl-ethyl), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or More than one chloro-substituted C 1-6 Alkyl (e.g., -CH 2 Cl, -CHC l 2 ) and alkoxy-substituted C 1-6 Alkyl (e.g., -CH 2 OCH 3 oh Yobi-CH 2 OCH 2 CH 3 ) are included, but are not limited to these.

[0222] In certain embodiments, R Z4 is a substituted or unsubstituted alkenyl, e.g., substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-3 Alkenyl, optionally substituted or unsubstituted C 3-4 Alkenyl, substituted or unsubstituted C 4-5 Alkenyl or substituted or unsubstituted or unsubstituted C 5-6It is alkenyl.

[0223] In certain embodiments, R Z4 is a substituted or unsubstituted alkynyl, e.g., substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 2-3 Alkynyl, optionally substituted or unsubstituted C 3-4 Alkynyl, substituted or unsubstituted C 4-5 Alkynyl or optionally substituted or unsubstituted C 5-6 It is alkynyl.

[0224] In certain embodiments, R Z4 is a substituted or unsubstituted carbocyclyl, for example Substituted or unsubstituted C 3-6 Carbocyclyl, substituted or unsubstituted C 3-4 Carbocycli , substituted or unsubstituted C 4-5 Carbocyclyl or substituted or unsubstituted C 5-6 Cal It is bocyclyl.

[0225] In certain embodiments, R Z4 is a substituted or unsubstituted heterocyclyl, for example Substituted or unsubstituted 3- to 6-membered heterocyclyl, substituted or unsubstituted 3- to 4-membered heterocyclyl substituted or unsubstituted 4- to 5-membered heterocyclyl or substituted or unsubstituted 5- to 6-membered heterocyclic It is Rocyclyl.

[0226] In certain embodiments, R Z4 is a substituted or unsubstituted aryl, e.g., or unsubstituted phenyl.

[0227] In certain embodiments, R Z4 is a substituted or unsubstituted heteroaryl, for example It is an optionally substituted 5-6 membered heteroaryl.

[0228] In certain embodiments, R Z4 -OR Z5 where R Z5 Honmei As defined in the specification, for example, R Z5 is hydrogen, methyl (C 1 ),ethyl( C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-Butyl (C 4 ), tert -Butyl (C 4 ), sec-Butyl (C 4 ), iso-butyl (C 4 ), n-pentyl ( C 5 ), 3-pentanyl (C 5 ), Amyl (C 5 ), neopentyl (C 5 ), 3-methyl -2-Butanyl (C 5 ), tertiary amyl (C 5 ) or n-hexyl (C 6 ).

[0229] In certain embodiments, R Z4 -SR Z5 where R Z5 Honmei As defined in the specification, for example, R Z5 is hydrogen, methyl (C 1 ),ethyl( C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-Butyl (C 4 ), tert -Butyl (C 4 ), sec-Butyl (C 4 ), iso-butyl (C 4 ), n-pentyl ( C 5), 3-pentanyl (C 5 ), Amyl (C 5 ), neopentyl (C 5 ), 3-methyl -2-Butanyl (C 5 ), tertiary amyl (C 5 ) or n-hexyl (C 6 ).

[0230] In certain embodiments, R Z4 is -N(R Z5 ) 2 For example, R Z4 teeth , -NH 2 or -NHR Z5 where R Z5 is defined herein. For example, R Z5 is hydrogen, methyl (C 1 ), ethyl (C 2 ), n-propyl ( C 3 ), isopropyl (C 3 ), n-Butyl (C 4 ), tert-Butyl (C 4 ), se c-Butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), Amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ) , tertiary amyl (C 5 ) or n-hexyl (C 6 ) or R Z4 -N (R Z5 ) 2 where the two R Z5 The group is connected to a substituted or unsubstituted compound. A heterocyclic ring, for example, a substituted or unsubstituted piperidinyl ring, a substituted or unsubstituted piperaziny ring, The aryl group forms a substituted or unsubstituted morpholinyl ring.

[0231] Specific L 3 Alkylene groups are contemplated herein. For example, in certain embodiments In L 3 is an alkylene group of the formula: [ka] where p is 1, 2 or 3; R Z7 and R Z8 Each instance of is independently hydrogen, Halo, substituted or unsubstituted C 1-6 Alkyl or -OR Z5 In a particular embodiment: In certain embodiments, p is 1. In certain embodiments, p is 2. In one embodiment, p is 3.

[0232] Also, specific L 3 Alkenylene groups are contemplated herein. For example, certain embodiments In the embodiment, L 3 is an alkenylene group of the formula: [ka] In the formula, q is 0, 1 or 2; R Z7 and R Z8 Each instance of is independently hydrogen, Halo, substituted or unsubstituted C 1-6 Alkyl or -OR Z5 In a particular embodiment: In certain embodiments, q is 0. In certain embodiments, q is 1. In one embodiment, q is 2.

[0233] Also, specific L 3Heteroalkylene groups are contemplated herein, for example, certain In an embodiment, L 3 is a heteroalkylene group of the formula: [ka] wherein w is 0 or 1 and p is 1, 2 or 3, or w is 1 where p is 0, 1, 2 or 3; R Z7 and R Z8 Each instance of Hydrogen, halo, substituted or unsubstituted C 1-6 Alkyl or -OR Z5 It is.

[0234] In certain embodiments, p is 0. In certain embodiments, p is In certain embodiments, p is 1. In certain embodiments, p is 2. , p is 3. In certain embodiments, w is 0. In the formula (I), w is 1. In certain embodiments, w is 0 and p is 1. In certain embodiments, w is 0 and p is 2. In one embodiment, w is 0 and p is 3. In certain embodiments, w is In certain embodiments, w is 1 and p is 2. In certain embodiments, w is 1 and p is 3.

[0235] For example, in certain embodiments where w is 0, L 3 Heteroalkylene Group Provided: [ka] In the formula, p and R Z8 is as defined herein.

[0236] In certain embodiments where w is 1, L 3 Heteroalkylene groups are provided. R: [ka] In the formula, p, R 27 and R Z8 is as defined herein.

[0237] In certain embodiments, R Z7 At least one example of is hydrogen. In any of the examples, in certain embodiments, R Z7 At least one instance of is halo, e.g., fluoro. In any of the above examples, certain embodiments In this state, R Z7 At least one instance of 1-6 Alkyl, e.g. For example, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, Substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 An exemplary R is an alkyl group. Z7 C 1-6 The alkyl group is Substituted or unsubstituted methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), isopropanol Pill (C 3 ), n-Butyl (C 4 ), tert-Butyl (C 4 ), sec-Butyl (C4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), Amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl ( C 5 ), n-hexyl (C 6 ), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more C substituted with more than 10 fluoro groups 1-6 Alkyl (e.g., -CF 3 , -CH 2 F, -CHF 2 , difluoroethyl and 2,2,2-trifluoro-1,1-dimethyl- ethyl), substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more chloro groups Replaced C 1-6 Alkyl (e.g., -CH 2 Cl, -CHCl 2 ) and alkoxy groups C replaced with 1-6 Alkyl (e.g., -CH 2 OCH 3 and -CH 2 OCH 2 CH 3 ) are included, but are not limited to. In any of the above examples, In embodiments, R Z7 At least one instance of is -CH 3 , -CF 3 , -CH 2 C H 3 (Et) or -CH(CH 3 ) 2 (iPr). In any of the above examples In certain embodiments, R Z7 At least one instance of -OR Z5 ,example For example, -OH.

[0238] In certain embodiments, R Z8 At least one example of is hydrogen. In any of the examples, in certain embodiments, R Z8 At least one instance of is halo, e.g., fluoro. In any of the above examples, certain embodiments In this state, R Z8 At least one instance of 1-6 Alkyl, e.g. For example, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, Substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 An exemplary R is an alkyl group. Z8 C 1-6 The alkyl group is Substituted or unsubstituted methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), isopropanol Pill (C 3 ), n-Butyl (C 4 ), tert-Butyl (C 4 ), sec-Butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), Amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl ( C 5 ), n-hexyl (C 6 ), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more C substituted with more than 10 fluoro groups 1-6 Alkyl (e.g., -CF 3 , -CH 2 F, -CHF 2 , difluoroethyl and 2,2,2-trifluoro-1,1-dimethyl- ethyl), substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more chloro groups Replaced C 1-6 Alkyl (e.g., -CH 2 Cl, -CHCl 2 ) and alkoxy groups C replaced with 1-6 Alkyl (e.g., -CH 2 OCH 3 and -CH 2 OCH 2 CH 3 ) are included, but are not limited to. In any of the above examples, In embodiments, R Z8 At least one instance of is -CH 3 , -CF 3 , -CH 2 C H 3 (Et) or -CH(CH 3 ) 2 (iPr). In any of the above examples In certain embodiments, R Z8 At least one instance of -OR Z5 ,example For example, -OH.

[0239] Exemplary L 3 Alkylene groups include, but are not limited to, the following: [ka]

[0240] Exemplary L 3 Alkenylene groups include, but are not limited to, the following: [ka]

[0241] Exemplary L 3 Heteroalkylene groups include, but are not limited to, : [ka]

[0242] In certain embodiments, the group [ka] (In the formula, L 3 is an alkylene or heteroalkylene group) is of the formula: [ka] [ka]

[0243] In certain embodiments, the group [ka] (Wherein, Y is -O-, L 3 is an alkylene or heteroalkylene group , which is the following formula: [ka] [ka]

[0244] In certain embodiments, the group [ka] (Wherein, Y is -NH-, L 3 is an alkylene or heteroalkylene group. is the formula: [ka]

[0245] In certain embodiments, the group [ka] (Wherein, Y is -O-, L 3 is an alkylene or heteroalkylene group , which is the following formula: [ka]

[0246] In certain embodiments, the group [ka] (Wherein, Y is -NH-, L 3 is an alkylene or heteroalkylene group. is the formula: [ka]

[0247] R 2 , R 11a and R 11b Various embodiments of the present invention As generally defined above, R 2 , R 11a and R 11bEach instance of is independently selected from H, -OH, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N 3 , -NO 2 , -SCN, -CN, -OR B1 , -SR B1 , -N(R B1 ) 2 , -N=NR B1 , -N=C(R B1 ) 2 , -N(OR B1 )(R B1 ), -C(=O)R B1 , -C(=O)OR B1 , -C(=O)SR B1 , -C(=O)N(R b1 ) 2 , -C(=O)N(OR B1 )(R B1 ), -OC(=O)R B1 , -OC(=O)OR B1 , -OC(=O)SR B1 , -OC(=O)N(R B1 ) 2 , -NR B1 C(=O)R B1 , -NR B1 C(=O)OR B1 , -NR B1 C(=O)SR B1 , -NR B1 C(=O)N(R B1 ) 2 , -SC(=O)R B2 , -SC(=O)OR B1 , -SC(=O)SR B1 , -SC(=O)N(R B1 ) 2 , -OS(=O) 2 R B2 , -OS(=O) 2 OR B1 , -SS(=O) 2 R B2 , -SS(=O) 2 OR B1 , -S(=O)RB2 , -SO 2 R B2 , -NR B1 SO 2 R B2 , or -SO 2 N(R B1 ) 2 and / or R 11a and R 11b taken together form an oxo (=O) group.

[0248] In certain embodiments, R 2 is H. In certain embodiments, R 2 is substituted or unsubstituted alkyl. In certain embodiments, R 2 is replaced or is unsubstituted alkenyl. In certain embodiments, R 2 is a substituted or unsubstituted In certain embodiments, R 2 -OR B1 A certain In embodiments, R 2 -SR B1 In certain embodiments, R 2 teeth, -N(R B1 ) 2 In certain embodiments, R 2 is H, halo, substituted or is unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, - OR B1 , -SR B1 or -N(R B1 ) 2 In certain embodiments, R 2 is F, Cl, Me, Et, n-Pr, methoxy, ethoxy, propoxy, butoxy, Ethynyl, hydroxybutynyl, methoxypropynyl, chloroethynyl or cyclopropynyl In certain embodiments, R2 CF 3 , amino or dimethyla In certain embodiments, R 2 is a non-hydrogen group at the alpha position. In certain embodiments, R 2 is a non-hydrogen group in the beta position.

[0249] In certain embodiments, R 11a and R 11b Each instance of is hydrogen. In certain embodiments, R 11a and R 11b One of the is hydrogen. In terms of form, R 11a and R 11b is hydrogen; and the other is -OR B1 , - S.R. B1 or -N(R B1 ) 2 In certain embodiments, R 11a and R 11b One of the groups is H; the other is -OH, -OMe, amino or dialkylamino. In certain embodiments, R 11b is a non-hydrogen group, R 11a Water In certain embodiments, R 11a is a non-hydrogen group, R 11b Water It is raw.

[0250] In certain embodiments, R 11a and R 11b are combined to form an oxo group. Form. R 4a , R 4b , R 6 , R 7a , R 7b , R 14 , R 17 , R 18 and R19 Various Embodiment

[0251] As generally defined above, R 4a , R 4b , R 7a and R 7b Each instance of is independently selected from hydrogen, -OH, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N 3 , -NO 2 , -SCN, -CN, -OR B1 , -SR B1 , -N(R B1 ) 2 , -N=NR B1 , -N=C(R B1 ) 2 , -N(OR B1 )(R B1 ), -C(=O)R B1 , -C(=O)OR B1 , -C(=O)SR B1 , -C(=O)N(R b1 ) 2 , -C(=O)N(OR B1 )(R B1 ), -OC(=O)R B1 , -OC(=O)OR B1 , -OC(=O)SR B1 , -OC(=O)N(R B1 ) 2 , -NR B1 C(=O)R B1 , -NR B1 C(=O)OR B1 , -NR B1 C(=O)SR B1 , -NR B1 C(=O)N(R B1 ) 2 , -SC(=O)R B2 , -SC(=O)OR B1 , -SC(=O)SR B1 , -SC(=O)N(R B1 ) 2 , -OS(=O)2 R B2 , -OS(=O) 2 OR B1 , -SS(=O) 2 R B2 , -SS(=O) 2 OR B1 , -S(=O)R B2 , -SO 2 R B2 , -NR B1 SO 2 R B2 , or -SO 2 N(R B1 ) 2 where R B1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R B1 The groups are joined to form a substituted or unsubstituted heterocyclic ring; R B2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, or R B1 Groups and R B2 The groups may be joined to form a substituted or unsubstituted heterocyclic ring; or optionally, R 4a and R 4b and / or R 7a and R 7b taken together form an oxo (=O) group.

[0252] In certain embodiments, R 4a and R 4b Each instance of is hydrogen. In the embodiment, R 4a and R 4bOne of the groups is hydrogen. Hey, R 4a and R 4b One of the groups is hydrogen; the other is a substituted or unsubstituted alkyl group. In particular, the alkyl group is substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl. In certain embodiments, R 4a and R 4b One of the groups is hydrogen; the other is Me, Et , ethenyl, ethynyl, propenyl or propynyl. In certain embodiments, R 4a and R 4b Each of is independently substituted or unsubstituted alkyl. In certain embodiments, R 4a and R 4b Each of is Me.

[0253] In certain embodiments, R 7a and R 7b Each instance of is hydrogen.

[0254] As generally defined above, R 6a and R 6b each independently represents hydrogen, halo, Substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted is alkynyl, [ka] represents a single bond or a double bond, provided that when a double bond is present in ring B, R 6a Also is R 6b If one of the groups is absent and a single bond is present in ring B, the hydrogen at C5 is It is in the Fa or Beta position.

[0255] [ka] In certain embodiments, R 6a and R 6b Each instance of is hydrogen. In certain embodiments, R 6a and R 6b Each instance of halo, e.g., full It's Oro.

[0256] [ka] In certain embodiments, R 6a is hydrogen and R 6b Ha, Hello, Substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted In certain embodiments, R 6a is hydrogen and R 6b Ha, ha In certain embodiments, R 6a is hydrogen, R 6b is a substituted or unsubstituted alkyl, e.g., substituted or unsubstituted C 1-6 Alkyl, Substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 Alkyl, for example, methyl, ethyl, propyl or isopropyl. In certain embodiments, R 6a is hydrogen and R 6b is a substituted or unsubstituted In certain embodiments, R 6a is hydrogen and R6b is replaced Or unsubstituted alkynyl.

[0257] [ka] In certain embodiments, R 6b is hydrogen and R 6a Ha, Hello, Substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted In certain embodiments, R 6b is hydrogen and R 6a Ha, ha In certain embodiments, R 6b is hydrogen, R 6a is a substituted or unsubstituted alkyl, e.g., substituted or unsubstituted C 1-6 Alkyl, Substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 Alkyl, for example, methyl, ethyl, propyl or isopropyl. In certain embodiments, R 6b is hydrogen and R 6a is a substituted or unsubstituted In certain embodiments, R 6b is hydrogen and R 6a is replaced Or unsubstituted alkynyl.

[0258] [ka] In certain embodiments, R 6a is hydrogen. [ka] In certain embodiments, R 6a is halo, e.g., fluoro; do. [ka] In certain embodiments, R 6a is a substituted or unsubstituted alkyl, For example, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, Substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 Alkyl, e.g., methyl The alkyl group is aryl, ethyl, propyl or isopropyl. [ka] In certain embodiments, R 6a is a substituted or unsubstituted alkenyl It is. [ka] In certain embodiments, R 6a is a substituted or unsubstituted alkynyl It is.

[0259] As generally defined above, R 17is hydrogen, halo, substituted or unsubstituted alkyl, Substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbazole aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or unsubstituted heteroaryl or -OR D1 In certain embodiments, R 17 is hydrogen. In certain embodiments, R 17 is a halo. In the embodiment, R 17 is substituted or unsubstituted alkyl. In R 17 is substituted or unsubstituted alkenyl. , R 17 is substituted or unsubstituted alkynyl. In certain embodiments, R 17 is substituted or unsubstituted carbocyclyl. In certain embodiments, R 17 teeth, In certain embodiments, R 17 is replaced or unsubstituted aryl. In certain embodiments, R 17 is replaced or non-replaced. In certain embodiments, R 17 -OR D1 (for example , -OH).

[0260] As generally defined above, R 14 is H or substituted or unsubstituted alkyl In certain embodiments, R 14 is H. In certain embodiments, R 14 is a substituted or unsubstituted alkyl (e.g., -CH 3 ).

[0261] As generally defined above, R 18 are independently hydrogen or a substituted or unsubstituted alkyl group. In certain embodiments, R 18 is hydrogen. In this state, R 18 is a substituted or unsubstituted alkyl (e.g., -CH 3 ).

[0262] As generally defined above, R 19 are independently hydrogen or a substituted or unsubstituted alkyl group. In certain embodiments, R 19 is hydrogen. In this state, R 19 is a substituted or unsubstituted alkyl (e.g., -CH 3 ).

[0263] In certain embodiments, R 14 is hydrogen and R 18 is -CH 3 and R 19 is -CH 3 It is.

[0264] In certain embodiments, R 14 is hydrogen and R 18 is -CH 3 and R 19 is hydrogen.

[0265] Further embodiments of formula (I) Various combinations of the above embodiments are further contemplated herein. For example, In certain embodiments, the compound of formula (I) is a compound of formula (Iw): [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer thereof. The compound may be a cyclic isomer, an isotopic variant, or an N-oxide, or a combination thereof. In certain embodiments, R 3b is hydrogen. In certain embodiments, The group -X in 1 R 3b is beta. In certain embodiments, R 3a Water or substituted or unsubstituted alkyl. In certain embodiments, R 2 Water Plain or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 It is. [ka] In certain embodiments, R 5 is alpha(lower) and R 6a teeth , hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b Both are water In certain embodiments, R 6a is halo, e.g., fluoro, or a In certain embodiments, R 6b is halo, e.g. fluoro, or is alkyl, R 6a is hydrogen. In certain embodiments, R 6a and R6b are both halo, e.g., fluoro. In certain embodiments, R 1 9 is methyl.

[0266] In certain embodiments, the compound of formula (I) is a compound of formula (Ix): [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer thereof. The compound may be a cyclic isomer, an isotopic variant, or an N-oxide, or a combination thereof. In certain embodiments, the group -OH at the C3 position is beta. In this state, R 3a is hydrogen or substituted or unsubstituted alkyl. In terms of form, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 It is. [ka] In certain embodiments, R 5 is alpha(lower) and R 6a teeth , hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b Both are water In certain embodiments, R 6a is halo, e.g., fluoro, or a In certain embodiments, R 6b is halo, e.g. fluoro, or is alkyl, R 6a is hydrogen. In certain embodiments, R 6a and R 6b are both halo, e.g., fluoro. In certain embodiments, R 1 9 is methyl.

[0267] In certain embodiments, the compound of formula (I) is a compound of formula (Iy): [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer thereof. The compound may be a cyclic isomer, an isotopic variant, or an N-oxide, or a combination thereof. In certain embodiments, the group -OH at the C3 position is beta. In this state, R 3a is hydrogen or substituted or unsubstituted alkyl. In terms of form, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 It is. [ka] In certain embodiments, R 5 is alpha(lower) and R 6a teeth , hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b Both are water In certain embodiments, R 6a is halo, e.g., fluoro, or a In certain embodiments, R 6b is halo, e.g. fluoro, or is alkyl, R 6a is hydrogen. In certain embodiments, R 6a and R 6b are both halo, e.g., fluoro.

[0268] In certain embodiments, the compound of formula (I) is a compound of formula (Iz): [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer thereof. The compound may be a cyclic isomer, an isotopic variant, or an N-oxide, or a combination thereof. In certain embodiments, the group -OH at the C3 position is beta. In this state, R 3a is hydrogen or substituted or unsubstituted alkyl. In terms of form, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 It is. [ka] In certain embodiments, R 5 is alpha(lower) and R 6a teeth , hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b Both are water In certain embodiments, R 6a is halo, e.g., fluoro, or a In certain embodiments, R 6b is halo, e.g. fluoro, or is alkyl, R 6a is hydrogen. In certain embodiments, R 6a and R 6b are both halo, e.g., fluoro.

[0269] In certain embodiments, the compound of formula (I) has the formula (I-a1), (I-a2) or or compound (I-a3): [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer thereof. The compound may be a cyclic isomer, an isotopic variant, or an N-oxide, or a combination thereof. In certain embodiments, R 3b is hydrogen. In certain embodiments, The group -OR 3b is beta. In certain embodiments, R 3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen -OR B1 In certain embodiments, R 11a is hydrogen and R 1 1b is hydrogen or -OR B1 In certain embodiments, R 6a and R 6 b are both hydrogen. In certain embodiments, R 6a For example, halo, In certain embodiments, R is fluoro, fluoro, or alkyl. 6b Halo, for example , fluoro, or alkyl; R 6a is hydrogen. In certain embodiments, R 6a and R 6b are both halo, e.g., fluoro.

[0270] In certain embodiments, the compound of formula (I) may also be represented by the formula (I-b1), (I-b2), or compounds of formula (I-b3): [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer thereof. The compound may be a cyclic isomer, an isotopic variant, or an N-oxide, or a combination thereof. In certain embodiments, R 3b is hydrogen. In certain embodiments, R 3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 In certain embodiments, R11a is hydrogen R 11b is hydrogen or -OR B1 In certain embodiments, R 6a oh YobiR 6b are both hydrogen. In certain embodiments, R 6a Halo, e.g. For example, fluoro, or alkyl. In certain embodiments, R 6b Ha, Hello , e.g., fluoro, or alkyl; R 6a is hydrogen. In this state, R 6a and R 6b are both halo, e.g., fluoro.

[0271] In certain embodiments, the compound of formula (I) may also be represented by the formula (I-c1), (I-c2), or compounds (I-c3): [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer thereof. The compound may be a cyclic isomer, an isotopic variant, or an N-oxide, or a combination thereof. In certain embodiments, R 3b is hydrogen. In certain embodiments, R 3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 In certain embodiments, R 11a is hydrogen R 11b is hydrogen or -OR B1 In certain embodiments, R 6a oh YobiR 6bare both hydrogen. In certain embodiments, R 6a Halo, e.g. For example, fluoro, or alkyl. In certain embodiments, R 6b Ha, Hello , e.g., fluoro, or alkyl; R 6a is hydrogen. In this state, R 6a and R 6b are both halo, e.g., fluoro.

[0272] In certain embodiments, the compound is a compound of formula (Id): [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer thereof. The compound may be a cyclic isomer, an isotopic variant, or an N-oxide, or a combination thereof. In certain embodiments, R 3b is hydrogen. In certain embodiments, The group -X in 1 R 3b is beta. In certain embodiments, R 3a Water or substituted or unsubstituted alkyl. In certain embodiments, R 2 Water Plain or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 It is. [ka] In certain embodiments, R 5 is alpha(lower) and R 6ateeth , hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b Both are water In certain embodiments, R 6a is halo, e.g., fluoro, or a In certain embodiments, R 6b is halo, e.g. fluoro, or is alkyl, R 6a is hydrogen. In certain embodiments, R 6a and R 6b are both halo, e.g., fluoro. In certain embodiments, R 1 9 is methyl. In certain embodiments, each R Z6 are independently hydrogen or It is methyl.

[0273] In certain embodiments, the compound is a compound of formula (Ie): [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer thereof. The compound may be a cyclic isomer, an isotopic variant, or an N-oxide, or a combination thereof. In certain embodiments, R 3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 Certain embodiments are In R 11ais hydrogen and R 11b is hydrogen or -OR B1 It is. [ka] In certain embodiments, R 5 is alpha(lower) and R 6a teeth , hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b Both are water In certain embodiments, R 6a is halo, e.g., fluoro, or a In certain embodiments, R 6b is halo, e.g. fluoro, or is alkyl, R 6a is hydrogen. In certain embodiments, R 6a and R 6b are both halo, e.g., fluoro. In certain embodiments, R 1 9 is methyl. In certain embodiments, each R Z6 are independently hydrogen or It is methyl.

[0274] In certain embodiments, the compound is a compound of formula (If): [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer thereof. The compound may be a cyclic isomer, an isotopic variant, or an N-oxide, or a combination thereof. In certain embodiments, R 3b is hydrogen. In certain embodiments, The group -X in 1 R 3b is beta. In certain embodiments, R 3a Water or substituted or unsubstituted alkyl. In certain embodiments, R 2 Water Plain or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1 It is. [ka] In certain embodiments, R 5 is alpha(lower) and R 6a teeth , hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b Both are water In certain embodiments, R 6a is halo, e.g., fluoro, or a In certain embodiments, R 6b is halo, e.g. fluoro, or is alkyl, R 6a is hydrogen. In certain embodiments, R 6a and R 6b are both halo, e.g., fluoro. In certain embodiments, R1 9 is methyl. In certain embodiments, each R Z6 are independently hydrogen or In certain embodiments, R Z5 is hydrogen or methyl.

[0275] In certain embodiments, the compound is a compound of formula (Ig): [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer thereof. The compound may be a cyclic isomer, an isotopic variant, or an N-oxide, or a combination thereof. In certain embodiments, R 3a is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 Certain embodiments are In R 11a is hydrogen and R 11b is hydrogen or -OR B1 It is. [ka] In certain embodiments, R 5 is alpha(lower) and R 6a teeth , hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b Both are water In certain embodiments, R 6a is halo, e.g., fluoro, or a In certain embodiments, R 6b is halo, e.g. fluoro, or is alkyl, R 6a is hydrogen. In certain embodiments, R 6a and R 6b are both halo, e.g., fluoro. In certain embodiments, R 1 9 is methyl. In certain embodiments, each R Z6 are independently hydrogen or In certain embodiments, R Z5 is hydrogen or methyl.

[0276] In certain embodiments, the compound is a compound of formula (Ih): [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer thereof. The compound may be a cyclic isomer, an isotopic variant, or an N-oxide, or a combination thereof. In certain embodiments, R 3b is hydrogen. In certain embodiments, The group -X in 1 R 3b is beta. In certain embodiments, R 3a Water or substituted or unsubstituted alkyl. In certain embodiments, R 2 Water Plain or -OR B1 In certain embodiments, R 11a is hydrogen and R 11b is hydrogen or -OR B1It is. [ka] In certain embodiments, R 5 is alpha(lower) and R 6a teeth , hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b Both are water In certain embodiments, R 6a is halo, e.g., fluoro, or a In certain embodiments, R 6b is halo, e.g. fluoro, or is alkyl, R 6a is hydrogen. In certain embodiments, R 6a and R 6b are both halo, e.g., fluoro. In certain embodiments, R 1 9 is methyl. In certain embodiments, R Z6 is isopropyl.

[0277] In certain embodiments, the compound is a compound of formula (Ii): [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer thereof. The compound may be a cyclic isomer, an isotopic variant, or an N-oxide, or a combination thereof. In certain embodiments, R 3ais hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen or -OR B1 Certain embodiments are In R 11a is hydrogen and R 11b is hydrogen or -OR B1 It is. [ka] In certain embodiments, R 5 is alpha(lower) and R 6a teeth , hydrogen. In certain embodiments, [ka] represents a double bond. In certain embodiments, R 6a and R 6b Both are water In certain embodiments, R 6a is halo, e.g., fluoro, or a In certain embodiments, R 6b is halo, e.g. fluoro, or is alkyl, R 6a is hydrogen. In certain embodiments, R 6a and R 6b are both halo, e.g., fluoro. In certain embodiments, R 1 9 is methyl. In certain embodiments, R Z6 is isopropyl.

[0278] Further embodiments of formula (I) include compounds of the formula: [ka] [ka] [ka] [ka] [ka]

[0279] In certain embodiments, the compound is the following compound: [ka] [ka] [ka] [ka] [ka] [ka] [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, or steric Isomers, tautomers, isotopic variants or N-oxides or combinations thereof This is the case.

[0280] In certain embodiments, the compound is the following compound: [ka] [ka] [ka] [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, or steric Isomers, tautomers, isotopic variants or N-oxides or combinations thereof This is the case.

[0281] In certain embodiments, the compound is the following compound: [ka] [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, or steric Isomers, tautomers, isotopic variants or N-oxides or combinations thereof This is the case.

[0282] In certain embodiments, the compound is the following compound: [ka] [ka] [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, or steric Isomers, tautomers, isotopic variants or N-oxides or combinations thereof This is the case.

[0283] In certain embodiments, the compound is the following compound: [ka] [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, or steric Isomers, tautomers, isotopic variants or N-oxides or combinations thereof This is the case.

[0284] In certain embodiments, the compound is the following compound: [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, or steric Isomers, tautomers, isotopic variants or N-oxides or combinations thereof This is the case.

[0285] In certain embodiments, the compound is the following compound: [ka] or a pharma- ceutically acceptable salt, solvate, prodrug, or steric Isomers, tautomers, isotopic variants or N-oxides or combinations thereof This is the case.

[0286] In certain embodiments, the compound of formula (I) is a compound of formula (Iq) Compound [ka] and pharma- ceutically acceptable salts thereof; During the ceremony: R 1 is substituted or unsubstituted alphatic; R 2 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted silyl Chloropropyl or -OR A2 where R A2 is hydrogen or a substituted or unsubstituted is alkylated; R 3a is hydrogen or -OR A3 where R A3 is hydrogen or a substituted or non-substituted is a substituted alkyl; R 3b is hydrogen; or R 3a and R 3b Is, together This forms an oxo (=O) group; R4 is hydrogen, substituted or unsubstituted alkyl or halogen; X is -C(R X ) 2 - or -O-, where R X is hydrogen or fluorine or one R X Groups and R 5b come together to form a double bond; R 5a and R 5b Each instance of is independently hydrogen or fluorine; R 6a is substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted Alkynyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl groups. a non-hydrogen group optionally substituted with fluorine; R 6b is a substituted or unsubstituted alkyl group optionally substituted with hydrogen or fluorine; and; [ka] represents a single bond or a double bond, provided that if a single bond is present, the hydrogen at C5 , which is the alpha configuration; Furthermore, however: (1)R X , R 5a and R 5b at least one of is fluorine; or (2)R 6a and R 6b At least one of the groups is a non-hydrogen group substituted with fluorine. or (3)R 6a is a non-hydrogen group containing 2 to 10 carbon atoms.

[0287] In certain embodiments, the compounds of the invention are pharma- ceutically acceptable salts.

[0288] As broadly described herein, C 5 The hydrogen in the formula ( The compound Iq) is C 5 In the formula, the hydrogen is alpha or the double bond is C 5 -C 6 Thus, compounds of formula (Iq) show reduced NMDA potentiation compared to compounds present in The product is a compound of formula (I-qA) and (I-qB): [ka] As well as pharma- ceutically acceptable salts thereof are included.

[0289] The group R of the compound of formula (Iq) 1 As generally defined herein, R 1 is a substituted or unsubstituted aliphatic, i.e. , substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted a It is alkynyl or a substituted or unsubstituted carbocyclyl.

[0290] In certain embodiments, R 1 is a substituted or unsubstituted alkyl, e.g., or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted exchange C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4- 5 Alkyl or substituted or unsubstituted C 5-6 An exemplary R is an alkyl group. 1C 1-6 a The alkyl group may be substituted or unsubstituted methyl (C 1 ), ethyl (C 2 ), n-propionate Lu (C 3 ), isopropyl (C 3 ), n-Butyl (C 4 ), tert-Butyl (C 4 ), sec-Butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-penta Nil (C 5 ), Amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), n-hexyl (C 6 ), 1, 2, 3, 4, 5, 6, 7, 8 , 9, 10 or more fluoro-substituted C 1-6 Alkyl (e.g., - CF 3 , -CH 2 F, -CHF 2 , difluoroethyl and 2,2,2-trifluoro- 1,1-dimethyl-ethyl), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more More than 1000 chloro-substituted C 1-6 Alkyl (e.g., -CH 2 Cl, -CHCl 2 ) and alkoxy-substituted C 1-6 Alkyl (e.g., -CH 2 OCH 3 , -C H 2 OCH 2 CH 3 , -CH 2 O-cyclopropyl) In certain embodiments, R 1 is a substituted alkyl, e.g., R1 Ha, Hello In certain embodiments, the alkyl group is an alkyl, an alkoxyalkyl, or an aminoalkyl group. R 1 is Me, Et, n-Pr, n-Bu, i-Bu, fluoromethyl, chloromethyl fluoromethyl, difluoromethyl, trifluoroethyl, difluoroethyl, 2,2,2-trifluoro-1,1-dimethyl-ethyl, methoxymethyl, methoxyethyl or ethoxymethyl.

[0291] In certain embodiments, R 1 is unsubstituted C 1-3 alkyl, e.g., R 1 is -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 or -CH 2 CH 2 CH 2 CH 3 It is.

[0292] In certain embodiments, R 1 is substituted with one or more fluorine atoms For example, R 1 is -CH 2 F, -CHF 2 Or -CF 3 It is.

[0293] In certain embodiments, R 1 -OR A1 Substituted with where R A1 is hydrogen or substituted or unsubstituted alkyl In certain embodiments, R 1 is -CH 2 OR A1For example, where R A1 is hydrogen, -CH 3 , -CH 2 CH 3 or -CH 2 CH 2 CH 3 It is.

[0294] In certain embodiments, R 1 is a substituted or unsubstituted alkenyl, e.g., or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-3 Alkenyl, substituted or is unsubstituted C 3-4 Alkenyl, substituted or unsubstituted C 4-5 Alkenyl or substituted or is unsubstituted C 5-6 alkenyl. In certain embodiments, R 1 is unsubstituted, or alkyl, halo, haloalkyl, alkoxyalkyl, or hydroxyl. ethenyl (C 2 ), Propylene (C 3 ) or butenyl (C 4 In certain embodiments, R 1 is unsubstituted or alkyl, halo, haloalkyl, alkoxyalkyl or hydroxyalkyl; and n is 0 or 1. In certain embodiments, n is 0 or 1, and n is 1 or 2. In R 1 is ethenyl.

[0295] In certain embodiments, R 1 is a substituted or unsubstituted alkynyl, e.g., or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 2-3 Alkynyl, substituted or is unsubstituted C3-4 Alkynyl, substituted or unsubstituted C 4-5 Alkynyl or substituted or is unsubstituted C 5-6 alkynyl. Exemplary substituted or unsubstituted R 1 Alkynyl group may be unsubstituted or alkyl, halo, haloalkyl (e.g., CF 3 ), alkoxy Alkyl, cycloalkyl (e.g., cyclopropyl or cyclobutyl) or hydroxyl substituted with ethynyl, propynyl or butynyl; In certain embodiments, R 1 is trifluoroethynyl, cyclopropane Pyrethynyl, cyclobutylethynyl and propynyl, fluoropropynyl and chloropropynyl In certain embodiments, R 1 is a non-permutation or substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or is selected from the group consisting of unsubstituted carbocyclyl and substituted or unsubstituted heterocyclyl. Ethynyl (C 2 ), Propynyl (C 3 ) or butynyl (C 4 In certain embodiments, R 1 is a substituted phenyl substituted with ethynyl (C 2 ), Propynyl (C 3 ) or butynyl (C 4 ) In certain embodiments, the phenyl substituents are halo, alkyl, trifluoro. one or more selected from the group consisting of alkyl, alkoxy, acyl, amino or amido is further substituted with more substituents. 1is replaced or unsubstituted pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, isopropyl Soxadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl substituted with aryl, thiadiazolyl or tetrazolyl; 2 ), Propionyl (C 3 ) or butynyl (C 4 ).

[0296] In certain embodiments, R 1 is unsubstituted or alkyl, halo, haloalkyl ethynyl, propynyl or substituted with alkyl, alkoxyalkyl or hydroxyl; is butynyl. In certain embodiments, R 1 is a substituted or unsubstituted aryl substituted ethynyl or propynyl. In certain embodiments, R 1 teeth, Unsubstituted phenyl or halo, alkyl, alkoxy, haloalkyl, trihaloalkyl or phenyl substituted with acyl, ethynyl or propynyl. In certain embodiments, R 1 is substituted with a substituted or unsubstituted carbocyclyl, ethynyl or propynyl. In certain embodiments, R 3a is replaced or Unsubstituted, substituted with cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl In certain embodiments, R 1 is replaced or ethynyl or propynyl substituted with unsubstituted heteroaryl. In the embodiment, R 1 is substituted or unsubstituted pyridinyl or pyrimidinyl; In certain embodiments, R is substituted, ethynyl or propynyl. 1 Is, place substituted or unsubstituted pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, Isoxazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl ethynyl or propynyl substituted with zolyl, thiadiazolyl, or tetrazolyl; In certain embodiments, R 1 is substituted with a substituted or unsubstituted heterocyclyl , ethynyl or propynyl. In certain embodiments, R 1 is replaced or unsubstituted, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl substituted , ethynyl or propynyl. In certain embodiments, R 1 is hydroxy propynyl or butynyl, substituted with aryl or alkoxy. In this state, R 1 is propynyl or butynyl substituted with methoxy or ethoxy. In certain embodiments, R 1 is an ethynyl or proline substituted with chloro. In certain embodiments, R 1 is substituted with trifluoromethyl It is also ethynyl or propynyl.

[0297] In certain embodiments, R 1 is a substituted or unsubstituted carbocyclyl, e.g., Substituted or unsubstituted C 3-6 Carbocyclyl, substituted or unsubstituted C 3-4 Carbocyclyl , substituted or unsubstituted C 4-5 Carbocyclyl or substituted or unsubstituted C 5-6 Carbo In certain embodiments, R 1 is a substituted or unsubstituted cyclopropane cyclobutyl or substituted or unsubstituted cyclobutyl. The group R of the compound of formula (Iq) 2 , R 3a , R 3b and R 4

[0298] As generally defined herein, R 2 is hydrogen, halogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted cyclopropyl or -OR A2 where , R A2 is hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R 2 is hydrogen. In certain embodiments, R 2 is a halogen, e.g., fluorine In certain embodiments, R is fluoro, chloro, bromo, or iodo. 2 Is, F In certain embodiments, R 2 is a substituted or unsubstituted C 1-6 Alkyl, e.g., substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 a alkyl or substituted or unsubstituted C 5-6 In certain embodiments, , R 2 -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 or cyclopropyl In certain embodiments, R2 -OR A2 In a particular embodiment, And R A2 is hydrogen. In certain embodiments, R A2 is replaced or non-replaced. Substituted alkyl, e.g., substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1- 2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alki , substituted or unsubstituted C 4-5 Alkyl or substituted or unsubstituted C 5-6 With alkyl In certain embodiments, R A2 is hydrogen, -CH 3 , -CH 2 CH 3 or -CH 2 CH 2 CH 3 , i.e., the formula -OH, -OCH 3 , -OCH 2 CH 3 or -O CH 2 CH 2 CH 3 Group R 2 In certain embodiments, R 2 is a non-hydrogen substituent in the alpha configuration. In certain embodiments, R 2 is beta are non-hydrogen substituents of the configuration.

[0299] As generally defined herein, R 3a is hydrogen or -OR A3 and here So, R A3 is hydrogen or substituted or unsubstituted alkyl; R 3b is hydrogen or ; or R 3a and R3b taken together form an oxo (=O) group.

[0300] In certain embodiments, R 3a and R 3b are both hydrogen.

[0301] In certain embodiments, R 3a and R 3b are united as oxo(=O) Form a group.

[0302] In certain embodiments, R 3a -OR A3 and R 3b is hydrogen. R 3a -OR A3 In certain embodiments, R 3a Alpha positioning or is the beta configuration. R 3a -OR A3 In certain embodiments, R 3a is the alpha configuration. R 3a -OR A3 In certain embodiments, R 3a In certain embodiments, R A3 is hydrogen. In certain embodiments, R A3 is a substituted or unsubstituted alkyl, e.g., substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 a alkyl or substituted or unsubstituted C 5-6 In certain embodiments, , R A3is hydrogen, -CH 3 , -CH 2 CH 3 or -CH 2 CH 2 CH 3 , i.e. Formula -OH, -OCH 3 , -OCH 2 CH 3 or -OCH 2 CH 2 CH 3 Group R 3a Offer This is what we provide.

[0303] As generally defined herein, R 4 is hydrogen, substituted or unsubstituted alkyl, or or halogen. In certain embodiments, R 4 is hydrogen. In the embodiment, R 4 is halogen, e.g., fluoro. And R 4 is a substituted or unsubstituted alkyl, e.g., substituted or unsubstituted C 1-6 Alki , substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4-5 Alkyl or unsubstituted or unsubstituted C 5-6 In certain embodiments, R 4 is C 1 Alki For example, -CH 3 Or -CF 3 In certain embodiments, R 4 Water element, -CH 3 Or -F. [ka] In certain embodiments, R 4 is a non-hydrogen substituent in the alpha configuration do. [ka] In certain embodiments, R 4 is a non-hydrogen substituent in the beta configuration .

[0304] The groups X, R of the compound of formula (Iq) 5a , R 5b , R 6a and R 6b As generally defined herein, X is -C(R X ) 2 - or -O-, Here, R X is hydrogen or fluorine, or one R X Groups and R 5b is, one R 5a and R 5b Each of is independently hydrogen or fluorine. R 6a is substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted carbocyclyl, substituted and unsubstituted heterocyclic Consists of aryl, substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl groups. a non-hydrogen group selected from the group, wherein the non-hydrogen group is optionally substituted with fluorine. R 6b is a substituted or unsubstituted alkoxy group optionally substituted with hydrogen or fluorine; R is a alkyl group; X , R 5a and R 5b At least one of the or (2) R 6a and R 6b At least one of the groups is substituted with fluorine. or (3) R 6a is a non-hydrogen atom containing 2 to 10 carbon atoms. It is based on

[0305] In certain embodiments, X is -O-. -CH 2 In certain embodiments, X is -CF 2 -It is.

[0306] In certain embodiments, R 5a and R 5b At least one of them is hydrogen In certain embodiments, R 5a and R 5b At least one of the In certain embodiments, R 5a and R 5b are both hydrogen In certain embodiments, R 5a and R 5b Both are fluorine. In certain embodiments, R X and R 5b together form a double bond, e.g., cis Or forms a trans double bond.

[0307] In certain embodiments, R 6a is not substituted with fluorine, as described herein. In certain embodiments, R 6a is replaced or Unsubstituted alkyl (e.g., -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 ), even if replaced or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted carbo cyclyl (e.g., isopropanol). In certain embodiments, R 6a teeth , a non-hydrogen group as described herein substituted with fluorine.

[0308] In certain embodiments, R 6a is a non-hydrogen group as described herein. R 6b is hydrogen. In certain embodiments, R 6a is described herein R is a non-hydrogen group such as 6b is optionally substituted with fluorine or an unsubstituted alkyl group. In certain embodiments, R 6b is substituted with fluorine In certain embodiments, R 6a is substituted with fluorine It is an alkyl group.

[0309] In certain embodiments, R 6b is hydrogen. In certain embodiments, R 6b is a substituted or unsubstituted alkyl, optionally substituted with fluorine, e.g. , substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted substitution C 4-5 Alkyl or substituted or unsubstituted C 5-6 It is an alkyl group. In the embodiment, R 6b is optionally substituted by fluorine 1 Alkyl, e.g. For example, -CH 3 Or -CF 3 It is.

[0310] In certain embodiments, R 6a is a substituted or unsubstituted alkyl, e.g., or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 1-2 Alkyl, substituted or unsubstituted substitution C 2-3 Alkyl, substituted or unsubstituted C 3-4 Alkyl, substituted or unsubstituted C 4 -5 Alkyl or substituted or unsubstituted C 5-6 An exemplary R is an alkyl group. 6a C 1- 6 The alkyl group may be substituted or unsubstituted methyl (C 1 ), substituted or unsubstituted ethyl (C 2 ), substituted or unsubstituted n-propyl (C 3 ), substituted or unsubstituted isopropyl (C 3 ) , substituted or unsubstituted n-butyl (C 4 ), substituted or unsubstituted tert-butyl (C 4 ), Substituted or unsubstituted sec-butyl (C 4 ), substituted or unsubstituted iso-butyl (C 4 ), Substituted or unsubstituted n-pentyl (C 5 ), substituted or unsubstituted 3-pentanyl (C 5 ), place Substituted or unsubstituted amyl (C 5 ), substituted or unsubstituted neopentyl (C 5 ), replacement or non Substituted 3-methyl-2-butanyl (C 5 ), substituted or unsubstituted tertiary amyl (C 5 ), replace or unsubstituted n-hexyl (C 6 ) but are not limited to. In the embodiment, R 6a has one or more fluorines, e.g., 1, 2, 3, 4 or more fluorine-substituted alkyl, as described above. In certain embodiments, R 6a -CF 3 , -CH 2 F, -CHF 2 , difluoroethylene or 2,2,2-trifluoro-1,1-dimethyl-ethyl). In the embodiment, R 6a -OR A6 substituted with the above group where R is an alkyl group as defined above. A6 is hydrogen or substituted or unsubstituted alkoxy. In certain embodiments, R 6a is -CH 2 OR A6 , -CH 2 CH 2 OR A6 or -CH 2 CH 2 CH 2 OR A6 , e.g., -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 or -CH 2 CH 2 CH 2 OCH 3 It is.

[0311] In certain embodiments, R 6a is optionally substituted with fluorine, is unsubstituted alkenyl, e.g., substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted substitution C 2-3 Alkenyl, substituted or unsubstituted C 3-4Alkenyl, substituted or unsubstituted C 4-5 Alkenyl or substituted or unsubstituted C 5-6 alkenyl. In the embodiment, R 6a is a substituted or unsubstituted vinyl (C 2 ) or replacement or non-replacement Allyl substitution (C 3 ).

[0312] In certain embodiments, R 6a is optionally substituted with fluorine, is unsubstituted alkynyl, e.g., substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted substitution C 2-3 Alkynyl, substituted or unsubstituted C 3-4 Alkynyl, substituted or unsubstituted C 4-5 Alkynyl or substituted or unsubstituted C 5-6 Alkynyl. In the embodiment, R 6a is a substituted or unsubstituted ethynyl (C 2 ) or replacement or non Substituted Propargyl (C 3 ).

[0313] In certain embodiments, R 6a is optionally substituted with fluorine, is an unsubstituted carbocyclyl, e.g., a substituted or unsubstituted C 3-6 Carbocyclyl, also substituted or unsubstituted C 3-4 Carbocyclyl, substituted or unsubstituted C 4-5 Carbocyclyl is substituted or unsubstituted C 5-6 In certain embodiments, R 6a is a substituted or unsubstituted cyclopropyl.

[0314] In certain embodiments, R 6a is optionally substituted with fluorine, is unsubstituted heterocyclyl, e.g., substituted or unsubstituted C 3-6 Heterocyclyl, also substituted or unsubstituted C 3-4 Heterocyclyl, substituted or unsubstituted C 4-5 Heterocyclyl or is substituted or unsubstituted C 5-6 It is a heterocyclyl.

[0315] In certain embodiments, R 6a is optionally substituted with fluorine, is unsubstituted aryl, for example, substituted or unsubstituted phenyl.

[0316] In certain embodiments, R 6a is optionally substituted with fluorine, is an unsubstituted heteroaryl, for example an optionally substituted 5- to 6-membered heteroaryl. do.

[0317] In certain embodiments, R 6a is 2 to 10 carbon atoms, e.g., 2 2 or more and 8 or less, 2 or more and 7 or less, 2 or more and 6 or less, 2 or more and 5 or more is a non-hydrogen group containing 1 to 5 carbon atoms, 2 to 4 carbon atoms, or 2 to 3 carbon atoms. For example, in certain embodiments, R 6a is a substituted or unsubstituted C 2-3 Alkyl, Substituted or unsubstituted C 2-3 Alkenyl, substituted or unsubstituted C 2-3 Alkynyl or Substituted or unsubstituted C 3 It is a carbocyclyl.

[0318] In certain embodiments, R X , R 5a and R5b At least one of the Fluorine; or R 6a and R 6b At least one of the groups is substituted with fluorine. R is a non-hydrogen group; 6a is a substituted or unsubstituted C 1-3 Alkyl, substituted or unsubstituted substitution C 1-3 Alkenyl, substituted or unsubstituted C 1-3 Alkynyl or substituted or unsubstituted substitution C 3 It is a carbocyclyl.

[0319] In certain embodiments, R 6a and R 6b are the same group. In terms of form, R 6a and R 6b are different groups, and R 6a The carbon attached to , (S) or (R) configuration. In certain embodiments, R 6a Attached to In certain embodiments, the carbon atom at R 6a Charcoal attached to The element is in the (R) configuration. In certain embodiments, R 6a -CF 3 and R 6b is hydrogen or C 1-4 In certain embodiments, R 6a teeth, A non-hydrogen group substituted with fluorine, R 6b is -CH 3 In a particular embodiment, Hey, R 6a -OR A6 group, where R A6 teeth , hydrogen, or substituted or unsubstituted alkyl. In certain embodiments, R 6a is a substituted or unsubstituted C 2-4 Alkyl, substituted or unsubstituted C 2-3 Alkenyl, Substituted or unsubstituted C 2-3 Alkynyl or substituted or unsubstituted C 3 Carbocyclyl R 6b -CH 3 In certain embodiments, R 6a is unsubstituted C 2- 4 Alkyl, unsubstituted C 2-3 Alkenyl or unsubstituted C 2-3 Alkynyl or unsubstituted C 3 Carbocyclyl, R 6b -CH 3 In certain embodiments, R 6a is a non-hydrogen group substituted with fluorine, and R 6b -CH 3 It is.

[0320] Various combinations of certain embodiments Various combinations of certain embodiments are further contemplated herein.

[0321] For example, X is -CH 2 - and R 5a and R 5b are both hydrogen. In an embodiment of the present invention, the compound of formula (I-qa): [ka] or a pharma- ceutically acceptable salt thereof. In certain embodiments, R 6a is a non-hydrogen group containing 2 to 10 carbon atoms. 6a and R 6bAt least one of the groups is a non-hydrogen group substituted with fluorine. In the embodiment, R 6a The carbon attached to the nucleophile is in the (S) configuration. In the embodiment, R 6a The carbon attached to is in the (R) configuration. In this state, R 6a is a methyl group optionally substituted with one or more fluorines (C 1 ), e.g., -CH 3 Or -CF 3 In certain embodiments, R 6 a is a substituted or unsubstituted ethyl (C 2 ), substituted or unsubstituted n-propyl (C 3 )Ma or substituted or unsubstituted isopropyl (C 3 In certain embodiments, R 6a -CH 2 OR A6 , -CH 2 CH 2 OR A6 or -CH 2 CH 2 CH 2 OR A 6 In certain embodiments, R 6a is a substituted or unsubstituted vinyl (C 2 ) or substituted or unsubstituted aryl (C 3 In certain embodiments, R 6a is a substituted or unsubstituted ethynyl (C 2 ) or substituted or unsubstituted propargyl (C 3 In certain embodiments, R 6a is a substituted or unsubstituted cyclopropyl In certain embodiments, R 6bis hydrogen. In certain embodiments, R 6b -CH 3 Or -CF 3 In certain embodiments, [ka] represents a single bond and the hydrogen at C5 is alpha. , [ka] represents a double bond. In certain embodiments, R 1 -CH 3 or -CH 2 C H 3 In certain embodiments, R 2 is hydrogen, -OH, -OCH 3 , -OC H 2 CH 3 , -OCH 2 CH 2 CH 3 , -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , cyclopropyl, fluoro or chloro. 2 is a non-hydrogen substituent in the alpha configuration. 2 is beta In certain embodiments, R 3a and R 3b Both Both are hydrogen. 3a and R 3b In unison, ═O (oxo). In certain embodiments, R 4 is hydrogen.

[0322] X is -CH 2 - and R 5a and R 5b In certain embodiments, In the form, a compound of formula (I-qb): [ka] or a pharma- ceutically acceptable salt thereof. In certain embodiments, R 6a is a non-hydrogen group containing 2 to 10 carbon atoms. 6a and R 6b At least one of the groups is a non-hydrogen group substituted with fluorine. In the embodiment, R 6a The carbon attached to the nucleophile is in the (S) configuration. In the embodiment, R 6a The carbon attached to is in the (R) configuration. In this state, R 6a is a methyl group optionally substituted with one or more fluorines (C 1 ), e.g., -CH 3 Or -CF 3 In certain embodiments, R 6 a is a substituted or unsubstituted ethyl (C 2 ), substituted or unsubstituted n-propyl (C 3 )Ma or substituted or unsubstituted isopropyl (C 3 In certain embodiments, R 6a is -CH 2 OR A6 , -CH 2 CH 2OR A6 or -CH 2 CH 2 CH 2 OR A 6 In certain embodiments, R 6a is a substituted or unsubstituted vinyl (C 2 ) or substituted or unsubstituted aryl (C 3 In certain embodiments, R 6a is a substituted or unsubstituted ethynyl (C 2 ) or substituted or unsubstituted propargyl (C 3 In certain embodiments, R 6a is a substituted or unsubstituted cyclopropyl In certain embodiments, R 6b is hydrogen. In certain embodiments, R 6b is -CH 3 Or -CF 3 In certain embodiments, [ka] represents a single bond and the hydrogen at C5 is alpha. , [ka] represents a double bond. In certain embodiments, R 1 is -CH 3 or -CH 2 C H 3 In certain embodiments, R 2 is hydrogen, -OH, -OCH 3 , -OC H 2 CH 3 , -OCH 2 CH2 CH 3 , -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , cyclopropyl, fluoro or chloro. 2 is a non-hydrogen substituent in the alpha configuration. 2 is beta In certain embodiments, R 3a and R 3b Both Both are hydrogen. 3a and R 3b In unison, ═O (oxo). In certain embodiments, R 4 is hydrogen.

[0323] X is -C(R X ) 2 - and one R X Groups and R 5b Together, trans In certain embodiments, the compound of formula (I-qc) forms a double bond: [ka] or a pharma- ceutically acceptable salt thereof. In certain embodiments, R 6a is a non-hydrogen group containing 2 to 10 carbon atoms. 6a and R 6b At least one of the groups is a non-hydrogen group substituted with fluorine. In the embodiment, R 6a The carbon attached to the nucleophile is in the (S) configuration. In the embodiment, R6a The carbon attached to is in the (R) configuration. In this state, R 6a is a methyl group optionally substituted with one or more fluorines (C 1 ), e.g., -CH 3 Or -CF 3 In certain embodiments, R 6 a is a substituted or unsubstituted ethyl (C 2 ), substituted or unsubstituted n-propyl (C 3 )Ma or substituted or unsubstituted isopropyl (C 3 In certain embodiments, R 6a -CH 2 OR A6 , -CH 2 CH 2 OR A6 or -CH 2 CH 2 CH 2 OR A 6 In certain embodiments, R 6a is a substituted or unsubstituted vinyl (C 2 ) or substituted or unsubstituted aryl (C 3 In certain embodiments, R 6a is a substituted or unsubstituted ethynyl (C 2 ) or substituted or unsubstituted propargyl (C 3 In certain embodiments, R 6a is a substituted or unsubstituted cyclopropyl In certain embodiments, R 6b is hydrogen. In certain embodiments, R 6b -CH 3 Or -CF 3 In certain embodiments, [ka] represents a single bond and the hydrogen at C5 is alpha. , [ka] represents a double bond. In certain embodiments, R 1 -CH 3 or -CH 2 C H 3 In certain embodiments, R 2 is hydrogen, -OH, -OCH 3 , -OC H 2 CH 3 , -OCH 2 CH 2 CH 3 , -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , cyclopropyl, fluoro or chloro. 2 is a non-hydrogen substituent in the alpha configuration. 2 is beta In certain embodiments, R 3a and R 3b Both Both are hydrogen. 3a and R 3b In unison, ═O (oxo). In certain embodiments, R 4 is hydrogen.

[0324] In certain embodiments, the compound of formula (Iq) is a compound of formula (I-qd): [ka] or a pharma- ceutically acceptable salt thereof. In certain embodiments, R 6 a is a non-hydrogen group containing 2 to 10 carbon atoms. 6 a and R 6b At least one of the groups is a non-hydrogen group substituted with fluorine. In certain embodiments, R 6a The carbon attached to is in the (S) configuration. In embodiments, R 6a The carbon attached to is in the (R) configuration. In terms of form, R 6a is a methyl group optionally substituted with one or more fluorines Lu (C 1 ), e.g., -CH 3 Or -CF 3 In certain embodiments, R 6a is a substituted or unsubstituted ethyl (C 2 ), substituted or unsubstituted n-propyl (C 3 ) or substituted or unsubstituted isopropyl (C 3 In certain embodiments, R 6a is -CH 2 OR A6 , -CH 2 CH 2 OR A6 or -CH 2 CH 2 CH 2 OR A6 In certain embodiments, R 6a is a substituted or unsubstituted vinyl (C 2 ) or substituted or unsubstituted aryl (C 3 In certain embodiments, R 6 a is a substituted or unsubstituted ethynyl (C 2 ) or substituted or unsubstituted propargyl (C 3 In certain embodiments, R 6a is a substituted or unsubstituted cyclopropyl In certain embodiments, R 6b is hydrogen. In certain embodiments, And R 6b -CH 3 Or -CF 3 In certain embodiments, [ka] represents a single bond and the hydrogen at C5 is alpha. , [ka] represents a double bond. In certain embodiments, R 1 -CH 3 or -CH 2 C H 3 It is.

[0325] In certain embodiments, the compound of formula (Iq) is a compound of formula (I-qe): [ka] or a pharma- ceutically acceptable salt thereof. In certain embodiments, R 6 ais a non-hydrogen group containing 2 to 10 carbon atoms. 6 a and R 6b At least one of the groups is a non-hydrogen group substituted with fluorine. In certain embodiments, R 6a The carbon attached to is in the (S) configuration. In embodiments, R 6a The carbon attached to is in the (R) configuration. In terms of form, R 6a is a methyl group optionally substituted with one or more fluorines Lu (C 1 ), e.g., -CH 3 Or -CF 3 In certain embodiments, R 6a is a substituted or unsubstituted ethyl (C 2 ), substituted or unsubstituted n-propyl (C 3 ) or substituted or unsubstituted isopropyl (C 3 In certain embodiments, R 6a is -CH 2 OR A6 , -CH 2 CH 2 OR A6 or -CH 2 CH 2 CH 2 OR A6 In certain embodiments, R 6a is a substituted or unsubstituted vinyl (C 2 ) or substituted or unsubstituted aryl (C 3 In certain embodiments, R 6 a is a substituted or unsubstituted ethynyl (C 2 ) or substituted or unsubstituted propargyl (C 3In certain embodiments, R 6a is a substituted or unsubstituted cyclopropyl In certain embodiments, R 6b is hydrogen. In certain embodiments, And R 6b -CH 3 Or -CF 3 In certain embodiments, R 1 teeth , -CH 3 or -CH 2 CH 3 It is.

[0326] In certain embodiments, the compound of formula (Iq) is a compound of formula (I-qf): [ka] or a pharma- ceutically acceptable salt thereof. In certain embodiments, R 6 a is a non-hydrogen group containing 2 to 10 carbon atoms. 6 a and R 6b At least one of the groups is a non-hydrogen group substituted with fluorine. In certain embodiments, R 6a The carbon attached to is in the (S) configuration. In embodiments, R 6a The carbon attached to is in the (R) configuration. In terms of form, R 6a is a methyl group optionally substituted with one or more fluorines Lu (C 1 ), e.g., -CH 3 Or -CF 3 In certain embodiments, R 6a is a substituted or unsubstituted ethyl (C 2), substituted or unsubstituted n-propyl (C 3 ) or substituted or unsubstituted isopropyl (C 3 In certain embodiments, R 6a is -CH 2 OR A6 , -CH 2 CH 2 OR A6 or -CH 2 CH 2 CH 2 OR A6 In certain embodiments, R 6a is a substituted or unsubstituted vinyl (C 2 ) or substituted or unsubstituted aryl (C 3 In certain embodiments, R 6 a is a substituted or unsubstituted ethynyl (C 2 ) or substituted or unsubstituted propargyl (C 3 In certain embodiments, R 6a is a substituted or unsubstituted cyclopropyl In certain embodiments, R 6b is hydrogen. In certain embodiments, And R 6b is -CH 3 Or -CF 3 In certain embodiments, R 1 teeth , -CH 3 or -CH 2 CH 3 It is.

[0327] In certain embodiments, the compound of formula (Iq) is: [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] and pharma- ceutically acceptable salts thereof.

[0328] Pharmaceutical Compositions In another aspect, the present invention provides a compound comprising a medicament comprising a pharmaceutically acceptable carrier and an effective amount of formula (I) The present invention provides a pharmaceutical composition comprising the compound of formula (I).

[0329] When used as pharmaceuticals, the compounds provided herein are typically formulated as pharmaceutical compositions. Such compositions may be prepared in a manner well known in the pharmaceutical art. Such compositions contain at least one active compound.

[0330] In one embodiment of the pharmaceutical composition, the carrier is a parenteral carrier, Oral or topical carrier.

[0331] The present invention relates to a compound of the invention or a pharmaceutical composition thereof for use as a medicine or medicament. It also relates to a composition.

[0332] Typically, the compounds provided herein are administered in a therapeutically effective amount. The amount of compound will depend on the condition being treated, the selected route of administration, the actual compound being administered, and the individual Taking into account the relevant circumstances, including the age, weight and response of the patient, the severity of the patient's symptoms, etc., This can be determined essentially by a physician.

[0333] The pharmaceutical compositions provided herein can be administered orally, rectally, transdermally, subcutaneously, intravenously, intramuscularly, or intravenously. Depending on the intended route of delivery, the present invention may be administered by a variety of routes, including intranasal and intranasal. The compounds provided herein are preferably administered as either injectable or oral compositions. It may be formulated either as an ointment, lotion or patch. (all for transdermal administration).

[0334] Compositions for oral administration may take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, to facilitate accurate dosing, the compositions are presented in unit dosage forms. The term "unit dosage form" refers to a unit dosage for human subjects and other mammals. refers to physically discrete units suitable as a single unit for delivering a desired therapeutic effect. Typical units contain a predetermined amount of active ingredient calculated as follows, together with suitable pharmaceutical excipients. Dosage forms may include prefilled, premeasured ampoules or syringes of liquid compositions or solid compositions. In the case of compositions, pills, tablets, capsules, etc. are included. The product is usually made up of trace components (about 0.1 to about 50% by weight, or preferably about 1 to about 40% by weight) ) and the remainder is used as a vehicle or carrier and to form the desired dosage form. It is a processing aid.

[0335] Liquid forms suitable for oral administration may be prepared using a suitable aqueous or non-aqueous vehicle, buffers, suspending agents, etc. and dispersants, colorants, flavorings, etc. The solid form may contain, for example, the following components: or compounds of a similar nature: binders (e.g., microcrystalline cellulose sugar, tragacanth or gelatin; excipients (e.g., starch or lactose disintegrants (e.g., alginic acid, Primogel, or corn starch); lubricants agents (e.g., magnesium stearate); lubricants (e.g., colloidal silicon dioxide); a sweetening agent (e.g., sucrose or saccharin); or a flavoring agent (e.g., peppermint , methyl salicylate or orange fragrance).

[0336] Injectable compositions are typically prepared in injectable sterile saline or phosphate buffered saline. Based on saline or other injectable carriers known in the art. The active compound in such compositions is typically a minor component, often in the range of about 0.05 to about 100%. 10% by weight, the remainder being the injectable carrier etc.

[0337] Transdermal compositions typically contain from about 0.01 to about 20% by weight of the active ingredient, preferably is about 0.1 to about 20% by weight, preferably about 0.1 to about 10% by weight, more preferably It is formulated as a topical ointment or cream containing the active ingredient in an amount ranging from about 0.5 to about 15% by weight. When formulated as an ointment, the active ingredient is typically formulated in a paraffinic or water-miscible ointment. Alternatively, the active ingredient may be combined with, for example, an oil-in-water cream base. Such transdermal formulations are well known in the art and are commonly used. They usually contain additional ingredients that improve the skin permeability of the active ingredient or the stability of the formulation. Such known transdermal formulations and ingredients are included within the scope provided herein. .

[0338] The compounds provided herein can also be administered by a transdermal device. Transdermal delivery can be achieved using reservoir or porous membrane types or solid matrix types. This can be achieved using a patch.

[0339] For compositions that are orally administrable, injectable, or topically administrable The components listed above are merely representative. Other materials and processing methods are described in Rem. ington's Pharmaceutical Sciences,17th ed. ition,1985,Mack Publishing Company,Easto , Part 8 of the 1990 Act, Pennsylvania, incorporated herein by reference. It has been done.

[0340] For compositions that are orally administrable, injectable, or topically administrable The components listed above are merely representative. Other materials and processing methods are described in Rem. ington's The Science and Practice of Pha rmacy,21st edition,2005,Publisher:Lippin Cott Williams & Wilkins, Part 8 (herein incorporated by reference) (incorporated herein by reference).

[0341] The compounds of the invention can also be administered in sustained release forms or from sustained release drug delivery systems. For a description of the release materials, see Remington's Pharmaceutical Sciences. ces.

[0342] The present invention also relates to pharma- ceutically acceptable formulations of the compounds of the present invention. In another embodiment, the formulation comprises water. The most common cyclodextrins contain one or more cyclodextrins on the linked sugar moieties. 6, 7 and 8 α-1,4 linked glycosyl groups, optionally including more than 100 substituents. These are α-, β-, and γ-cyclodextrins, which consist of mesocyclic units, respectively. ethylated, hydroxyalkylated, acylated and sulfoalkyl ether substituted In certain embodiments, the cyclodextrin is , sulfoalkyl ether β-cyclodextrins, such as Captisol® Sulfobutyl ether β-cyclodextrin, also known as sulfobutyl ether β-cyclodextrin (SbC). See US Pat. No. 5,376,645. In certain embodiments, the formulation comprises In more particular embodiments, the formulation comprises: Contains hexapropyl-β-cyclodextrin (10-50% in water).

[0343] The present invention also relates to pharma- ceutically acceptable acid addition salts of the compounds of the present invention. The acids which may be used to prepare acceptable salts include non-toxic acid addition salts, i.e., pharmacologically acceptable salts. Salts containing a commercially acceptable anion, such as hydrochloride, hydroiodide, hydrobromide, Nitrate, sulfate, bisulfate, phosphate, acetate, lactate, citrate, tartrate, amber salts, maleates, fumarates, benzoates, para-toluenesulfonates, etc. It is an acid that

[0344] The following formulation examples illustrate representative pharmaceutical compositions that may be prepared in accordance with the present invention. However, the present invention is not limited to the following pharmaceutical compositions.

[0345] Exemplary Formulation 1—Tablets: A compound of the invention is administered as a dry powder with a dry gelatin binder in approximately 1 A small amount of magnesium stearate is added as a lubricant. The mixture is pressed into tablets of 240-270 mg each (80-90 mg of active compound per tablet). To form a substance.

[0346] Exemplary Formulation 2—Capsules: The compound of the present invention is administered as a dry powder in a starch diluent in approximately 1 The mixture may be mixed in a weight ratio of 1:1. The mixture may be packed into 250 mg capsules (12 mg per capsule). 5 mg of active compound).

[0347] Exemplary Formulation 3—Solution: A compound of the invention (125 mg) is dissolved in sucrose (1.75 g) and and xanthan gum (4 mg), and the resulting mixture was blended and passed through a No. 10 mesh filter. The mixture was then passed through a sieve and mixed with microcrystalline cellulose and cellulose acetate. It can be mixed with an aqueous solution of sodium carboxymethylcellulose (11:89, 50 mg). Dilute sodium benzoate (10 mg), flavor, and color with water and add with stirring. Sufficient water can then be added to bring the total volume to 5 mL.

[0348] Exemplary Formulation 4—Tablets: A compound of the invention is administered as a dry powder with a dry gelatin binder in approximately 1 A small amount of magnesium stearate is added as a lubricant. The mixture is pressed into tablets of 450-900 mg (150-300 mg of active compound). Form.

[0349] Exemplary Formulation 5 - Injectable: A compound of the invention is administered in a sterile buffered saline injectable aqueous medium. The compound may be dissolved or suspended in water to a concentration of approximately 5 mg / mL.

[0350] Exemplary Formulation 6—Tablets: A compound of the invention is administered as a dry powder with a dry gelatin binder in approximately 1 A small amount of magnesium stearate is added as a lubricant. The mixture is pressed into tablets of 90-150 mg each (30-50 mg of active compound per tablet). ) is formed.

[0351] Exemplary Formulation 7—Tablets: A compound of the invention is administered as a dry powder with a dry gelatin binder in approximately 1 A small amount of magnesium stearate is added as a lubricant. The mixture is pressed into tablets of 30-90 mg each (10-30 mg of active compound per tablet). is formed.

[0352] Exemplary Formulation 8—Tablets: A compound of the invention is administered as a dry powder with a dry gelatin binder in approximately 1 A small amount of magnesium stearate is added as a lubricant. The mixture is pressed into tablets of 0.3 to 30 mg each (each tablet contains 0.1 to 10 mg of active compound). To form a substance.

[0353] Exemplary Formulation 9—Tablets: A compound of the invention is administered as a dry powder with a dry gelatin binder in approximately 1 A small amount of magnesium stearate is added as a lubricant. The mixture is pressed into tablets of 150-240 mg each (50-80 mg of active compound per tablet). To form a substance.

[0354] Exemplary Formulation 10—Tablets: A compound of the invention is administered as a dry powder with a dry gelatin binder in an amount of approximately They may be mixed in a weight ratio of 1:2. A trace amount of magnesium stearate is added as a lubricant. The mixture is pressed into tablets of 270-450 mg each (90-150 mg of active ingredient per tablet). Compounds) are formed.

[0355] Injection dose levels range from about 0.1 mg / kg / hour to at least 10 mg / kg / hour. (all ranging from about 1 to about 120 hours, particularly 24 to 96 hours). Preloading bolus of about 10 mg / kg or more Adequate steady-state levels can also be achieved by administering a maximum total dose of Amounts are not expected to exceed about 2 g / day for a 40-80 kg human patient.

[0356] For prevention and / or treatment of long-term conditions, treatment regimens typically last for many months or Over the course of many years, oral dosing is preferred for patient convenience and tolerance. For drugs, oral administration of 1-5 doses, especially 2-4 doses, typically 3 doses per day is typical. With these dosing patterns, each dose is about 0.01 to about 20 mg. g / kg of a compound provided herein, with preferred doses being about 0.1 to about 10 mg / kg, particularly about 1 to about 5 mg / kg.

[0357] Transdermal doses generally have blood pressure levels similar to or lower than those achieved with injection doses. It is selected to provide a medium concentration.

[0358] When used to prevent the development of CNS disorders, the compounds provided herein at the dosage levels described above, typically in subjects at risk of developing the condition. May be administered on the advice and under the supervision of a physician. Risk of developing certain conditions Subjects with a history of the condition are generally those with a family history of the condition or who have undergone genetic testing. or subjects identified by screening as being particularly susceptible to developing the condition. can be. Methods of Assessment, Treatment and Use

[0359] Evaluating or treating patients, e.g., patients with a disorder described herein The methods are, among others, described herein. In some embodiments, A compound as described (e.g., an effective amount of a compound as described herein) is administered to a patient. In some embodiments, the method optionally further comprises obtaining a patient sample. The levels of 24(S)-hydroxycholesterol compared to the process and the control standard Obtaining and / or evaluating the samples for changes in the In certain embodiments, in response to the evaluation, the patient is treated with a method as described herein. The patient is treated with a compound described herein for a disorder in which the of 24(S)-hydroxycholesterol or structurally related sterols or Steroids, oxysterols, NMDAR agonists or NMDAR positive allotropes Peripheral telic modulator (PAM), endogenous activity of 24(s)-hydroxycholesterol or a compound that enhances (e.g., increases) the endogenous amount of Compounds that inhibit the enzyme that metabolizes cholesterol, such as 24-hydroxycholesterol. or a compound of formula (I) which inhibits cyclohexyl 7 alpha-hydroxylase (CYP39) In some embodiments, the patient is administered a compound described herein, such as a compound of The compound is an NMDAR antagonist or NAM or 24(s)-hydrogenase. Compounds that decrease the endogenous activity or amount of oxycholesterol (e.g., 24(s Compounds that activate the enzyme that produces hydroxycholesterol, e.g., cholesterol It is a compound that activates cyclohexyl 24(S)-hydroxylase (CYP46).

[0360] "Acquire" or "acquiring" means As these terms are used herein, it is understood that the term "directly obtains" or "directly obtains" a physical entity or value. or "indirectly acquiring" ownership of a physical entity or value, e.g., a numerical value. "Directly obtaining" refers to obtaining a substance by carrying out a process (e.g., a synthetic method or "Indirect" means obtaining a physical entity or value by performing a measurement or analytical procedure. "Acquiring from another entity or source (e.g., directly acquiring a physical entity or value)" means Refers to receiving a physical entity or value directly from a third-party laboratory (a laboratory that has received a certificate from the laboratory). Obtaining may involve performing a process that involves a physical change of a physical substance, e.g., a starting material. Exemplary transformations include producing a physical entity from two or more starting materials. to produce a substance, to shear or fragment a substance, to separate or purify a substance combining two or more distinct entities into a mixture; Examples of chemical reactions include breaking or forming molecular bonds. Direct obtaining involves performing a process that involves a physical change of a sample or another substance; For example, an analytical process that involves a physical change of a substance, such as a sample, analyte, or reagent. (sometimes referred to herein as "physical analysis"), analytical methods, such as the following: performing a method comprising one or more of: To separate or purify a fragment or other derivative thereof from other substances; The analyte or a fragment or other derivative thereof may be mixed with another substance, e.g., a buffer, solvent or or reactant; or, for example, between a first atom and a second atom of the analyte. By breaking or forming covalent or non-covalent bonds; or by using reagents or or by altering the structure of its fragments or other derivatives, e.g. Breaking or destroying a covalent or non-covalent bond between a first atom and a second atom of a reagent The structure of the analyte or its fragment or other derivative is altered by forming This includes transforming it into a

[0361] "Obtaining a sample" as that term is used herein means to obtain a sample, e.g. For example, the “direct” or “indirect” acquisition of a tissue or nucleic acid sample. "Direct acquisition of the sample" refers to taking ownership of the sample. "And" means to carry out a process (e.g., to carry out a physical method such as surgery or extraction). "Indirectly obtaining a sample" means obtaining a sample by Receive samples from an entity or source (e.g., a third-party laboratory from which the samples were obtained directly) Taking a sample directly refers to taking a physical substance, e.g., a starting material ( For example, the physical properties of a tissue, e.g., a tissue within a human patient or tissue previously isolated from a patient. Exemplary transformations include the creation of physical entities from starting materials. Preparing the body, dissecting or scraping tissue; or nucleic acid sample); To bring entities together into a mixture; to break or form covalent or noncovalent bonds The direct acquisition of samples is a method of performing chemical reactions involving the or other processes involving physical changes in matter, such as those described above. Includes.

[0362] As used herein, a "candidate" patient is one who has a higher risk of developing the disease than a control patient or group of patients. Patients who are "non-candidates" are those who have a high probability of responding to a particular therapeutic regimen. Patients who are less likely to respond to a particular therapeutic regimen than a control patient or group of patients be.

[0363] The compounds and pharmaceutical compositions provided herein include those for use in humans and non-human mammals. and a therapeutic agent for preventing and / or treating a CNS condition in a mammal, comprising Thus, as previously mentioned, the present invention finds use in the enumerated treatment methods. Methods and preparations of compounds for such methods and medicaments useful in such methods - Patents.com The present invention includes and extends within its scope the use of such compounds for the purposes of In such a manner, the compounds described herein may be used to treat, for example, CNS conditions in mammals. To treat (e.g., schizophrenia, depression, bipolar disorder (e.g., I and / or I I) Schizoaffective disorder, mood disorder, anxiety disorder, personality disorder, psychosis, obsessive-compulsive disorder, post-traumatic Stress disorder (PTSD), autism spectrum disorder (ASD), mood disorders (mild depression), social anxiety disorder rest disorder, obsessive-compulsive disorder (OCD), pain (e.g., painful syndrome or disorder), sleep disorder, Memory disorders (e.g., memory dysfunction), dementia, Alzheimer's disease, seizure disorders (e.g., epilepsy) epilepsy), traumatic brain injury (TBI), stroke, addictive disorders (e.g., opiates, cocaine, addiction to alcohol and / or alcohol), autism, Huntington's disease, insomnia, Parkinson's In some embodiments, the compound is intended as a therapeutic agent for treating a condition such as tinnitus, withdrawal syndrome, or tinnitus. In some embodiments, the compounds described herein improve learning in a subject (e.g., For example, it can be used to improve cognitive function. In one embodiment, the compounds of the present invention are useful in treating depression, anxiety, mood disorders, sleep disorders, memory disorders (e.g. For example, memory impairment, traumatic brain injury, stroke, epilepsy, cognitive dysfunction It is useful in the treatment of schizophrenia and psychiatric disorders. In embodiments, the compounds described herein are useful in treating overdose, e.g., drug overdose. (e.g., an overdose of ketamine or PCP).

[0364] Exemplary CNS conditions related to NMDA modulation include adjustment disorders, anxiety disorders (obsessive-compulsive disorder, trauma, post-traumatic stress disorder, social phobia, generalized anxiety disorder), cognitive impairment (including Alzheimer's disease, dementia and other forms of dementia), dissociative disorders, eating disorders, mood disorders (depression, bipolar disorder, (including polarizing disorders and dysthymic disorders), schizophrenia or other psychotic disorders (schizophrenia emotional disorders), sleep disorders (including insomnia), substance abuse-related disorders, personality disorders (obsessive-compulsive personality disorder, Autism spectrum disorders (including those involving mutations in the Shank protein) Neurodevelopmental disorders (including Rett syndrome), pain (including acute and chronic pain), seizures Sexual disorders (status epilepticus and monogenic forms of epilepsy, e.g., Dravet disease, and tuberculosis) Stroke, traumatic brain injury, movement disorders (including chronic sclerosis complex (TSC)), Huntington's disease and Parkinson's disease) and tinnitus.

[0365] In another embodiment, a subject susceptible to or suffering from a condition associated with brain excitability is A method of evaluating or treating a mammal suffering from a complication is provided, the method comprising administering an effective amount of the The method includes administering one or more of the pharmaceutical compositions described herein.

[0366] In another embodiment, a method of inducing sedation or anesthesia is provided. Adjustment disorder, anxiety disorder, cognitive disorder, dissociative disorder, eating disorder, mood disorder, schizophrenia or other Psychotic disorders, sleep disorders, substance-related disorders, personality disorders, autism spectrum disorders, neurodevelopmental disorders, May cause symptoms related to pain, seizure disorders, stroke, traumatic brain injury, movement disorders and tinnitus Methods for evaluating or treating mammals suffering from watermelon or symptoms thereof are provided. can be.

[0367] In yet another aspect, pharmaceutical agents, such as, inter alia, those for the treatment of the above-mentioned conditions and diseases or There is provided the use of the compounds of the invention as pharmaceutical agents in prophylaxis.

[0368] In yet another embodiment, the present invention is directed to treating one of the above-mentioned conditions and diseases. Methods for preparing a medicament for the prevention or prophylaxis of a disease are provided.

[0369] In yet another aspect, the present invention provides a method for treating, preventing, or preventing a disease or condition. and providing a method for preventing, curing or managing such a disease. A prophylactically or therapeutically effective amount of the composition of the present invention is administered to a subject in need of treatment, amelioration or management. The method includes administering the compound or a pharmaceutical composition thereof.

[0370] In yet another aspect, the present invention provides a method for treating a disease or condition associated with brain excitability. The present invention provides a use of a compound of the present invention for the manufacture of a medicament. The illness or condition is depression, anxiety, schizophrenia, sleep disorders, memory disorders and mood disorders. are selected.

[0371] In yet another aspect, the present invention provides a method for treating disorders associated with brain excitability, comprising administering to a mammalian animal, comprising administering to said animal an effective amount of an anti-inflammatory drug to said mammalian animal. The present invention provides a method of treating a mammal, e.g., a human, comprising administering to the mammal an effective amount of the compound of the present invention. The method includes treating with a compound of the invention or a composition thereof.

[0372] In yet another aspect, the present invention provides a method for the preparation of a compound of the present invention in combination with another pharmacologically active agent. It is provided for use in conjunction with

[0373] The compounds provided herein can be administered as the sole active agent or can be administered in combination with other agents. Concomitant administration can be, for example, separate, sequential, This may proceed by any technique apparent to those skilled in the art, including simultaneous and alternating administration. EXAMPLES

[0374] In order that the invention described herein may be more fully understood, the following examples are set forth. The synthetic and biological examples described herein are based on the chemical structures provided herein. The compounds, pharmaceutical compositions and methods are provided to illustrate the invention and are not intended to be limiting of the scope of the invention. However, they should not be construed as limiting their scope.

[0375] material and method The compounds provided herein can be prepared from readily available starting materials by the following general methods. The methods and procedures can be used to prepare the compounds. Typical or preferred process conditions (including i.e., reaction temperature, time, molar ratios of reactants, solvent, pressure, etc.) are given, It will be appreciated that other process conditions may be used unless otherwise stated. The conditions may vary with the particular reactants or solvents used, but such conditions are within the scope of the present invention. This can be determined by the vendor through routine optimization.

[0376] Moreover, as will be apparent to one of skill in the art, certain functional groups may undergo undesired reactions. Conventional protecting groups may be necessary to prevent the formation of aryl groups that are suitable for certain functional groups. The selection of suitable protecting groups, as well as suitable protecting and deprotecting conditions, are well known in the art. For example, numerous protecting groups and their introduction and removal are described in detail in TWGree, ne and PGMWuts,Protecting Groups in O rganic Synthesis,Second Edition,Wiley,Ne w York, 1991 and the references cited therein.

[0377] The compounds provided herein can be isolated and purified by known standard procedures. Such procedures include recrystallization, column chromatography, or HPLC. The following schemes are representative of (but not limited to) those listed herein. The present invention is presented together with details regarding the preparation of exemplary substituted biaryl amides. The compounds can be prepared by one skilled in the art of organic synthesis using known or commercially available starting materials and and reagents.

[0378] The enantiomerically pure compounds provided herein can be purified according to any method known to those of skill in the art. For example, they can be prepared by chiral synthesis from suitable optically pure precursors. They can be prepared by chiral or asymmetric synthesis or by any conventional method, e.g. by chromatographic resolution using a diastereoisomeric column, TLC, or by diastereoisomeric separation. The preparation of isomers, their separation and regeneration of the desired enantiomer from the racemate. For example, “Enantiomers, Racemates and Resol utions,” J. Jacques, A. Collet, and SH Wilen ,(Wiley-Interscience,New York,1981);SH Wilen, A. Collet, and J. Jacques, Tetrahedron. ,2725(1977);ELEliel Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and SHWilen Tables of Resolving Agents nd Optical Resolutions 268 (ELEliel ed. ,Univ.of Notre Dame Press,Notre Dame,IN, 1972,Stereochemistry of Organic Compound s,Ernest L.Eliel,Samuel H.Wilen and Lewi s N. Manda (1994 John Wiley & Sons, Inc.) and and Stereoselective Synthesis A Practical A pproach,Miha'ly No'gra'di(1995 VCH Publi Shers, Inc., New York, NY.

[0379] In certain embodiments, the enantiomerically pure compounds of the present invention are available in racemic and preferably The compound can be obtained by reaction with an optically active acid or base. Suitable acids or bases include Bighley et al., 1995, Encyclopedia of Pharmaceut Salt Forms of Dical Technology, vol.13 rugs and Adsorption,Swarbrick & Boylan,e ds.,Marcel Dekker,New York;ten Hoeve & H .Wynberg, 1985, Journal of Organic Chemist ry 50:4508-4514;Dale & Mosher,1973,J.Am. Chem. Soc. 95:512; and CRC Handbook of Optics al Resolution via Diastereomeric Salt Fo rmation, the contents of which are incorporated herein by reference in their entirety. Some of the things mentioned are:

[0380] Enantiomerically pure compounds can be produced by the specific resolving agent and the specific acid used. Depending on the solubility properties of the enantiomers, they may be recovered from the crystallized diastereomers or from the mother liquor. The identity and optical purity of the particular compounds so recovered can be determined by methods known in the art. These can then be measured by known polarimetry or other analytical methods. Diasteroisomers can be separated, for example, by chromatography or They can be separated by fractional crystallization, and the desired enantiomer can be isolated by treatment with an appropriate base or acid. The other enantiomer can be obtained from the racemate in a similar manner, or can be fabricated from the initial separation. In certain embodiments, enantiomerically pure The compounds can be separated from the racemate by chiral chromatography. A variety of chiral columns and eluents are available for use in separating the chiral isomers. Suitable conditions for separation can be determined empirically by methods known to those skilled in the art. Exemplary chiral columns available for use in separating enantiomers are provided in CHIRALCEL® OB, CHIRALCEL® OB-H, CHIRALCEL (registered trademark) OD, CHIRALCEL (registered trademark) OD-H, CH IRALCEL® OF, CHIRALCEL® OG, CHIRAL CEL® OJ and CHIRALCEL® OK are some of the However, the present invention is not limited to the above.

[0381] Synthesis procedure A general process for preparing the compounds of the invention is provided as a further embodiment of the invention. These are provided and illustrated in generalized Schemes 1-13 and Examples 1-36. For Schemes 1-13, unless otherwise defined, R' is alkyl and R 23 teeth, R 23a or R 23b ;X 1 , L 1 , R 1 , R 3a , R 3b , R 23a and R 23b is as described herein. Scheme 1. Synthesis of 3α-substituted-3β-hydroxysteroids [ka] Scheme 2. Synthesis of 3α-substituted-3β-hydroxysteroids [ka] Scheme 3. Synthesis of 3β-amino- and 3β-alkylamino steroids [ka] Scheme 4. Synthesis of steroid sulfates [ka] Scheme 5. Synthesis of steroid 3β-esters and amides [ka] Scheme 6.3-Synthesis of oxosteroids [ka] Scheme 7. Synthesis of 21-heteroaryl-3β-hydroxysteroids [ka] Scheme 8. Synthesis of 3α-substituted-3β-hydroxysteroids [ka] Scheme 9. Synthesis of 3α-substituted-3β-hydroxysteroids [ka] Scheme 10. Synthesis of 3α-substituted-3β-hydroxysteroids [ka] Scheme 11. Synthesis of 3α-substituted-3β-hydroxysteroids [ka] Scheme 12. Synthesis of 3α-substituted-3β-hydroxysteroids [ka] Scheme 13. Synthesis of 3α-substituted-3β-hydroxysteroids [ka]

[0382] Example 1. Preparation of compound ST-200-A-001 [ka] Preparation of compound 2: Dissolve ketone 1 (50.0 g, 0.17 mo) in toluene (600 mL). l,1.0eq) and ethylene glycol (62mL), Acid (1.4 g, 7.28 mmol) was added. The reaction mixture was then heated to 100° C. in a Dean-Stark Heat to reflux overnight with a trap. LCMS showed complete consumption of starting material. The mixture was cooled to room temperature, diluted with ethyl acetate (500 mL) and sodium bicarbonate. It was washed with saturated aqueous thorium solution (300 mL x 2) and brine (300 mL x 2). The organic phase was dried over sodium sulfate and concentrated in vacuo to give the crude product 2 ( 64.0 g, 100%) which was used directly in the next step without further purification. 1 H NMR: (400 MHz, CDCl3) δ 5.35 (d, J=5.6 Hz, 1H), 3.97-3.82 (m, 4H), 3.59-3.47 ( m, 1H), 2.34-2.21(m, 2H), 2.06-1.94 (m, 2H), 1.90-1.74 (m, 3H), 1.73-1.64 (m, 1H) ), 1.63-1.33 (m, 10H), 1.32-1.19 (m, 1H) , 1.14-1.03 (m, 1H), 1.01 (s, 3H), 0.99- 0.93 (m, 1H), 0.86 (s, 3H).

[0383] Preparation of compound 3: Dry CH 2 Cl 2 Compound 2 (32 g, 96 mm ol, 1.0eq) was added to a solution of Dess-Martin (81g, 192mmol, 2. 0 eq) was added in portions at 0° C. The reaction mixture was then stirred at room temperature for 3 The mixture was stirred for 2 h. TLC (PE:EA=3:1) showed that the starting material was completely consumed. The mixture was diluted with NaHCO 3 / Na 2 S 2 O 3 = 1:3 saturated aqueous solution (1L) The organic phase was washed with brine (500 mL) and 2 SO 4 and the solvent was removed by drying at 40°C. Evaporation gave the crude product 3 (33.0 g, 100%), which was further purified. It was used directly in the next step without purification. 1 H NMR: (400 MHz, CDC l3) δ 5.34 (d, J=5.2 Hz, 1H), 3.77-4.00 (m, 4H), 3.19-3.39 (m, 1H), 2.83 (dd, J= 16.44, 2.13 Hz, 1H), 2.38-2.59 (m, 1H), 2.21-2.37 (m, 1H), 1.95-2.09 (m, 3H), 1. 54-1.73 (m, 4H), 1.74-1.90 (m, 2H), 1.37 -1.51 (m, 3H), 1.21-1.34 (m, 2H), 1.19 ( s, 3H), 0.98-1.12 (m, 1H), 0.83-0.93 (m, 3H).

[0384] Preparation of MAD: Compound 5 (96 g, 436 mmol, 1. 0 eq) solution at room temperature. 3 Solution (109 mL, 218 mmol, 0.5 eq , 2M in hexane) was added, at which point methane gas was immediately evolved. The resulting mixture was stirred at room temperature for 1 h and used in the next step without any purification. The solution was prepared as a solution of MAD in toluene.

[0385] Preparation of compound 4: MAD (218 mmol, 2.3 eq, A solution of compound 4 (3 A solution of 3 g, 96 mmol, 1.0 eq) was added dropwise under nitrogen over 1 h. Then The reaction mixture was stirred for 30 min and MeMgBr (205 mL, 288 mmol, 3. A solution of 0.0 eq. (1.4 M in toluene) was added dropwise at -78°C. The reaction mixture was The mixture was heated to 40° C. and stirred at this temperature for 3 hours. TLC (PE:EA=3:1) showed that the starting material The mixture was then diluted with NH 4 Cl saturated aqueous solution (200mL) The combined organic phase was poured into ethyl acetate and extracted with EA (150 mL x 2). 2 SO 4 Dry with The crude product was obtained by evaporating the solvent. The product was purified by silica gel chromatography eluting with 5:1 The product (7.64 g, 22%) was obtained as a white powder. 1 H NMR: (400 MHz, CDCl3) δ 5.30 (d, J=5. 2 Hz, 1H), 3.75-4.04 (m, 4H), 2.42 (d, J =13.6 Hz, 1H), 1.88-2.12 (m, 3H), 1.73-1 .86 (m, 2H), 1.64-1.72 (m, 2H), 1.52-1.6 3 (m, 4H), 1.35-1.51 (m, 4H), 1.19-1.32 (m, 1H), 1.12-1.18 (m, 1H), 1.10 (s, 3H ), 0.99-1.03 (m, 3H), 0.92-0.98 (m, 1H), 0.86 (s, 3H).

[0386] Compound INT A: Compound 4 (6.0g, 17.3mmol) in THF (200mL) A solution of 1.0 eq) was added to aqueous HCl (35 mL, 1 M) and acetone (35 mL). The reaction mixture was stirred at room temperature overnight. TLC (PE:EA=3:1) The reaction mixture was then diluted with EA (200 mL). NaHCO 3 Wash with saturated aqueous solution (200 mL) of Na 2 SO 4 and dried under reduced pressure. Evaporation under reduced pressure gave the product (5.2 g, 99.2%). 1 H NMR: (400 MHz, CDCl3) δ 5.27 (d, J=6.8 Hz, 1H ), 2.45-2.35 (m, 2H), 2.09-1.84 (m, 4H) , 1.82-1.57 (m, 6H), 1.50-1.35 (m, 4H), 1.26-1.08 (m, 4H), 1.05 (s, 3H), 0.95 ( s, 3H), 0.86 (s, 3H).

[0387] Compound A_001_1: PPh in THF (50 mL) 3 CH 3 Br (28.3g, 7 To a solution of t-BuOK (8.96 g, 9.35 mmol) in THF (20 mL) at room temperature After stirring for 1 hour, the mixture was dissolved in THF (10 mL). The reaction mixture was stirred for 3 h. The reaction mixture was cooled to room temperature and saturated NH 4 Quench with Cl and extract with EA The combined organic layers were washed with brine, dried and concentrated to give the crude product. The resulting product was purified by flash column chromatography (PE / EA=15 / 1). Compound A_001_1 (3.2 g, Y=80%) was obtained as a white solid by purification. Ta. 1 H NMR: (400 MHz, CDCl3) δ 5.32 (d, J= 5.2 Hz, 1H), 4.65-4.64 (m, 2H), 2.50-2.4 2 (m, 2H), 2.27-2.22 (m, 1H), 2.07-1.97 (m, 1H), 1.87-1.68 (m, 4H), 1.68-1.49 (m , 7H), 1.40-1.15 (m, 4H), 1.12 (s, 3H), 1.05 (s, 3H), 1.04-0.96 (m, 1H), 0.80 (s , 3H).

[0388] Preparation of compound A_001_2: CH 2 Cl 2 (5 mL) of compound A_001_1( 300mg, 1.0mmol, 1.0eq) and methyl propiolate (250mg, 3 To a solution of 1.0 mmol, 3.0 eq) was added Et 2 AlCl(4 1 mL, 4.0 mmol, 4.0 eq, 1M in toluene) was added dropwise, and the reaction mixture was then cooled to room temperature. The mixture was stirred overnight. TLC (PE / EA=3 / 1) showed that the starting material was completely consumed. The solution was then diluted with NaHCO 3 Wash with saturated aqueous solution (5 mL) of Na 2 SO 4 Dry with The crude product was obtained by drying and concentrating under redu...

Claims

1. A composition comprising a compound of formula (I-w) or a pharma- ceutically acceptable salt thereof for use in a method of treating a patient having a central nervous system (CNS) disease or disorder associated with NMDA receptor modulation, the method comprising: a) obtaining a patient sample as required; b) obtaining and / or evaluating the sample for a change in the level of 24(S)-hydroxycholesterol as compared to a control standard; c) administering said composition to said patient having an altered level of 24(S)-hydroxycholesterol in said sample. The compound of formula (I-w) has the following structure: 【Chemistry 1】 wherein: X 1 is -O-; R 3b is hydrogen; R 3a is hydrogen, unsubstituted C 1-6 Alkyl or halogen or -OR aa C substituted with 1-6 alkyl, R aa is C 1-10 is alkyl; R 2 , R 11a and R 11b Each instance of is independently hydrogen; R 6a and R 6b each is independently hydrogen; and 【Chemistry 2】 represents a single bond or a double bond, provided that when a double bond is present, R 6a Or R 6b is absent and when a single bond is present, the hydrogen at C5 is in the alpha or beta position; R 19 is hydrogen or -CH 3 and Z is, 【Chemistry 3】 The composition is selected from:

2. 2. The composition for use according to claim 1, for treating memory impairment in said patient or for improving learning in said patient.

3. 2. The composition for use according to claim 1, for treating said patient for drug overdose.

4. 4. The composition for use according to any one of claims 1 to 3, wherein the CNS disease or disorder associated with NMDA receptor modulation is selected from schizophrenia, depression, bipolar disorder (I and II), schizoaffective disorder, mood disorders, anxiety disorders, personality disorders, psychosis, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), autism spectrum disorder (ASD), dysthymia, social anxiety disorder, obsessive-compulsive disorder (OCD), pain syndromes and disorders, sleep disorders, memory disorders, dementia, Alzheimer's disease, traumatic brain injury (TBI), stroke, addictive disorders, autism, Huntington's disease, insomnia, Parkinson's disease, withdrawal syndromes, and tinnitus.

5. The composition for use according to claim 4, wherein the CNS disease or disorder associated with NMDA receptor modulation is dementia.

6. The composition for use according to claim 4, wherein the CNS disease or disorder associated with NMDA receptor modulation is Alzheimer's disease.

Citation Information

Patent Citations

  • Methods of treating disorders associated with high cholesterol levels

    JP2005508368A